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Abstract
A unique feature of retroviruses is that two copies of the genomic RNA are packaged in 
each particle. The selective encapsidation of viral genomes is ensured by the binding of 
the Nucleocapsid to a specific motif on the RNA genome, the packaging signal (Psi). 
The Psi regions of many retroviruses overlap with sequences that promote the 
dimerisation of the genome, the dimerisation initiation site (DIS), and it has been 
suggested that the two mechanisms are closely linked.
The aim of the research presented herein was to identify the sequences and structural 
elements required for the dimerisation of HIV-2 genomic RNA and to investigate the 
relationship between HIV-2 genome dimerisation and encapsidation, infectivity and 
particle morphogenesis.
Mutations of two palindromic sequences, introduced in an infectious molecular clone of 
the H IV -2rod isolate, revealed that a palindrome within HIV-2 Psi was important for 
genome dimerisation. In contrast with previous studies, the palindrome termed DIS is 
not required for genome dimerisation and viral replication.
Viruses bearing mutations within the Psi region failed to dimerise and to replicate in T- 
cells, a defect that could not be rescued by targeting more genomes to the cells. Psi- 
deleted viruses also displayed a defect in particle morphogenesis. A reduced packaging 
efficiency, combined with the presence of RNA monomers or unstable dimers in these 
virions, resulted in the production of fewer mature particles. However an increase in the 
number of particles containing two cores was observed.
Further characterisation of the sequences and structural elements required for RNA 
dimerisation, packaging and viral replication showed that the formation of stem B is not 
critical for viral replication. However, a GGAG purine-rich motif at position 392-395 of 
the H IV -2rod genome is absolutely essential for genome dimerisation and viral 
infectivity, and a correlation was observed between dimer formation and viral 
replication.
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Chapter 1: Introduction
1 Introduction
1.1 The origins of HIV and AIDS
1.1.1 The discovery of HIV
•  The identification o f AIDS and HIV
Acquired immunodeficiency syndrome or AIDS was first reported in the early 1980’s, 
when a growing number of previously healthy homosexual patients presented with 
pneumocystis carinii pneumonia, mucosal candidiasis, Kaposi’s sarcoma and multiple 
viral infections, including human Cytomegalovirus (hCMV) (Friedman-Kien et al., 
1982; Gottlieb et al., 1981; Mildvan et al., 1982; Stahl et al., 1982). All patients were 
found to be lymphopenic and to have an acquired immunodeficiency syndrome.
The etiological agent of AIDS, lymphadenopathy associated virus (LAV), was isolated 
in 1983 from lymphocytes of a patient presenting with multiple lymphadenopathy 
(Barre-Sinoussi et al., 1983). LAV was described as a typical type C RNA tumour virus 
and antibodies from the serum of this patient reacted with proteins from human T-cell 
leukaemia virus type 1 (HTLV-1). However, specific antibodies against HTLV-1 did 
not precipitate the proteins of the new isolate.
In the same year, another study reported the isolation of HTLV-1 from patients with 
AIDS (Gallo et al., 1983). However, two new viruses, named HTLV-III and AEDS- 
associated retrovirus (ARV), were subsequently isolated from patients with AIDS 
(Gallo et al., 1984; Gallo et al., 1983; Levy et al., 1984; Popovic et al., 1984; 
Samgadharan et al., 1984) and it was later agreed that LAV, ARV and HTLV-III were
15
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the same vims isolate and represented the causative agent of AIDS. LAV/HTLV-III was 
later renamed human immunodeficiency vims type 1 (HIV-1) as it became apparent that 
this vims was not related to C-type oncoretrovimses like HTLV (Coffin et al., 1986).
A few years later, another retrovirus was isolated in Western Africa from patients with 
AIDS (Clavel et al., 1986a). This new retrovirus presented similarities with HIV-1 both 
morphologically and biologically as its tropism and cytopathic effect on CD4+ T-cells 
were similar to that of HIV-1 (Bmn-Vezinet et al., 1987; Clavel et al., 1986a; Clavel et 
al., 1986b). Yet the sequence homology at the protein level appeared very limited, with 
around 50 and 55 % homology for the Gag (group-specific antigen) and Pol 
(Polymerase) proteins respectively and only 35 % homology for the envelope (Env) 
glycoprotein (Franchini et al., 1987; Guyader et al., 1987). Semm from a macaque 
infected with simian T-cell leukaemia virus-type III (STLV -IIImac; also known as 
simian immunodeficiency vims macaque or SIV mac; Daniel et al., 1985; Kanki et al., 
1985c) could recognise the Envelope glycoprotein from the new retrovims while serum 
from an HIV-1 infected patient could not (Clavel et al., 1986a). The serological cross­
reactivity was in fact restricted to the major core protein Gag and it was suggested that 
this new retrovims, later named HIV-2, was only distantly related to HIV-1. Amino acid 
sequence comparison confirmed that HIV-2 was more closely related to an SIV isolate 
from African green monkeys (SIV agm) than it was to HIV-1 (Franchini et al., 1987). 
Another human T-lymphotropic vims isolated from apparently healthy Senegalese 
women and named HTLV-IV showed high similarities and serological cross-reactivity 
with SIV agm (Kanki et al., 1986). HTLV-IV was confirmed to belong to the HIV-2 
lineage following nucleotide sequence comparison (Hahn et al., 1987).
16
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• Nomenclature
The Retroviridae family comprises seven classes of viruses (Fauquet et al., 2005). HIV- 
1 and -2 belong to the Lentivirinae class. Other Lentivirinae, named as such due to the 
slow progression of the disease they cause, include simian, feline and bovine 
immunodeficiency viruses (respectively SIV, FIV and BIV), Visna Maedi virus 
(VISNA), caprine arthritis encephalitis virus (CAEV) and equine infectious anaemia 
virus (ELAV).
The other classes of exogenous Retroviridae are the Alpharetrovirinae (type species: 
avian leukaemia virus, ALV and Rous sarcoma virus, RSV), Betaretrovirinae (mouse 
mammary tumour virus, MMTV and Mason-Pfizer monkey virus, MPMV), 
Gammaretrovirinae (murine and feline leukaemia virus, MLV and FLV), 
Deltaretrovirinae (HTLV and bovine leukaemia virus, BLV), Epsilonretrovirinae 
(walleye dermal sarcoma virus, WDSV) and the Spumavirinae (human and simian 
Foamy virus, HFV and SFV).
1.1.2 The emergence of HIV: how, where and when?
Despite allegations that an oral OVP-polio vaccine contaminated by SIV was 
responsible for the emergence of HIV and the AIDS pandemic (Hooper, 1999), it has 
now been agreed among the scientific community that it was not the origin of HIV 
(Berry et al., 2001; Berry et al., 2005). Instead, HIV-1 and -2 are thought to have arisen 
following several zoonotic transmission events from SIV-infected non-human primates 
to humans in Africa (Gao et al., 1999; Gao et al., 1992; Hahn et al., 2000; Hirsch et al., 
1989; Huet et al., 1990; Keele et al., 2006; Sharp et al., 1995). Five lines of evidence 
have been used to support the hypothesis of a zoonotic origin of HIV-1 and -2:
17
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similarities in genome organisation, phylogenetic relatedness, prevalence in the natural 
host, geographic coincidence and plausible route of transmission (Sharp et al., 1995).
•  Evolution o f HIV-2 from the SIVsm lineage
HIV-2, which was discovered in Western Africa and is only endemic there (Clavel et 
al., 1986a; Kanki et al., 1986), has been found to be closely related to SIV mac and 
SIV agm due to sequence homology and serological cross-reactivity (Daniel et al., 1985; 
Franchini et al., 1987; Hahn et al., 1987; Kanki et al., 1985a; Kanki et al., 1985b; Kanki 
etal., 1985c).
Isolation and characterisation of an isolate of SIV from sooty mangabeys (Cercocebus 
atys), SIV sm, confirmed that HIV-2 was more closely related to the SIV sm lineage than 
to HIV-1 (Hirsch et al., 1989; Marx et al., 1991; Santiago et al., 2005; Sharp et al., 
1995; see Figure 1.1). Sequence comparisons between SIV sm, SIV mac and HIV-2 
suggested that SIV sm had infected humans in Western Africa and captive Rhesus 
macaques (RhMac; Macaca mulatto) and had evolved as HIV-2 and SIV mac, 
respectively (Gao et al., 1992; Hirsch et al., 1989). Further evidence that sooty 
mangabeys are the natural primate reservoir of HIV-2 comes from the identical genomic 
organisation of HIV-2 and SIV sm (Guyader et al., 1987; Hirsch et al., 1989), which both 
encode the vpx open reading frame (ORF) that is missing in HIV-1 and any other 
lentiviruses (Franchini et al., 1988; Yu et al., 1988).
Finally, this hypothesis is also supported by the geographical proximity and the close 
contacts existing between sooty mangabeys and humans in Western Africa, where sooty 
mangabeys are hunted for their meat and kept as pet animals (Hahn et al., 2000).
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Figure 1.1: Evolutionary relationships of primate lentiviruses.
The tree was derived by maximum likelihood analysis of Pol protein sequences. Horizontal 
branch lengths are drawn to scale. Asterisks denote clades (to the right) supported in at least 
80% of bootstrap replicates. Adapted from (Beer, 1999).
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There are now eight reported HIV-2 groups or clades (formerly subtypes), A through H 
(Chen et al., 1997; Damond et al., 2004; Gao et al., 1994; Yamaguchi et al., 2000), each 
thought to have originated from a single cross-species transmission event (Chen et al., 
1996; Gao et al., 1992; Hahn et al., 2000; Sharp et al., 1995). However, only group A 
and B were able to establish as human epidemics, with spread limited to Western Africa 
and countries such as Brazil, Portugal and France due to former colonisation, historical 
links and immigration pattern (Remy, 1998; Schim van der Loeff and Aaby, 1999; 
Smallman-Raynor and Cliff, 1991; Soriano et al., 2000). Groups C through H have only 
been isolated once, suggesting that they are primary zoonotic transfer events (Chen et 
al., 1997; Damond et al., 2004; Gao et al., 1994; Yamaguchi et al., 2000). In contrast to 
groups C-G, which have not been reported in symptomatic individuals, group H 
corresponds to a highly divergent HIV-2 isolate that is clearly pathogenic (Damond et 
al., 2004).
The most common recent ancestor of SIV in sooty mangabeys has been dated to the
fliearly 19 century and HIV-2 group A and B have been proposed to have entered the 
human population approximately in 1930 (Wertheim and Worobey, 2009).
•  Evolution o f HIV-1 from the SIVcpz lineage
Serological cross-reactivity, similar genomic organisation and partial sequence 
homology between HIV-1 and SIV isolated from wild chimpanzees {Pan troglodytes 
troglodytes) in Gabon, SIV cpz, have been reported (Huet et al., 1990; Peeters et al., 
1989), suggesting that HIV-1 may have evolved from the SIV cpz lineage.
Further analysis of different SIV cpz strains confirmed that HIV-1 clustered 
phylogenetically with SIV cpz (Gao et al., 1999; Keele et al., 2006; van Heuverswyn et
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al., 2006) and that three cross-species transmission events gave rise to the major (M), 
new (N) and outlier (O) HIV-1 groups (see Figure 1.1).
While it seems well established now that chimpanzees are the natural reservoir of HIV- 
1 group M and N, the source of HIV-1 group O remains less clear (Keele et al., 2006). 
Interestingly, an HIV-1 group O-like virus was discovered in wild gorillas {Gorilla 
gorilla), SIV gor, and found to cluster with HIV-1 group O (Takehisa et al., 2009; van 
Heuverswyn et al., 2006). While the phylogenetic relationship between SIV cpz, SIV gor 
and HIV-1 suggests that P. t. troglodytes apes were the original reservoir of the viruses 
found in chimpanzees, gorillas and human, it is not known whether chimpanzees 
transmitted group-0 like virus to gorillas and humans independently or whether gorillas 
served as an intermediary host for the human infection (Takehisa et al., 2009).
Despite having crossed the species barrier on three occasions, HIV-1 group M 
represents the only zoonosis that resulted in a pandemic. In fact, HIV-1 group N is only 
found in a few individuals in Cameroon (Simon et al., 1998; Yamaguchi et al., 2006) 
and HIV-1 group O seems to also localise around Cameroon (Peeters et al., 1997; 
Vanden Haesevelde et al., 1994), even though a few cases have been reported in Europe 
and USA, mainly in immigrants from central Africa (CDC, 1996; Loussert-Ajaka et al., 
1995).
HIV-1 appears to have originated in west central Africa (Gabon, Cameroon, Equatorial 
Guinea and the Republic of Congo), where P. t. troglodytes and G. gorilla are found 
(Gao et al., 1999; Sharp et al., 2001; van Heuverswyn et al., 2006). Although it is 
difficult to precisely date the emergence of the HIV-1 lineage, the sequences of African 
HIV-1 group M isolates from the 1960’s have been authenticated (Worobey et al., 2008; 
Zhu et al., 1998) and it has been proposed that HIV-1 group M emerged around 1930
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(Hahn et al., 2000; Korber et al., 2000; Sharp et al., 2001; Sharp et al., 2000; Wertheim 
and Worobey, 2009).
1.2 The epidemiology of HIV
1.2.1 The global AIDS pandemic
According to the 2008 report on the global AIDS pandemic from the joint United 
Nations programme on HIV/AIDS (UNAIDS), there was an estimated 33 million [30 - 
36 million] people worldwide living with HIV in 2007 (UNAIDS and World Health 
Organization, 2008). Although the annual number of new infections has decreased from 
an estimated 3 million in 2001 to 2.7 million in 2007, the overall number of people 
living with HIV has increased, partly due to the prolonged life expectancy of HIV 
patients on antiretroviral therapy (ART). The introduction and more widespread use of 
highly active ART (HAART) might also account for the reduction in the number of 
deaths due to AIDS from 2 million in 2001 to 1.7 million in 2007 (UNAIDS and World 
Health Organization, 2008).
1.2.2 The worldwide distribution of HIV
•  The AIDS pandemic in Sub-Saharan Africa
Even though the HIV pandemic has spread worldwide and is present on every continent 
(Figure 1.2 top panel), the African continent, and in particular Sub-Saharan Africa, 
bears a disproportionate share of the global burden of HIV.
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A global view of HIV infection, 2007 
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Figure 1.2: The global AIDS pandemic.
Percentage of HIV prevalence among adults worldwide (top panel; adults aged 15+) and in 
Africa (bottom panel; adults aged 15-49) in 2007 as reported by UNAIDS. Adapted from the 
2008 report on the global AIDS pandemic from UNAIDS (UNAIDS and World Health 
Organization, 2008).
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Indeed, Sub-Saharan Africa remains by far the most affected region, with an estimated 
22 million people infected with HIV in 2007 and with HIV prevalence reaching almost 
30 % in countries such as Mozambique (Figure 1.2 bottom panel). Sub-Saharan Africa 
is currently home to 67 % of all people living with HIV and 75 % of all AIDS deaths in 
2007 occurred in this region (UNAIDS and World Health Organization, 2008).
•  HIV in Asia
Asia is the second most affected part of the world, with an estimated 5 million people 
living with HIV and 380,000 new cases in 2007 (UNAIDS and World Health 
Organization, 2008). South-East Asia (Thailand, Cambodia, Viet Nam and Indonesia) 
appears to have the highest HIV prevalence, between 1 and 2 %.
•  HIV in Eastern Europe and Central Asia
Eastern Europe and Central Asia account for approximately 4.5 % of all the HIV 
infections, with an estimated 1.5 million people living with the virus, mostly in Russia 
(69 %) and Ukraine (29 %). Approximately 4 % of the annual new infections and 2.9 % 
of AIDS deaths occur in this region (UNAIDS and World Health Organization, 2008).
•  HIV in North America and Western Europe
In Western Europe and North America, an estimated 81,000 people were newly infected 
with HIV in 2007, bringing the number of people living with HIV to 2 million. North 
America alone accounts for more than half of the cases, with 1.2 million infected 
people. Compared to other regions, relatively few people die of AIDS (31,000), most 
likely due to the widespread use and availability of HAART in those richer countries.
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This also results in an increase in number of people living with the virus, as the life 
expectancy of patients is greatly augmented when HAART is used.
•  HIV in Latin America and the Caribbean
Latin America represents 5 % of HIV cases worldwide, with an estimated 1.7 million 
people living with the virus according to UNAIDS. 140,000 people became infected and 
63,000 died because of AIDS in 2007.
In the Caribbean, 230,000 people live with HIV, three quarters of them in the 
Dominican Republic and Haiti. In 2007, an estimated 20,000 new infections and 14,000 
deaths were reported for this region (UNAIDS and World Health Organization, 2008).
1.2.3 The HIV-2 epidemic
The emergence of HIV-2 occurred in Western Africa and to date, this region remains 
the only place where the virus is endemic (Schim van der Loeff and Aaby, 1999). 
Groups or subtypes A and B, the only HIV-2 groups that spread outside of Western 
Africa, account for the majority of HIV-2 infections (Norrgren et al., 1997; Schim van 
der Loeff and Aaby, 1999 and references therein).
In rural communities of Guinea-Bissau, HIV-2 prevalences of 8-10 % in the adult 
population (aged 15+) have been reported (Poulsen et al., 1989; Wilkins et al., 1993). 
Surrounding countries such as The Gambia, Senegal and Ivory Coast usually have lower 
prevalence rates, between 2 and 3 % (Remy, 1998), even though a prevalence of around 
8 % was reported amongst commercial sex workers in Senegal and Ivory Coast (Ghys 
et al., 1997; Langley et al., 1996). This figure was reported to reach 28 % in The 
Gambia (reviewed in Reeves and Dorns, 2002). HIV-2 has not spread to other regions of
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Africa and the cases reported have been mainly sporadic ones (Schim van der Loeff and 
Aaby, 1999). Similarly, the HIV-2 prevalence in Europe and North America is very 
low, with the number of reported cases often below one hundred per country, and most 
cases can be traced back to Western Africa through the bias of population movements 
(Remy, 1998; Schim van der Loeff and Aaby, 1999). Due to their colonial past in 
Western Africa, Portugal and France are the two European countries with the highest 
HIV-2 prevalence (Smallman-Raynor and Cliff, 1991). In Portugal, HIV-2 accounts for 
10-13 % of HIV infections and 4.5 % of AIDS cases (Soriano et al., 2000).
Although HIV-2 is endemic in Western Africa, the prevalence in this region is stable or 
in decline, while the rate of HIV-1 and dual HrV-l/HIV-2 infections has increased, 
suggesting that HIV-2 transmission (via the heterosexual route) is not as efficient as that 
of HIV-1 and that HIV-2 may be competed out by HIV-1 in the context of a dual 
infection (Anderson and May, 1996; Kanki et al., 1994; Schim van der Loeff and Aaby, 
1999).
1.3 The pathogenesis of HIV
1.3.1 Course of infection with HIV
The typical course of an infection with HIV is presented in Figure 1.3. Following the 
initial exposure, patients experience an asymptomatic incubation period of 
approximately two to four weeks. In so-called ‘typical progressors’, the incubation 
period is followed by three phases: acute infection, clinical latency and AIDS, that span 
over eight to ten years (reviewed in Pantaleo and Fauci, 1996).
The acute phase of an HIV infection is characterised by a mononucleosis- or flu-like 
syndrome that appears three to six weeks after primary infection (Coffin et al., 1997).
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Figure 1.3: Typical course of an HIV infection.
Relationship between HIV genome copy number (viral load, red) and CD4T T-cell count (blue) 
over the typical course of an untreated HIV infection. The disease course, viral load and CD4+ 
T-cell count may vary considerably from one patient to another (adapted from Pantaleo et al., 
1993b).
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Even though HIV targets CD4+ cells such as helper T lymphocytes (Dalgleish et al., 
1984; Klatzmann et al., 1984a; Klatzmann et al., 1984b), dendritic cells (DCs) are likely 
to be the first cells infected by the virus in the mucosa and are thought to play a key role 
in the dissemination of HIV in the infected host, and transmission to T-cells in 
particular (Granelli-Pipemo et al., 1999; Rowland-Jones, 1999). During the acute phase, 
viral replication is rapid, with viral titres as high as 107 copies of HIV RNA per ml 
plasma, causing a steep decrease in the level of those CD4+ T-cells in the peripheral 
blood in the first two to eight weeks following infection (see Figure 1.3; Gaines et al., 
1990). The increased viremia is often associated with an activation of CD8+ T-cells, 
which target the infected cells, and with antibody production. The efficacy of the CD8+ 
T-cells response has been suggested to influence the progression of the disease 
(Pantaleo et al., 1997).
Following the acute phase of infection, typical progressors enter a long phase of clinical 
latency that can last for up to ten years. Viral replication remains active during latency 
and the count of CD4+ T-cells decreases slowly (Embretson et al., 1993; Pantaleo et al., 
1993a; Piatak et al., 1993). However, a CD4+ T-cell count of 500 per pi or more is not 
usually associated with symptoms. Follicular dendritic cells (FDCs) appear to constitute 
a reservoir for the virus during the latent stage of infection and play an important role 
for viral persistence due to their close proximity to activated CD4+ T-cells (Burton et 
al., 2002).
When the CD4+ T lymphocyte count falls below 200 cells per pi, the disease progresses 
to AIDS and patients present an increased susceptibility to opportunistic infections. 
Approximately 10-15 % of HIV infected patients, termed rapid progressors, present an 
unusually rapid progression to AIDS within two to three years of primary infection (for 
review, see Pantaleo and Fauci, 1996). On the other hand, a small percentage of patients
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(5 %) do not show signs of disease progression over a prolonged period of time, up to 
twenty years, and remain asymptomatic. These individuals, called long-term non 
progressors (LTNPs), present stable CD4+ T-cell counts (>500 cells per pi) for several 
years, increased CD8+ T-cell count and often undetectable plasma viral load (Cao et al., 
1995; Lifson et al., 1991; Pantaleo et al., 1995; Sheppard et al., 1993). Viral replication 
of HIV-1 and HIV-2 variants from LTNPs appears slower than that of viruses from 
normal progressors (Blaak et al., 1998; Blaak et al., 2006; Quinones-Mateu et al., 2000) 
and it was found that replication of HIV-2 variants from LTNPs replicated slower than 
HIV-1 from asymptomatic/LTNP individuals (Blaak et al., 2006). In LTNPs, the 
expression of inhibitory natural killer (NK) receptors on CD8+ peripheral blood 
mononuclear cells (PBMCs) is similar to that of healthy individuals (Costa et al., 2003) 
and the NK cell cytotoxic response is reduced (Mavilio et al., 2003; O'Connor et al.,
2007). In addition, neutralising antibodies titres are found to be higher than in normal 
progressors (Cao et al., 1995; Pantaleo et al., 1995). Finally, HIV-1 and HIV-2 variants 
isolated from LTNPs have been reported to carry large deletions in the nef (negative 
factor) gene, suggesting that the Nef protein plays a role in HIV pathogenesis (Blaak et 
al., 1998; Deacon et al., 1995; Kirchhoff et al., 1995; Rhodes et al., 2000; Switzer et al., 
1998; Trible et al., 2007).
1.3.2 Differences in pathogenicity between HIV-1 and HIV-2
It has long been noted that HIV-2 is less virulent than HIV-1 and several studies have 
provided strong evidence supporting this difference in pathogenicity (reviewed in De 
Silva et al., 2008; Rowland-Jones and Whittle, 2007).
Firstly, the plasma viral load and replication rate of HIV-2 has been shown to be lower 
than for HIV-1 (Berry et al., 1998; Damond et al., 2002; Gottlieb et al., 2002; MacNeil
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et al., 2007; Popper et al., 1999). However, amounts of total cellular and integrated 
proviral DNA are similar between HIV-1 and HIV-2, suggesting that poor proviral 
establishment cannot explain the lack of virulence of HIV-2 (MacNeil et al., 2007). 
Comparison between replication of HIV-1 and HIV-2 variants in long-term aviremic 
individuals showed a difference in the replication rate of the two viruses similar to that 
observed in normal progressors (Blaak et al., 2006).
The low plasma viral load may account for the low transmission rate observed with 
HIV-2 (reviewed in Jaffar et al., 2004; Schim van der Loeff and Aaby, 1999). In regions 
where both HIV-1 and HIV-2 are present, the prevalence of HIV-2 remains stable or 
decreases whereas HIV-1 prevalence increases, suggesting that the two viruses do not 
transmit at the same rate (Anderson and May, 1996; De Cock et al., 1993; Kanki et al., 
1994). Mother-to-child HIV-2 transmission has also been shown to be a much rarer 
event than in HIV-1 infections and HTV-1/H1V-2 dually infected mothers seemed to 
transmit HIV-1 alone in the majority of cases (Adjorlolo-Johnson et al., 1994; Ekpini et 
al., 1997; O'Donovan et al., 2000).
An enhanced immune response is also a characteristic of HIV-2 infection. Long-term 
non progression is more common in HIV-2 than HIV-1 infections (Berry et al., 2002; 
Poulsen et al., 1989) and the rate of CD4+ T-cell decline in HIV-2 infected individuals 
is slower compared to HIV-1 infection (Jaffar et al., 1997). This higher CD4+ T-cell 
count is associated with a greater NK cell cytolytic response and broader cytokine 
secretion compared to HIV-1 infection (Nuvor et al., 2006).
Strong Gag-specific CD4+ T-cell response and CD8+ cytotoxic T lymphocyte (CTL) 
response have been proposed to further help control viremia in HIV-2 infected patients 
(Duvall et al., 2006; Jennes et al., 2008; Leligdowicz et al., 2007) and HIV-2-specific T-
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cells have been shown to maintain a polyfunctional profile (Duvall et al., 2008), 
constituting a hallmark for non-progressive HIV-2 infection.
In addition, the neutralising antibody response has been shown to be different between 
HIV-1 and HIV-2 infections. HIV-2 infection triggers a broad, low-magnitude 
neutralising response whereas HIV-1 is characterised by a narrow, high-magnitude 
response (Rodriguez et al., 2007).
Interestingly, dendritic cells were shown to be less susceptible to HIV-2 than to HIV-1 
infection (Duvall et al., 2007). Since DCs have been proposed to be the ‘port of entry’ 
of HIV upon primary infection and to be implicated in the dissemination of HIV, this 
might partly account for the lower pathogenicity of HIV-2.
Finally, immune activation has been implicated in the pathogenicity of HIV (De Silva et 
al., 2008 and references therein). Contrary to HIV-infected human and SIV-infected 
Rhesus macaques, the observation that SIV-infected sooty mangabeys do not develop 
AIDS despite high viremia and low level of specific CD8+ T-cell response led to the 
suggestion that immune activation may play an important role in the pathogenicity of 
HIV (Silvestri et al., 2003). Indeed, maintenance and regeneration of the T lymphocyte 
population and lower levels of aberrant immune activation and apoptosis were observed 
compared to pathogenic HIV and SIV infections. Accordingly, a recent study of SIV sm 
in its natural host has suggested that the killing of the CD4+ T-cells by HIV might not 
represent the main determinant of disease progression (Gordon et al., 2008). 
Interestingly, the HIV-2 and SIV sm Nef proteins were shown to downregulate the T-cell 
receptor (TCR)-CD3 complex on infected cells, preventing overactivation of infected 
cells and activation-induced cell death. This Nef-mediated suppression of immune 
activation present in HIV-2 and SIV sm was lost in the HIV-1 lineage (Schindler et al.,
2006) and may contribute to the difference in virulence between HIV-1 and HIV-2.
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Supporting this hypothesis, HIV-1 variants isolated from -LTNPs possessed large 
deletions in the nef gene (Blaak et al., 1998; Kirchhoff et al., 1995; Rhodes et al., 2000; 
Trible et al., 2007). Similarly, truncations in the nef ORF appear characteristic of 
attenuated HIV-2 infections as these were found in 14 % of asymptomatic HIV-2 
infections but in only 4 % of normal HIV-2 infected progressors (Switzer et al., 1998).
1.3.3 Interaction with the host
There has been increasing evidence that host species have developed certain innate 
immunity mechanisms to counteract retroviral replication. For example, proteins from 
the family of human apolipoproteins, most notably APOBEC3G (apolipoprotein B 
mRNA-editing enzyme catalytic subunit 3G), were shown to restrict HIV-1 and HIV-2 
replication by using both a deaminase-dependent and -independent mechanism 
(reviewed in Holmes et al., 2007). This restriction was shown to be species-specific 
(Bogerd et al., 2004; Mariani et al., 2003) and to be counteracted by the Vif (virion 
infectivity factor) protein of HIV, which prevents the packaging of APOBEC3G into 
nascent budding virions and triggers its proteasomal degradation (Sheehy et al., 2003). 
Another restriction factor, Tripartite motif protein 5a (TRIM5a), was later identified 
and shown to restrict HIV replication in RhMac cells (reviewed in Huthoff and Towers,
2008). Similarly, SIV replication was found to be restricted by human TRIM5a. The 
TRIM5a proteins act by binding to the retroviral capsid (CA) and interfering with 
reverse transcription as well as later stages of viral replication. It was recently reported 
that a specific residue in HIV-2 CA (proline 119) determines sensitivity to cynomolgus 
monkey and human TRIM5a (Song et al., 2007a). Interestingly, a study in the HIV-2 
community cohort Caio in Guinea-Bissau has revealed that HIV-2 CA encoding proline 
residues at three key positions, including at position 119, were found more frequently in
32
Chapter 1: Introduction
individuals with low viral load (Onyango et al., unpublished data reported in De Silva et 
al., 2008). This so-called p26PPP capsid seemed to be less stable and the PPP-encoding 
viruses appeared to generate stronger T-cell response compared to viruses lacking the 
proline residues. It was suggested that the presence of prolines at these positions might 
promote a better exposure of CA to TRIM5a-mediated restriction, leading to a better 
control of viral replication by the host. Supporting this hypothesis, non-PPP-encoding 
viruses were found to be enriched in HIV-2 infected patients progressing to AIDS. This 
implies that specific capsid sequences could influence the progression of the disease and 
therefore represent an interesting tool to help predict and monitor disease progression. 
Conversely, the presence of PPP in the capsid of HIV-2 isolated from AIDS patients 
such as H IV -2rod shows that this factor alone cannot be considered a marker of low 
viral load and slow disease progression.
It is interesting to note that TRIM5a is strongly induced by interferon (IFN) and that 
HIV-2 has been shown to be restricted by high levels of human TRIM5a (Ylinen et al.,
2005). Another IFN-induced tripartite motif protein, TRIM22, was also shown to 
restrict HIV-1 replication by inhibiting the budding of Gag virus-like particles (VLPs) 
and affecting Gag trafficking (Barr et al., 2008).
More recently, a protein named tetherin (also known as B cell stromal factor 2 [Bst-2] 
or CD317) was shown to block HIV-1 particle release (Neil et al., 2008; Van Damme et 
al., 2008). Tetherin is IFN-induced, similarly to TRIM5a and TRIM22, and its antiviral 
activity was shown to be blocked by the viral protein u (Vpu) in the case of HIV-1 and 
Env for HIV-2.
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1.4 The HIV particle
Like all retroviruses studied to date, HIV-1 and HIV-2 virions contain two copies of 
their single-stranded RNA genome, non-covalently linked near their 5' end (Coffin et 
al., 1997). The virus is released from the cell in an immature form that undergoes 
maturation via proteolytic processing of the Gag and Gag-Pol polyproteins by the 
virally encoded protease. The mature virion contains a cone-shaped condensed core 
composed of the capsid protein and containing the dimeric genome coated by the 
nucleocapsid protein as well as the viral enzymes (reverse transcriptase, integrase, 
protease) necessary for HIV replication in the target cell (see Figure 1.4). Enveloping 
the capsid, the cell-derived lipid membrane is coated with the matrix protein on the 
inside and the envelope glycoproteins on the exposed surface.
1.4.1 HIV genome organisation
Despite sequence homology of only 50 to 60 %, HIV-1 and HIV-2 share a relatively 
similar genomic organisation (Alizon et al., 1984; Clavel et al., 1986b; Franchini et al., 
1987; Guyader et al., 1987).
The genome of the H IV -2rod isolate, shown in Figure 1.5, is a 9671 nucleotides (nt) 
long positive-sense single strand RNA and comprises three major ORFs, gag, pol and 
env, as well as six accessory genes, vif, nef, tat (trans-activator of transcription), rev 
(regulator of viral expression), vpr (viral protein r) and vpx (viral protein x; Guyader et 
al., 1987).
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Figure 1.5: HIV-2 genome organisation.
The HIV-2 genome is a single-stranded positive-sense RNA of 9671 nt. The viral genome 
contains two long terminal repeats (LTRs) and several ORFs encoding the Gag, Pol, Env, Vif, 
Vpx, Vpr, Tat, Rev and Nef proteins. The 5' and 3' untranslated regions comprise the regulatory 
elements: TAR, Prms’-activation responsive; PBS, primer binding site; SD, splice donor; x¥, 
packaging signal; PolyA, poly(A) signal. The Rev responsive element (RRE) is located within 
the env ORF. The 5' LTR includes a repeat (R) and a unique 5' (U5) region. The 3' LTR 
includes a unique 3' (U3) and R region. The length and position of each element is indicated in 
the box. Figure is to scale.
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As shown in Figure 1.4, the gag gene encodes the structural proteins matrix (MA), 
capsid (CA) and nucleocapsid (NC), two spacer peptides p l and p2 and the late domain 
p6 . The pol ORF is divided into pro and pol and encodes the viral enzymes. Pro 
encodes the viral protease (PR) and Pol encodes the RNA-dependent DNA polymerase 
or reverse transcriptase (RT) and the integrase (IN). The reverse transcriptase also 
exerts an RNase H (RH; DNA-RNA heteroduplex dependent Ribonuclease) activity. 
The env gene encodes the Envelope precursor glycoprotein (gp), gpl40 and gpl60 in 
HIV-2 and HIV-1 respectively. Cleavage of the precursor by a host protease gives rise 
to the surface (SU) and transmembrane (TM) glycoproteins, gpl25 and gpl20 and gp36 
and gp40 for HIV-2 and HIV-1 respectively (Clavel et al., 1986a; Freed et al., 1989; 
McCune et al., 1988).
The six accessory genes are located between the pol ORF and the U3 region and encode 
proteins involved in transcription (Tat), viral infectivity (Vif, Vpr and Vpx), mRNA 
export (Rev) and downregulation of cell surface CD4 and MHC (major 
histocompatibility complex) class I (Nef; reviewed by Cullen, 1998). All six genes are 
present in HIV-1 as well as HIV-2 except for vpx, which is only present in HIV-2 and 
SIVs isolated from most species and is thought to have arisen from a duplication of an 
ancestor vpr gene (Tristem et al., 1992). In HIV-1, the vpx gene is replaced by vpu, a 
unique feature of the SIVcpz/HIV-1 lineage. A detailed description of the function of 
each protein is presented is section 1.4.2.
Located at the extremities of the RNA genome, the untranslated regions (UTR) contain 
regulatory elements important for several stage of the virus life cycle such as 
transcription, splicing, reverse transcription, genome dimerisation and encapsidation. In 
particular, the 5' leader RNA comprises the ^/-responsive element TAR, the primer 
binding site (PBS), the major splice donor (SD), the packaging signal (Psi or VF) and the
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Polyadenylation (polyA) signal, which is also present at the 3' end of the genome due to 
its location within the repeat (R) region. Finally, the Rev-responsive element (RRE) is 
located within the env ORF.
At the 5' and 3' ends of the genome lie the long terminal repeats (LTR) composed of a 
repeat (R) and a unique (U5 and U3, respectively) region. The unique regions are 
duplicated during reverse transcription when the RT enzyme jumps from the 5' to the 3' 
end of the genomic RNA template (see section 1.5.2).
Like the cellular messenger RNAs (mRNAs), the RNA genome and the viral mRNAs 
are capped at their 5' end and polyadenylated at their 3' end.
1.4.2 HIV proteins
•  The structural protein Gag
The Gag polyprotein is translated from the full-length unspliced genomic RNA and has 
a molecular weight (MW) of approximately 57 kilodaltons (kDa), although two other 
HIV-2 Gag isoforms translated from downstream initiation codons have been described 
(p50 and p44; Herbreteau et al., 2005).
The polyprotein is cleaved by the viral protease during particle maturation to produce 
the matrix (pl7), capsid (p26) and nucleocapsid (p7) proteins as well as the late domain 
p6 and two spacer peptides p l and p2 (see Figure 1.4). The five cleavage sites were 
found to be processed at different rates and in the following order: NC/p2 > MA/CA ~ 
p l/p 6 > NC/pl > CA/p2 (for review see Ganser-Pomillos et al., 2008 and references 
therein). The specific sequence and rate of cleavage have been shown to be important 
for particle morphogenesis and infectivity (Erickson-Viitanen et al., 1989; Pettit et al., 
1994; Tritch et al., 1991).
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Matrix
Located at the amino (N)-terminus of the Gag (p57) polyprotein, the HIV-2 matrix 
protein is 134 amino acids (aa) long, with a MW of approximately 17 kDa. A 14-carbon 
fatty acid (myristate) is cotranslationally added to a glycine at the N-terminus of MA, 
suggesting that it is associated to lipid bilayers (Jacobs et al., 1989; Rein et al., 1986). It 
was therefore suggested that matrix could play a role in targeting the Gag polyprotein to 
the plasma membrane during the assembly process and myristylation was indeed shown 
to be absolutely required for retroviral particle assembly (Bryant and Ratner, 1990; Rein 
et al., 1986; Wang and Barklis, 1993). In addition, myristylation of MA has been 
proposed to influence MA multimerisation during assembly (Bouamr et al., 2003).
MA was also reported to participate in the recruitment of the viral envelope 
glycoprotein into nascent particles (Dorfman et al., 1994b; Freed and Martin, 1995; Yu 
et al., 1992). Most of MA, apart from its carboxy (C)-terminus, was found to be 
required for Env incorporation (Dorfman et al., 1994b) and it appeared that minor 
changes in the conformation of MA were sufficient to abrogate the interaction between 
the two proteins (Yu et al., 1992). N-terminal residues of HIV-1 MA, together with 
residues at the C-terminus of the gp41 cytoplasmic tail, were shown to be involved in 
the Env-MA interaction (Freed and Martin, 1996; Murakami and Freed, 2000).
In addition to its role in particle morphogenesis, MA has been implicated in an early 
step post-infection. A small amount of mature phosphorylated HIV-2 MA can be 
detected inside the viral core (Gallay et al., 1995b) and MA was reported to associate 
with components of the pre-integration complex (PIC; Bukrinsky et al., 1993b). HIV-1 
MA was shown to promote the nuclear import of the PIC during infection of non­
dividing cells (Bukrinsky et al., 1993a). To do so, it was proposed that a tyrosine 
residue at the C-terminus of HIV-1 MA was phosphorylated by a cellular protein kinase,
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resulting in the interaction of MA with the integrase (Gallay et al., 1995a; Gallay et al., 
1995b). However, it was subsequently demonstrated that the infectivity defect of the 
MA mutants was only observed in the absence of a functional Vpr (Heinzinger et al., 
1994; von Schwedler et al., 1994). Furthermore, the MA-IN interaction was not 
confirmed (Fouchier et al., 1997) and the role of MA in early post-entry steps therefore 
remains unclear.
While MA plays a major role in particle assembly through membrane association and 
envelope incorporation, it does not appear to be involved in HIV genome encapsidation 
(Lee and Linial, 1994; Poon et al., 1998). However, in other retroviruses, MA has been 
linked with genome dimerisation and RSV MA mutants were found to display a 
dimerisation defect (Parent et al., 2000).
Capsid
CA (p26) is the most abundant protein in the virion. CA is composed of two domains; 
the N-terminal ‘core’ domain (NTD; residues 1-145), involved in virion maturation and 
cyclophilin A (cypA) binding, and the C-terminal ‘dimerisation’ domain (CTD; residues 
151-231), which functions in Gag-Gag interaction and particle assembly (reviewed by 
Freed, 1998). The C-terminal region of CA comprises a stretch of 20 conserved amino 
acids, termed the major homology region (MHR), which is essential for viral replication 
(Mammano et al., 1994).
The cellular peptidyl prolyl isomerase cyclophilin A was shown to specifically interact 
with the NTD of HIV-1 CA, and the immunosuppressive drug cyclosporine A and its 
non-immunosuppressive analogues prevented this interaction, blocking the 
incorporation of CypA into HIV-1 virions and impairing HIV-1 replication (Franke and 
Luban, 1996; Franke et al., 1994b; Gamble et al., 1996; Luban et al., 1993; Thali et al.,
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1994). CypA has also been shown to interact with the capsid of incoming virions in the 
target cells (Hatziioannou et al., 2005). The CA-CypA interaction was proposed to be 
important at an early stage of the virus life cycle (Thali et al., 1994). CypA was 
postulated to play a role in the uptake of HIV in PBMCs and T-cells (Sherry et al., 
1998) and viral cDNA synthesis was found to be reduced in the absence of CypA 
incorporation (Braaten et al., 1996). A study that analysed the effect of CypA on viral 
replication independently of cell attachment suggested that CypA plays distinct roles in 
entry and post-entry events of HIV-1 replication (Saphire et al., 2002). Since 
cyclophilins such as CypA are involved in the regulation of protein folding, 
incorporation of CypA into HIV-1 virions may be required for the uncoating of the viral 
nucleoprotein complex following viral entry. The crystal structure of the NTD of CA in 
complex with CypA revealed that CypA could weaken the association between the CA 
strips that composed the capsid lattice, therefore promoting the disassembly of the viral 
core (Gamble et al., 1996).
In addition to its role in early post-entry event, CA plays a crucial role during particle 
assembly (reviewed in Ganser-Pomillos et al., 2008). Mutations in the CA CTD were 
shown to impair viral replication and reduce particle production, suggesting that the 
CTD is required for particle assembly (Dorfman et al., 1994a; Joshi et al., 2006; Jowett 
et al., 1992; Zhang et al., 1996). Gag multimerisation was affected by CTD mutations 
(Bumiston et al., 1999; Franke et al., 1994a) and structural data supported a role in viral 
assembly (Gamble et al., 1997). Further mutational analysis of the CTD dimer interface, 
as defined by crystallography studies (Gamble et al., 1997), confirmed that CA 
dimerisation was important for particle assembly (Ganser-Pomillos et al., 2004; von 
Schwedler et al., 2003a). Mutations of the MHR also resulted in a severe defect in 
particle production (Mammano et al., 1994) and Gag multimerisation (Chang et al.,
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2007). In contrast, mutations of the NTD of CA blocked viral replication but did not 
affect particle assembly and release. Interestingly, CA NTD mutations impaired particle 
morphogenesis, especially mature capsid formation, as the virions produced contained 
circular or aberrant cores instead of cone-shaped cores (Dorfman et al., 1994a; Scholz et 
al., 2005; Tang et al., 2007; von Schwedler et al., 1998; von Schwedler et al., 2003a). 
Consequently, a model was proposed for the role of CA NTD in particle assembly (von 
Schwedler et al., 1998). Following proteolytic cleavage of the MA-CA junction, the 
NTD of CA is refolded into a beta-hairpin/helix structure, creating a new CA-CA dimer 
interface that is essential for the formation of a condensed conical core.
It has also been suggested that CA may be required for the incorporation of the Gag-Pol 
precursor into virions, a step that is necessary for the recruitment of the RT, IN and PR 
enzymes into the budding virions (Huang and Martin, 1997; Srinivasakumar et al.,
1995). In particular, the MHR and CTD of CA were found to be critical for the 
packaging of the Gag-Pol precursor, although other regions of CA are involved.
Finally, HIV-1 CA has also been implicated in RNA dimerisation (Kafaie et al., 2009). 
Disruption of helix 1, at the N-terminus of CA, was shown to trigger a dimerisation 
defect similar to that observed in protease-deficient viruses.
Nucleocapsid
NC is a small basic protein that coats the genomic RNA in virions. During proteolysis, 
HIV NC can be found in three forms, pl5, p9 and p7, which correspond to the 
precursors NC-pl-p6 , NC-pl and the mature NC, respectively. The NC domain of Gag 
p55, the proteolytic cleavage intermediates p l5  and p9, and the fully cleaved NC p7 
protein all possess nucleic acid binding activity (Berkowitz et al., 1993; Cruceanu et al., 
2006).
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NC contains two conserved cysteine-histidine boxes (C-X2-C-X4-H-X4-C; CCHC) 
called zinc fingers motifs (Covey, 1986; South et al., 1990). The CCHC motifs of 
retroviral NC proteins were found to bind zinc (Green and Berg, 1989; South et al., 
1990) and mutations that inhibited zinc binding led to the production of non-infectious 
particles (Meric and Goff, 1989; Meric et al., 1988), suggesting that the zinc binding 
domain of NC plays an important role in viral infectivity. In HIV-1, the two zinc fingers 
are not functionally equivalent. The first (N-terminal) CCHC motif was shown to be 
critical for RNA binding and encapsidation as well as viral replication, whereas the 
second CCHC motif appeared dispensable for RNA packaging (Dorfman et al., 1993; 
Gorelick et al., 1993; Schwartz et al., 1997). The context of the zinc finger also 
appeared to be important as inverting the position of the two motifs led to a strong 
defect. The situation is different in HIV-2, where both CCHC motifs are required for 
RNA binding (Matsui et al., 2009).
NC is involved in many crucial steps of the virus life cycle (reviewed by Thomas and 
Gorelick, 2008). For example, NC is a key element in the selection of the genomic RNA 
during packaging and it facilitates the stabilisation of the genomic RNA dimer during 
particle maturation, as described in sections 1.6.3 and 1.7.2 respectively. In addition, 
many mutations in NC result in defects in virus assembly and release (Dorfman et al., 
1993; Grigorov et al., 2007; Poon et al., 1996), suggesting that NC plays a role in 
particle assembly, and it has been proposed that NC participates in Gag multimerisation 
(Bumiston et al., 1999; Cimarelli et al., 2000; Franke et al., 1994a). Finally, NC has 
been shown to promote the placement of the tRNA^ 5 primer onto the PBS (Feng et al., 
1999; Hargittai et al., 2004; Huang et al., 1998; Prats et al., 1988) and to be required for 
efficient reverse transcription and integration of the PIC into the genome of the host cell 
(Thomas and Gorelick, 2008). For example, NC has been implicated in the initiation of
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the minus-strand synthesis from the tRNA^5 (Li et al., 1996), strand transfer and 
specific plus-strand priming (Guo et al., 1997; Post et al., 2009).
The late domain p6
As its name suggests, the late domain p6 plays a major role late in the virus life cycle by 
allowing the release of the budding particles from the infected cells in a membrane 
fission event (reviewed in Freed, 1998; Fujii et al., 2007; Gottlinger, 2001; Martin- 
Serrano, 2007). Indeed, HIV-1 p6 mutant viruses appear to be tethered to the plasma 
membrane and therefore accumulate at the cell surface (Gottlinger et al., 1991). The 
release function of p6 is mediated by a PTAP amino acid motif, conserved amongst 
lentiviruses (Gottlinger et al., 1991; Huang et al., 1995), or a conserved PPxY motif in 
the case of the late ‘L’ domain of oncoretroviruses such as RSV (Wills et al., 1994). In 
HIV, p6 mediates the release of the nascent virions by interacting with components of 
the ESCRT (endosomal sorting complexes required for transport) machinery (see Fujii 
et al., 2007; and Martin-Serrano, 2007 for review). In particular, the ESCRT-I 
component TsglOl (tumor susceptibility gene 101) has been shown to interact with the 
PTAP motif of HIV-1 p6 , promoting HIV-1 release (Garrus et al., 2001; Martin-Serrano 
et al., 2001). In addition, HIV-1 p6 and ELAV p9 interact with a cellular protein called 
AIPl/Alix (ALG-2-interacting protein 1) through a conserved YPxnL motif (Strack et 
al., 2003).
In addition to its role in particle release, the p6 late domain was shown to promote the 
encapsidation of Vpr in viral particles, mainly through the binding of Vpr to a 
conserved (Lxx)4 sequence (Jenkins et al., 2001; Kondo and Gottlinger, 1996; Lu et al., 
1995; Paxton et al., 1993) and an FxFG motif (Zhu et al., 2004).
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• The polymerase and protease
The viral protease and polymerase are translated as part of the Gag-Pol precursor from 
the unspliced genomic RNA following a -1 frameshifting event during Gag translation 
(Jacks et al., 1988). Ribosomal frameshifting occurs at the site of a slippery sequence 
followed by a hairpin structure. The role of the latter is thought to be to slow the 
ribosome down and allow the -1 frameshift (reviewed in Brierley and Dos Ramos,
2006). A 7 nt spacer is located between the slippery sequence and the hairpin structure 
of HIV-1 but is absent in HIV-2. In HIV-1, the ratio of Gag/Gag-Pol is 20:1, 
corresponding to a frameshifting efficiency of 5 %, and has been shown to be critical for 
viral infectivity, genome dimerisation and particle assembly (Karacostas et al., 1993; 
Shehu-Xhilaga et al., 2001a).
The Gag-Pol precursor is processed by the viral protease PR into MA, CA, p2, NC, p6 * 
(a modified p6 due to the frameshift), PR (plO), RT (p51 and p66) and IN (p32), as 
depicted in Figure 1.4. The RT enzyme comprises an RNA-dependent DNA polymerase 
and an RNase H activity and accomplishes the reverse transcription of the RNA genome 
into the proviral cDNA. Finally, the integrase triggers the integration of the proviral 
cDNA into the genome of the host cell.
•  The envelope glycoprotein
The HIV-2 envelope glycoprotein is translated from a singly spliced mRNA of 
approximately 4.3 kb. The Env precursor (gpl40) is cleaved by a cellular protease into 
two subunits, the surface glycoprotein gpl25 and the transmembrane glycoprotein gp36 
and contains a leader (L) signal at its N-terminus (see Figure 1.4). Env mediates viral 
entry by binding of gpl25 to the CD4 receptor and CC-chemokine receptor 5 (CCR5) or
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CXC-chemokine receptor 4 (CXCR4) co-receptor. The viral envelope subsequently 
fused with the plasma membrane due to the fusogenic activity of gp36.
The HIV-2 Env is also involved in the release of HIV-2 particles from infected cells, an 
activity that has been named enhancement of virus release (Bour et al., 2003; Bour et 
al., 1996; Ritter et al., 1996). This function of HIV-2 Env mimics the activity of Vpu in 
HIV-1, which was also shown to enhance virus release in a cell-type dependent manner 
(Strebel et al., 1989; Terwilliger et al., 1989), and is assumed by two distinct motifs 
located in the cytoplasmic tail and the ectodomain of Env (Abada et al., 2005). It was 
suggested that a cellular factor was involved in the inhibition of HIV-1 release and that 
Vpu blocked this antiviral activity (Neil et al., 2007). Indeed, HIV-1 was shown to be 
restricted by a host protein termed tetherin/Bst-2, which prevents the release of budding 
virions from the plasma membrane of infected cells (Neil et al., 2008; Van Damme et 
al., 2008). In HIV-1, the accessory protein Vpu counteracts the antiviral activity of 
tetherin and enhances particle release. In HIV-2, this function is assumed by the Env 
glycoprotein, using a mechanism as yet unknown but likely to involved a cellular co­
factor (Stuart Neil, personal communication), even though there have been some 
evidence that HIV-2 Env is able to down-regulate surface expression of Bst-2 (John 
Guatelli, personal communication) and to re-localise Bst-2 to a cytoplasmic 
compartment (Paula Cannon, personal communication).
•  Accessory proteins
HIV-1 and -2 both encode six accessory proteins. Tat, Rev and Nef are translated from 
multiply spliced viral mRNAs of approximately 2 kb, while Vif, Vpu/Vpx and Vpr are 
synthesised from singly spliced mRNAs of approximately 4 kb.
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Fully spliced mRNA transcripts can be exported out of the nucleus by the cellular 
machinery and are therefore translated relatively early in the virus life cycle. On the 
other hand, the nuclear export of singly spliced mRNAs, similarly to that of the 
unspliced genomic RNA, is inhibited by the host cell machinery in charge of preventing 
the export and translation of incompletely spliced cellular mRNAs. As a result, HIV-1 
and HIV-2 have developed an independent way to export intron-containing mRNAs, 
using the Rev protein (Cullen, 1998; Malim et al., 1989a; Malim et al., 1989b). Because 
it contains both a nuclear localisation and a nuclear export signal (NLS and NES, 
respectively), Rev is able to shuttle in and out of the nucleus and triggers the nuclear 
export of incompletely spliced viral RNAs by binding to an RNA target located in the 
env ORF, the Rev-responsive element or RRE (Malim and Cullen, 1991; Malim et al., 
1990; Tiley et al., 1992). To mediate nuclear export, Rev interacts with the cellular 
Crml (chromosome region maintenance 1) protein, a nucleocytoplasmic shuttle protein 
which is able to interact with the Rev NES and cellular nucleoporins (Bogerd et al., 
1998). Interestingly, the ATP-dependent DEAD box RNA helicase DDX3 was shown to 
be required for the Crml/Rev-mediated nuclear export activity (Y edavalli et al., 2004). 
In addition to its crucial role in the regulation of viral protein expression, Rev has been 
proposed to affect RNA packaging and protein translation in HIV-1 (reviewed in Groom 
et al., 2009).
Tat is a toms-activator of HIV-1 and HIV-2 LTR-driven gene expression (Cullen, 1986; 
Dayton et al., 1986; Guyader et al., 1987), which regulates the transcription of the 
provirus by binding to the /raws-activation responsive element TAR located downstream 
of the promoter region, in the 5' leader RNA (Fenrick et al., 1989; Jakobovits et al., 
1988). The structure of TAR, and in particular the presence of an exposed loop and a 
side bulge, were shown to be important for /raws-activation (Berkhout et al., 1990;
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Berkhout and Jeang, 1989; Feng and Holland, 1988). Tat-mediated /ra/w-activation of 
HIV gene expression was suggested to involve the phosphorylation of the RNA 
polymerase II (Pol II) CTD. It has been demonstrated that Tat forms a complex with a 
cellular protein termed cyclin T1 and that this Tat-cyclin T complex binds to the TAR 
stem-loop with high affinity. Tat was also shown to immunoprecipitate with a cyclin- 
dependent kinase, CDK9 (Zhu et al., 1997), which appears to be recruited by cyclin T1 
(Wei et al., 1998). CDK9 and cyclin T1 form the positive transcription elongation factor 
b (P-TEFb). Recruitment of CDK9 leads to the phosphorylation of Pol II CTD and 
enhancement of its processivity (reviewed by Cullen, 1998).
The negative factor Nef, which plays a major role in immune evasion and HIV 
pathogenesis, exerts several functions during HIV infection (for review, see Cullen, 
1998; Fackler et al., 2007; Malim and Emerman, 2008). Nef is responsible for the 
down-regulation of cell surface CD4 (Aiken et al., 1994) and MHC class I (Le Gall et 
al., 1998), resulting in the inhibition of antigen presentation to CTL and a decrease of 
CTL-mediated cell lysis (Collins et al., 1998). Nef expression was also shown to disturb 
several signalling and trafficking pathways (Roeth and Collins, 2006). Finally, N ef was 
shown to play a key role in T-cell activation. In most lentiviruses, Nef inhibits T-cell 
activation; however, this function was lost in the lineage that gave rise to HIV-1 
(Schindler et al., 2006), contributing to the increased pathogenesis of HIV-1 compared 
to HIV-2 or SIV. Indeed, Nef has the ability to slow down the internalisation and 
recycling of TCR-CD3 complexes, impairing their accumulation at the immunological 
synapse - site of antigen-presentation and T-cell activation - and therefore reducing T- 
cell activation (reviewed by Fackler et al., 2007). However, Nef proteins from 
‘pathogenic’ viruses such as HIV-1 do not down-regulate cell surface levels of CD3, 
resulting in an increased activation sensitivity of T-cells and cell death (Schindler et al.,
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2006). Some exceptions to this pattern exist as HIV-2 and SIV mac Nef induce the 
decrease of CD3 at the cell surface despite these viruses being pathogenic (Fackler et 
al., 2007).
The main role of HIV Vif is to block the antiviral activity of human APOBEC3G and 
APOBEC3F (Malim and Emerman, 2008). APOBEC3G is a cellular cytidine deaminase 
expressed in cell lines such as H9 and CEM (non-permissive to HIV infection), which 
inhibits HIV replication using cytidine deaminase-dependent and -independent 
mechanisms (Bishop et al., 2008; Holmes et al., 2007; Sheehy et al., 2002). HIV Vif 
prevents the incorporation of APOBEC3G into nascent particles and targets 
APOBEC3G to the proteasome where it is degraded (Sheehy et al., 2003).
Vpr is packaged into HIV virions due to its interaction with the p6 domain of Gag 
(Cullen, 1998). Vpr contains a NLS and is involved in the nuclear import of the PIC, 
particularly in non-dividing cells (Heinzinger et al., 1994). In addition, Vpr has been 
shown to be cytopathic for cells and to delay or block the G2 to mitosis transition of the 
cell cycle (Malim and Emerman, 2008). Vpr was found to interact with DCAF1 (DDB1- 
Cul4A-associated factor), which is a receptor of the Cul4A (cullin 4A)-DDB1 
(damaged-DNA-specific binding protein 1) ubiquitin (Ub) ligase (Le Rouzic et al.,
2007), and this interaction appeared critical for its ability to arrest the cell cycle in G2 
(Dehart and Planelles, 2008).
In HIV-1, Vpr also facilitates infection of macrophages, a function assumed by the Vpx 
protein in HIV-2 and SIV sm- Indeed, HIV-2 and SIV sm infection of macrophages or 
monocyte-derived DCs is dependent upon Vpx expression (Goujon et al., 2007; Sharova 
et al., 2008), suggesting that Vpx helps overcome a (yet unknown) restriction 
mechanism in macrophages. Interestingly, Vpx interacts with the same cul4A-DDBl-
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DCAF1 complex as Vpr (Le Rouzic et al., 2007), possibly targeting that unknown 
restriction factor to the proteasome for degradation.
1.5 The HIV life cycle
Many aspects of the life cycle of HIV-2 are similar to that of HIV-1. An overview is 
presented in Figure 1.6.
1.5.1 Receptor binding and entry
HIV-1 enters the target cell through the binding of its surface Envelope glycoprotein 
(gpl20) to the CD4 cell surface marker (Dalgleish et al., 1984). Binding to a co-receptor 
is also required and CCR5 and CXCR4, two proteins from the family of seven- 
transmembrane-domain G-protein-coupled receptors, were identified as HIV-1 co­
receptors (Deng et al., 1996; Dragic et al., 1996; Feng et al., 1996a). Macrophage-tropic 
HIV strains use CCR5, whereas T-cell-tropic strains of HIV use CXCR4. This 
difference in co-receptor usage explains the resistance of certain high risk populations to 
HIV-1, as it was found that those individuals lack CCR5 (Liu et al., 1996; Samson et al.,
1996).
Unlike HIV-1, primary isolates of HIV-2 have been shown to use a wide range of co­
receptors, including CCR1, CCR2b, CCR3, CCR4, CCR5, and CXCR4 (McKnight et 
al., 1998). In addition, HIV-2 differs slightly from HIV-1 in that it can enter the cell in a 
CD4-independent manner, using CXCR4 as a main receptor (Endres et al., 1996; 
Reeves et al., 1997).
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Figure 1.6: The HIV-2 life cycle.
Abbreviations are as defined in the text. Figure courtesy of S.D. Griffin.
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HIV entry occurs through the binding of a gp 125 trimer to CD4 followed by fusion of 
the viral envelope to the plasma membrane.
In addition to the virus-cell interaction-mediated entry, HIV is efficiently transmitted 
from cell to cell, using the virological synapse formed upon contact between an infected 
and an uninfected cell (Hubner et al., 2009). It is believed that cell-cell HIV 
transmission is more efficient than virus-cell transmission, probably because it protects 
the virus from the immune system (Martin and Sattentau, 2009).
1.5.2 Reverse transcription
Following the release of the capsid into the cytoplasm of the cell, the viral genome is 
stripped of its CA and MA layers in a process known as uncoating. As discussed in 
section 1.4.2, CypA is thought to play a role in uncoating the viral genome. The remains 
of the viral core, a nucleoprotein complex composed of the RNA genome associated 
with RT, IN, Vpr and Vpx, a few MA molecules as well as a small amount of CA and 
NC, constitutes the pre-integration complex or PIC (Fouchier and Malim, 1999), which 
protects the viral RNA and proviral DNA from nucleases (Tanchou et al., 1995) and 
constitutes the site of the reverse transcription. The RT enzyme and tRNA7^ 5 primer are 
provided by the incoming virion. A schematic of reverse transcription is presented in 
Figure 1.7.
Reverse transcription takes place in the cytoplasm of the cell and starts with the 
synthesis of the minus strand (-) strong stop (ss) cDNA from the tRNA primer (Figure 
1.7, step 1). Once the RT enzyme reaches the 5' end of the genome, its RNase H activity 
triggers the degradation of the RNA in the RNA-DNA duplex, i.e. RNA sequences from 
the 5' end to the PBS (step 2).
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The (-) ssDNA is then transferred to the 3' end of the genome, where its R region 
anneals to the complementary R sequence on the viral RNA (step 3). This first strand 
transfer may be inter- or intra-molecular (van Wamel and Berkhout, 1998), which 
allows the virus to recombine during reverse transcription (Hu and Temin, 1990b). The 
(-) ssDNA is elongated from the R region to the PBS (step 4) and the RNA template 
from the RNA-DNA is degraded (step 5), with the exception of two RNase-resistant 
regions, the central and 3' polypurine tracts (cPPT and PPT respectively) which serve as 
primer for the positive (+) strand DNA synthesis. Following the initiation of (+) strand 
DNA synthesis from the two polypurine tracts (step 6), the tRNA primer is degraded 
(step 7) and the 3' extremity of the (+) strand DNA jumps to the 5' end of the (-) strand 
DNA and anneals to the 5' copy of the PBS (second strand transfer, step 8). Finally, the 
(+) and (-) strand DNAs synthesis is completed (step 9), creating a central flap on the 
(+) strand DNA at the site of the cPPT that is subsequently removed (step 10). The 
proviral DNA now contains a copy of the U3-R-U5 region, forming the LTR, at each 
extremity of the genome. During or after reverse transcription, the PIC is transported 
into the nucleus of the cell, through interaction of the NLS of certain PIC components 
with the nuclear pores complex. Nuclear import of the PIC is thought to be mediated 
mainly by the Vpr protein for HIV-1 (Mahalingam et al., 1997) and the Vpx protein for 
HIV-2 during infection of non-dividing cells (Fletcher et al., 1996; Mueller et al., 2004; 
Pancio et al., 2000).
1.5.3 Integration
Once the PIC has been imported in the nucleus, the proviral DNA can integrate into the 
genome of the host cell, a step that is necessary for a productive HIV infection.
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Integration occurs in three steps (reviewed in Delelis et al., 2008; Vandegraaff and 
Engelman, 2007). First, an IN tetramer binds to the LTRs on the linear proviral DNA 
and catalyses the 3' endonucleotide cleavage of a dinucleotide, known as 3' processing, 
generating 3'-hydroxyl groups and 5' overhangs. The cleaved DNA is then integrated 
into weakly conserved palindromic sequence on the host chromosome by a DNA strand- 
transfer reaction catalysed by the integrase. The 3'-hydroxyl groups is used by IN to cut 
the 5 base pairs (bp) target and the 3' viral ends are joined to the 5'-phosphate of the cut, 
creating a DNA recombination intermediate with joined viral 3' ends and free 5' ends. 
Finally, DNA repair of the DNA recombination intermediate yields a 5 bp duplication 
of the target DNA flanking the integrated provirus.
Integration of HIV-1 and HIV-2 has been shown to occur preferentially in 
transcriptionally active sites of the host genome, with high gene density and high GC 
content (MacNeil et al., 2006; Mitchell et al., 2004; Schroder et al., 2002). Interestingly, 
the rate of integration into heterochromatin, which results in a block of viral replication, 
was found to be higher in HIV-2 compared to HIV-1 infected individuals (MacNeil et 
al., 2006), possibly contributing to the lower pathogenicity of HIV-2.
For HIV-1, the preferential integration in transcription units was found to be lost in cells 
depleted of a cellular protein called lens epithelium-derived growth factor p75 or 
LEDGF/p75 (reviewed by Engelman and Cherepanov, 2008). LEDGF/p75 is a cellular 
co-factor of lentiviral integrases and has been shown to stimulate the binding of the 
integrase to the chromatin (Busschots et al., 2005).
The integrated provirus may remain latent or is transcribed by the cellular machinery as 
described below. Latency is an important aspect of HIV pathogenesis that is affected by 
the site of integration and cis- and trans-acting factors (Han et al., 2007; Lassen et al., 
2004; Marcello, 2006). Although reactivation of the HIV genome remains poorly
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understood, it is believed that several factors such as T-cell activation and nuclear factor 
kappa B (NF-kB) are involved (Mok and Lever, 2008).
1.5.4 Synthesis and processing of viral RNAs
Viral mRNA transcripts are synthesised by the cellular machinery, namely the RNA 
polymerase II. The U3 region of the 5' LTR constitutes the promoter region and as such 
binds a series of factors that regulate transcription (Kingsman and Kingsman, 1996). For 
example, two binding sites for NF-kB are present in a region called the transcriptional 
enhancer. Binding of the transcription factors TFIID (a complex of TATA-binding 
protein [TBP] and TBP-associated factor [TAF]) and SP1 also results in a stimulation of 
HIV transcription. On the other hand, NFAT-1 (nuclear factor of activated T-cells 1) 
and USF (upstream stimulatory factor) recognise sequences located in the cA-acting 
negative regulatory element and inhibit HIV transcription.
As described in section 1.4.2, the viral protein Tat also plays an important role in 
stimulating HIV gene expression. To do so, Tat binds to the TAR stem-loop in the R 
region of the 5' LTR, recruits the two components of the protein kinase P-TEFb, cyclin 
T1 and CDK9, thereby promoting the phosphorylation of Pol II CTD and enhancing its 
processivity. It was shown that recruitment of the P-TEFb kinase to the promoter region 
was the sole role of the Tat-TAR interaction as artificial recruitment of P-TEFb was 
both necessary and sufficient to activate LTR-driven gene expression in the absence of 
Tat and TAR (Bieniasz et al., 1999).
Following transcription, viral mRNAs encoding for Tat, Rev and Nef are fully spliced 
and exported out of the nucleus by the cellular machinery. The situation is slightly more 
complex for other viral mRNAs such as Env mRNA and the genomic RNA, which are 
incompletely spliced but still need to be exported to the cytoplasm for Env, Gag and
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Gag-Pol expression as well as genome encapsidation. Intron-containing RNAs remain 
in the nucleus where they are normally targeted for degradation. However, the Rev 
protein ensures the nuclear export and expression of incompletely spliced mRNAs, as 
detailed in section 1.4.2.
1.5.5 Synthesis and processing of viral proteins
Once in the cytoplasm of the cell, viral mRNAs are transported either to the free 
polyribosomes or to the rough endoplasmic reticulum (RER) to be translated by the 
cellular machinery (Coffin et al., 1997).
•  Translation o f the Envelope glycoprotein
Cap-dependent translation of Env starts on free ribosomes and shortly thereafter the 
leader (L) peptide emerges. This hydrophobic peptide is recognised by the signal 
recognition particle (SRP), which docks onto the membrane of the RER, and is inserted 
into the lipid bilayer. The Env protein is cotranslationally translocated across the RER 
membrane, where two modifications occur. First, the L peptide is proteolytically 
removed by a cellular signal peptidase and second, the protein is glycosylated. The 
synthesis of the hydrophobic cytoplasmic tail prevents the release of Env into the lumen 
of the RER and secretion from the cell, allowing the protein to be correctly folded and 
assembled into trimers prior to transport to the plasma membrane. The folded protein is 
able to interact with its receptor, CD4, and the Vpu protein of HIV-1 is known to 
degrade CD4 to prevent early interaction events (Willey et al., 1992). In HIV-2, gpl40 
itself and Nef were proposed to limit premature contact between Env and CD4 by 
targeting CD4 for degradation (Cucchiarini et al., 1995; Lindwasser et al., 2007),
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although the role of gpl40 on CD4 destabilisation was not confirmed (Bour and Strebel, 
1996). Env is trafficked to the cell surface through the Golgi network and the secretory 
pathway, and is subjected to further post-translational modifications during this process.
•  Translation o f the Gag and Gag-Polprecursors
The Gag and Gag-Pol polyproteins are translated from the unspliced genomic RNA on 
free polysomes in the cytosol of the cell. To date, there is still controversy as to which 
translation initiation mechanism is used to produce these proteins. While some studies 
have proposed that Gag and Gag-Pol translation is cap-dependent and occur through 
ribosome scanning of the 5' UTR, there is evidence suggesting that Gag translation is 
governed by an internal ribosome entry site (IRES) activity (Yilmaz et al., 2006). In 
particular, the regulatory elements present in the 5' UTR of many lentiviruses constitute 
strong structural barriers for the ribosome to overcome, for which a cap-independent 
translation mechanism would provide an interesting alternative. In both HIV-1 and 
HIV-2, IRES have been identified within the gag coding sequence (Buck et al., 2001; 
Herbreteau et al., 2005). In addition, Brasey and co-workers identified an IRES in the 
HIV-1 5' UTR that was active during the G2/M phase (Brasey et al., 2003), when the 
efficiency of cap-dependent translation is reduced. However, two other studies showed 
that the HIV-1 5' UTR inhibited translation of a gag reporter construct, suggesting that 
it did not contain an IRES (Buck et al., 2001; Miele et al., 1996). As a result, it has been 
proposed that HIV-1 uses both cap-dependent and -independent initiation mechanisms, 
ensuring optimal Gag production in response to changes in the cellular environment and 
progression of HIV infection (Yilmaz et al., 2006). However, it is not clear whether a 
similar coordinate use of ribosome scanning and IRES activity exists in HIV-2. Three 
IRES have been identified in the gag coding region, which direct the translation of three
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Gag isoforms, p57, p50 and p44 (Herbreteau et al., 2005), and it was proposed that high 
concentrations of Gag could inhibit the IRES-mediated translation of p57 Gag by 
binding to the HIV-2 5' UTR (Ricci et al., 2008). Interestingly, self-regulation of its 
own translation by the Gag protein has been observed with HIV-1 (Anderson and Lever, 
2006). In this case, low concentrations of Gag resulted in a stimulation of translation, 
mediated by the MA domain of Gag, and high Gag concentrations triggered an 
inhibition of Gag translation that was dependent on the binding of NC to the packaging 
signal. These observations, together with the lack of separate ‘translation’ and 
‘packaging’ pools of HIV-1 and HIV-2 genomic RNA (Dorman and Lever, 2000), 
suggest that there is a competition between HIV translation and packaging in order to 
achieve the correct balance between production of the structural protein Gag and 
assembly of new particles.
Gag is modified cotranslationally at its N-terminus by the addition of a myristate on the 
first glycine residue, which is critical for the membrane targeting of Matrix. In addition, 
the matrix domain of Gag is phosphorylated, a modification that is thought to reveal the 
NLS in MA and to play a role in the PIC nuclear import (Bukrinsky et al., 1993a; von 
Schwedler et al., 1994).
The Gag-Pol polyprotein is synthesised following a -1 ribosomal frameshifting event, as 
described in section 1.4.2.
•  Proteolytic processing
The Env precursor gpl40 is cleaved by a cellular protease into gpl25 and gp36. Gag 
and Gag-Pol polyproteins are cleaved after particle assembly, during the maturation of 
the virion, by the virally encoded protease, providing the structural proteins MA, CA 
and NC, p i, p2 and p6, which functions have been detailed in section 1.4.2.
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1.5.6 Assembly, release and virion maturation
For assembly to occur, all components of the viral particle must reach the site of 
assembly, i.e. traffic to the plasma membrane. While Env seems to traffic with the 
secreted cellular proteins through the Golgi network and ER, it is not clear which 
pathway the genomic RNA and Gag polyprotein utilise to reach the site of particle 
assembly, and whether these traffic together as a complex or are targeted independently 
of each other (Klein et al., 2007; Swanson and Malim, 2006).
•  Intracellular trafficking o f HIV Gag
Due to the presence of a myristate at its N-terminus, the Matrix protein has been 
suggested to play a role in targeting Gag to the plasma membrane. Binding of MA to the 
plasma membrane has been shown to require both the myristylation of the N-terminus 
and downstream basic residues (Ono and Freed, 1999; Paillart and Gottlinger, 1999; 
Spearman et al., 1994; Zhou et al., 1994) and is determined by the degree of exposure of 
the myristate moiety, which would be high in the context of the Gag polyprotein and 
low in the case of the mature MA protein, as described in the myristyl switch model 
(reviewed in Freed, 1998; Gottlinger, 2001). This model is supported by a nuclear 
magnetic resonance (NMR) structural analysis of HIV-1 MA that showed that the 
myristate is sequestered in the context of MA, which is mainly monomeric, and exposed 
in MA-CA polypeptides, which can trimerise (Tang et al., 2004).
Several studies that used confocal microscopy and FRET (fluorescence resonance 
energy transfer) have shown that the endosomal pathway was implicated in HIV Gag 
trafficking to the plasma membrane (Nydegger et al., 2003; Perlman and Resh, 2006). 
Some reports also proposed that the late endosomal compartment or multivesicular
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bodies (MVBs) were the site of HIV-1 assembly in certain cell-types such as 
macrophages (Nydegger et al., 2003; Ono and Freed, 2004; Pelchen-Matthews et al., 
2003; Raposo et al., 2002; Sherer et al., 2003). Recently, it was shown that, under 
certain circumstances, MVBs could support the productive assembly of an HIV-1 
16EK/29/31KE MA mutant in macrophages and T-cells (Joshi et al., 2009). However, 
whether HIV assembly occurs in MVBs remains a controversial subject, as it was 
shown that HIV Gag does not interact with cellular markers of MVBs such as CD63 
(Gomez and Hope, 2006). Several studies have reported that endocytosis and re- 
intemalisation account for the endosomal localisation of Gag and that plasma membrane 
is the primary site of assembly (Finzi et al., 2007; Jouvenet et al., 2006). In particular, 
Jouvenet and co-workers demonstrated that (i) Gag localisation at the plasma membrane 
preceded its endosomal accumulation in several cell lines including primary 
macrophages, (ii) microtubule or endosome motility was not required for HIV-1 
assembly in macrophages and (iii) particles were not released when assembly was 
targeted to endosomal compartments. A recent study analysing the assembly of 
individual HIV-1 virions in live cells supports this model and confirmed that the plasma 
membrane is the primary site of HIV-1 assembly (Jouvenet et al., 2008). Further studies 
have also suggested that HIV assembly in macrophages does indeed occur at the plasma 
membrane. In their report, Deneka et al. proposed that HIV-1 assembles into an 
intracellular plasma membrane domain, containing the tetraspanins CD81, CD9 and 
CD53, that is distinct from endosomes (Deneka et al., 2007). Interestingly, these results 
were corroborated by the analysis of HIV trafficking in monocyte-derived macrophages 
using a biarsenical labelling system (Gousset et al., 2008). A combination of plasma 
membrane and apparently internal Gag staining was observed, the latter moving to the 
site of synapse formation after cell-cell contact with an uninfected T-cell. This suggests
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that the tetraspanin-rich intracellular compartment might serve as a reservoir for rapid 
presentation of virus at cell-cell junctions.
Supporting this model further, the analysis of the cellular localisation of ESCRT 
components in infected and uninfected T-cells and macrophages revealed that only 3 % 
of total ESCRT staining localised with the MVBs (Welsch et al., 2006). Mostly, 
components of the ESCRT machinery were found on tubular-vesicular endosomal 
membranes. The ESCRT labelling on endosomes was twice as concentrated in 
macrophages compared to T-cells, while labelling was twice more abundant at the 
plasma membrane of T-cells, possibly explaining early suggestions that HIV-1 can 
assemble in late endosomes in macrophages.
•  Host factors involved in HIV Gag trafficking
Several host factors have been linked with Gag intracellular trafficking. Cholesterol was 
shown to be important for Gag mobility in cells (Gomez and Hope, 2006) and 
Phosphatidylinositol-(4,5)-biphosphate [PI(4,5)P2], a member of the phosphoinositide 
family of lipids which participates in directing cellular proteins to the plasma membrane 
(McLaughlin and Murray, 2005), was also found to play an important role in directing 
Gag to the plasma membrane (Ono et al., 2004). Interestingly, structural studies have 
demonstrated that PI(4,5)P2 binds to the myristylated matrix domain of HIV-1 Gag, 
inducing a conformational change and triggering the exposure of the myristate moiety 
(Saad et al., 2006). This event, called the myristyl switch, has been shown to be critical 
for the anchoring of MA into lipid bilayers, as discussed above. The role of PI(4,5)P2 in 
providing an anchor for Gag in the plasma membrane and triggering the myristyl switch 
helps provide an explanation for the observation that depletion of PI(4,5)P2 induces the 
relocalisation of HIV-1 assembly to MVBs (Ono et al., 2004).
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It has also been suggested that the cytoskeleton is used and HIV-1 Gag was shown to 
interact with the suppressor of cytokine signalling 1 (Ryo et al., 2008), resulting in an 
increased level of microtubule-associated Gag (Nishi et al., 2009). Furthermore, 
depletion of the kinesin family member 4 (KIF4), a microtubule-stimulated ATPase, 
resulted in an accumulation of Gag in perinuclear clusters, an increased Gag 
degradation and an inhibition of VLP production (Martinez et al., 2008).
HIV-1 MA has been shown to interact with the 5 subunit of the clathrin adaptor protein 
(AP)-3 complex (Dong et al., 2005), which is involved in the endocytic pathway. 
Depletion of AP-3 decreases particle release and alters Gag trafficking pattern. The 
ESCRT-I component TsglOl, which interacts with Gag via the late domain p6, has also 
been found to control HIV-1 Gag trafficking to the plasma membrane (Goff et al., 
2003), with both the p6- and Ub-binding motifs of TsglOl being required for this 
function.
The ADP ribosylation factor (Arf) and Golgi-localised y-ear containing Arf-binding 
(GGA) proteins were also shown to be involved in Gag trafficking and particle release 
(Joshi et al., 2008). GGA overexpression disrupted Arf activity, resulting in the 
inhibition of particle production due to the decreased Gag-membrane binding and the 
sequestering of Gag in intracellular compartments. This altered Gag trafficking was 
associated with a reduction in retrovirus particle production. These data suggest that 
GGA acts as a modulator of HIV-1 release and Arf as a critical cellular cofactor in 
retroviral Gag trafficking to the plasma membrane.
Finally, the ATP-binding cassette protein from the E subfamily, ABCE1, was also 
implicated in particle assembly but its exact role remains unclear (Zimmerman et al., 
2002).
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• Trafficking o f the genomic RNA to the plasma membrane
Several studies have tried to determine whether the RNA and Gag traffic independently 
or together to the plasma membrane. Using confocal microscopy and FRET, Poole and 
co-workers identified that HIV-1 Gag and genomic RNA interacted at a perinuclear 
localisation, suggesting that pericentriolar region might be the site at which HIV-1 Gag 
selectively associates with the genomic RNA (Poole et al., 2005). However, these 
results were obtained following overexpression and have not been observed by others. 
Nonetheless, the pericentriolar region has been shown to be the site of MPMV Gag 
accumulation and immature capsid assembly (Sfakianos et al., 2003), and depletion of 
the heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2) trafficking factor, which 
has been implicated in HIV-1 RNA trafficking due to homology between the nucleotide 
sequence of the MHR in Gag and the hnRNP A2 response element (Mouland et al., 
2001), resulted in a similar pericentriolar accumulation of HIV-1 RNA (Levesque et al., 
2006). Finally, the dsRNA-binding protein Staufen, which has been proposed to play a 
role in HIV-1 RNA encapsidation (Mouland et al., 2000), may take part in genomic 
RNA trafficking since human Staufen is involved in mRNA transport and contains a 
tubulin-binding domain (Wickham et al., 1999).
To date, there is no evidence to support the idea that HIV genomic RNA traffics to the 
plasma membrane independently of Gag (reviewed in Swanson and Malim, 2006). 
Interestingly, it has been proposed that for MLV, pre-budding complexes containing 
Env, Gag and the genomic RNA were formed on endosomes and subsequently 
transported to the plasma membrane (Basyuk et al., 2003). One could envisage a similar 
pattern in HIV involving Gag, Env and the genomic RNA trafficking via the endocytic 
pathway (Murakami, 2008).
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• Genome encapsidation and dimerisation
RNA packaging or encapsidation is the specific capture of the genomic RNA by the 
structural protein Gag amongst the vast excess of cellular mRNAs and spliced viral 
RNA species. To achieve this specificity, the NC domain of Gag recognises a highly 
structural motif in the 5' UTR of the unspliced RNA, termed the packaging signal or Psi 
OF), and targets RNA incorporation into nascent virions. The detailed process of 
genome packaging in lentiviruses will be described in section 1.6.
A unique feature of retroviruses is that each particle contains two copies of the RNA 
genome. Early studies of type C retroviruses revealed that the two copies of the genome 
were non-covalently linked at their 5' extremity, in a region termed the dimer linkage 
site or DLS (Bender et al., 1978; Bender and Davidson, 1976; Kung et al., 1976). 
Dimerisation is believed to occur in stages, with the first interaction occurring through 
Watson-Crick and non canonical bonds between partial or complete complementary 
palindromic sequences (for review see Paillart et al., 2004b). The process of genome 
dimerisation will be the subject of a more detailed introduction in section 1.7.
To date, it remains unknown whether the dimerisation of the genomic RNA occurs prior 
to or after particle release. In either case, two copies of the RNA have to be selectively 
encapsidated by the Gag polyprotein.
•  Recruitment o f the retroviral Envelope
As mentioned previously, Env traffics to the plasma membrane via the Golgi/ER and is 
then recruited to the site of viral budding by a mechanism that remains poorly 
understood. A model has been proposed in which Gag indirectly interacts with Env via 
a cellular intermediate, tail-interacting protein of 47 kDa or TIP47 (Lopez-Verges et al.,
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2006). TTP47 has been proposed to act as a bridge between HIV-1 Env and MA and 
disruption of the MA-TIP47 interaction or depletion of TIP47 was reported to abrogate 
Env incorporation and decrease viral infectivity (Lopez-Verges et al., 2006).
Analysis of the envelope-pseudotyping phenomenon, by which a vims can incorporate 
an exogenous Env, also suggests that Env recruitment is not a random mechanism, as 
co-expression of HIV-1 Gag and MLV Env results in a patchy Env staining as opposed 
to a diffuse staining when Env is expressed alone (Jorgenson et al., 2009). It was 
hypothesised that viral budding creates a unique lipid environment that would recmit 
the mature, i.e. cleaved, Env protein.
•  Particle assembly and release
Once all the elements have reached the correct site of assembly, retroviral particles can 
assemble. The composition of a typical retroviral particle is approximately as follow: 
Gag accounts for 47 %, lipids for 30 % and the genome for 2.2 % of the particle mass 
(Krausslich, 2008). The rest of the particle mass is accounted for by the viral (e.g. Env, 
IN, RT, Vpr) and cellular proteins (e.g. CypA, actin) that are incorporated in the virion. 
An important aspect of particle assembly is the multimerisation of the structural protein 
Gag, a necessary step considering that approximately 2400 Gag molecules constitute the 
lattice of a 66 nm retroviral particle (Krausslich, 2008). The Gag domains involved in 
multimerisation have been described in section 1.4.2. In vitro studies showed that CA- 
NC proteins assemble into VLPs more efficiently than CA alone (Campbell and Vogt,
1995). Furthermore, CA-NC assembles into VLPs in vitro in the absence of any other 
viral elements, even though the presence of nucleic acid strongly enhanced capsid 
formation and VLP assembly (Campbell and Rein, 1999; Campbell and Vogt, 1995; 
Ganser et al., 1999). RNAse treatment was found to disrupt Gag multimerisation in vitro
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(Bumiston et al., 1999) and MLV mutants bearing deletion in the packaging signal were 
shown to encapsidate cellular RNA (Muriaux et al., 2001) providing further evidence 
that RNA probably plays a role in retroviral assembly. In addition, NC was shown to be 
required for Gag multimerisation (Bumiston et al., 1999; Franke et al., 1994a) and it 
appeared that the RNA binding domain of NC was necessary for this activity (Cimarelli 
et al., 2000). Altogether, these studies support the hypothesis that the NC domain of the 
Gag precursor binds to and recmits either genomic or cellular RNA, which has been 
proposed to act as a scaffold for the assembly of the capsid (Campbell and Rein, 1999; 
Campbell and Vogt, 1997; Ganser et al., 1999; Hogue et al., 2009; Muriaux et al., 2001; 
Muriaux et al., 2002; Rulli et al., 2007).
HIV particle formation is believed to occur in a single assembly event as the hexameric 
lattice that forms the capsid is in one piece, even though it is incomplete (Briggs, 2008). 
Despite great advances in the past few years to decipher and understand the 
morphogenesis of HIV particles, many aspects remain to be solved.
In recent years, great efforts have been developed to understand the process of HIV 
release and many cellular cofactors have been characterised. However, many aspects 
still remain unclear. It has now been clearly established that HIV ‘hijacks’ the 
components of the ESCRT machinery to assemble at the plasma membrane and bud 
from the cell (reviewed in Fujii et al., 2007; Martin-Serrano, 2007; Morita and 
Sundquist, 2004).
As mentioned in section 1.4.2, the p6 domain of Gag interacts with the ESCRT-I 
component TsglOl and the protein AIPl/Alix (Garrus et al., 2001; Martin-Serrano et 
al., 2001; Strack et al., 2003). ESCRT-I is a component of the machinery that promotes 
the vesiculation of the endosomal membrane during cellular budding, a process that 
resembles enveloped-virus budding, by sorting ubiquitinated transmembrane proteins
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(cargo) into MVB vesicles. This ATP-dependent process is also dependent on ESCRT- 
II and ESCRT-II complexes. The p6-Alix interaction is thought to promote particle 
release by connecting Gag with components of the ESCRT-III complex, such as 
chromatin modifying protein 4 (CHMP4; von Schwedler et al., 2003b). This hypothesis 
is supported by the fact that rescue of HIV-1 late domain mutants by AIPl/Alix depends 
upon its ability to bind CHMP4 (Fisher et al., 2007; Usami et al., 2007).
Particle release is mediated by the ESCRT machinery and enhanced by the Vpu protein 
in HIV-1 and Env in HIV-2. Recent studies have indeed demonstrated that these two 
proteins function to overcome factors such as tetherin (Neil et al., 2008) and the 
calcium-modulating cyclophilin ligand (Varthakavi et al., 2008) that restrict the release 
of HIV.
•  Particle maturation
Immature particles are released from the cell and subsequently undergo a protease- 
dependent maturation event. The viral protease is self-cleaved from the Gag-Pol 
precursor and proteolytically processes the Gag precursor and the remaining of Gag-Pol 
to release the mature forms of MA, CA, NC, RT and IN. These cleavages trigger a 
conformational change in the virions, the capsid forming a conical core underneath the 
MA-layered lipid membrane. Based on in v/Yro-assembled capsids, a model has been 
proposed for the mature HIV particle assembly, named the ‘fullerene’ model, in which 
viral cores are organised on conical hexagonal lattices composed of hexameric CA rings 
with five pentamers at the narrow end and seven at the wide end, with a cone angle of 
19.2 degrees (Ganser et al., 1999; Li et al., 2000). A similar hexagonal unit has been 
observed by cryo-electron microscopy (cryo-EM) and thin-section electron microscopy 
for authentic mature HIV-1 cores (Briggs et al., 2003; Welker et al., 2000), suggesting
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that the hexameric unit seen in the in v/Yro-assembled CA tubes is relevant to mature 
HIV particles.
Inside the core, the dimeric RNA genome is coated with NC. It has been demonstrated 
that the RNA dimer in the mature particle is more stable than RNA dimers in immature 
particles. Studies of protease-defective viruses have shown that the electrophoretic 
mobility, density-sedimentation profile and thermal stability of these dimers were 
different from that of wild type dimers (Fu et al., 1994; Fu and Rein, 1993; Oertle and 
Spahr, 1990; Stewart et al., 1990). The NC protein is thought to promote this maturation 
of the dimer, by triggering the transition from a loose dimer to an more stable dimer 
(reviewed in Paillart et al., 2004b), as described in section 1.7.2.
1.6 Genome encapsidation in retroviruses
1.6.1 C/s-acting RNA packaging signal
The genome of retroviruses represents less than 1 % of total RNA present in an infected 
cell (Coffin et al., 1997). Hence, retroviruses have developed highly specific 
mechanisms to selectively package their genomic RNA over the vast excess of cellular 
RNA on one hand, and over spliced viral RNA species on the other hand (reviewed in 
D'Souza and Summers, 2005; Lever, 2007).
Studies of simple retroviruses have revealed that the cis-acting RNA sequences required 
for packaging were located in the 5' UTR of the genome (Katz et al., 1986; Mann et al., 
1983; Sorge et al., 1983; Watanabe and Temin, 1982) and it was supposed that the RNA 
sequence required for HIV genome encapsidation would also be located in this region. 
The location of the packaging determinant Psi (T1) 3' of the major splice donor would 
ensure that only unspliced genomic RNA was incorporated into nascent virions.
69
Chapter 1: Introduction
Mutagenesis analysis of the 5' leader RNA of HIV-1 revealed that a 19 nt region, 
located downstream of the major splice donor, was necessary for efficient RNA 
packaging (Lever et al., 1989). This was confirmed by further studies which also 
mapped the packaging signal to the region between the SD and the gag AUG start 
codon (Aldovini and Young, 1990; Clavel and Orenstein, 1990). Interestingly, as well 
as decreasing overall RNA packaging, Psi mutations also reduced the specificity of 
encapsidation and spliced viral RNAs were packaged in the mutant virions (Luban and 
Goff, 1994). These Psi deletions also resulted in a reduction of viral infectivity 
(Aldovini and Young, 1990; Clavel and Orenstein, 1990; Lever et al., 1989), and in 
some cases, aberrant particle morphology was observed (Aldovini and Young, 1990; 
Clavel and Orenstein, 1990). However, none of the deletions introduced resulted in a 
complete abolition of RNA packaging, suggesting that the packaging determinant may 
be multipartite. Supporting this hypothesis, the first 40 nt of the gag gene were found to 
be important for HIV-1 encapsidation (Luban and Goff, 1994). The introduction of 5' 
gag sequences in an HIV-1 vector was also found to enhance gene transfer by thirtyfold 
and increase RNA encapsidation by fourfold (Parolin et al., 1994). However, it is 
interesting to note that translation of Gag does not enhance HIV-1 encapsidation, as 
introduction of a stop codon in CA had no effect on the packaging efficiency of an HIV- 
1 vector (McBride et al., 1997). Deletions of sequences 5' of the SD, which overlap with 
the RNA sequence shown to be involved in genome dimerisation (Darlix et al., 1990; 
Laughrea and Jette, 1994; Skripkin et al., 1994), have been shown to affect HIV-1 
encapsidation (Clever and Parslow, 1997; Kim et al., 1994; McBride and Panganiban, 
1996, 1997). Sequences in the TAR, Poly(A) and PBS stem-loops were also found to 
affect HIV-1 RNA encapsidation to some extent (Helga-Maria et al., 1999; McBride et 
al., 1997). Overall, it appears that the major HIV-1 cw-acting packaging determinant
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lies approximately 120 nt upstream of the gag AUG and up to 40 nt into the gag coding 
sequence, with some elements at the 5' extremity of the genome also influencing the 
packaging process.
Despite having only one pool of RNA for packaging and translation (Dorman and 
Lever, 2000), HIV-1 can efficiently package RNA vectors that do not produce Gag, 
using a /r<ms-packaging mechanism (McBride et al., 1997). In fact, HIV-1 was shown 
to use both a trans- and a cA-packaging mechanism (Kaye and Lever, 1998), even 
though it was proposed to preferentially package its genome in cis, encapsidation being 
enhanced when the RNAs encode the Gag protein (Poon et al., 2002).
1.6.2 Secondary structure of the HIV-1 packaging signal
The structure of the HIV-1 5' UTR has been determined by biochemical probing, mass 
spectrometry, free-energy minimisation and phylogenetic analysis (Baudin et al., 1993; 
Clever et al., 1995; Harrison and Lever, 1992; Wilkinson et al., 2008; Yu et al., 2008). 
The first extensive study of the HIV-1 leader secondary structure came from Harrison 
and Lever (Harrison and Lever, 1992). The HIV-1 5' UTR was shown to be highly 
structured and to form several stem-loop structures between the PBS and the start of the 
gag coding sequence. In particular, this study showed that Psi folds into one of these 
stem-loops and that the 19 nt deletion described by Lever et al. (1989) disrupted this 
stem-loop as well as surrounding structures. Baudin et al. also analysed the structure of 
the HIV-1 leader using biochemical modifications and found that the SD and Psi folded 
into structures similar to those described by Harrison and Lever (Baudin et al., 1993). 
Further biochemical probing by Clever and co-workers confirmed the formation of four 
stem-loops and reported that the sequences creating the stems were particularly 
conserved (Clever et al., 1995). More recently, mass spectroscopy and SHAPE
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(selective 2'-hydroxyl acylation analysed by primer extension) were applied to the HIV- 
1 Psi RNA (Wilkinson et al., 2008; Yu et al., 2008). These methods confirmed the 
existence of the four stem-loop structures previously identified and revealed that the 
compact cloverleaf morphology exhibited by the Psi region is stabilised by long-range 
tertiary interactions.
Taken together, these independent studies identified a first stem-loop upstream of the 
SD named stem-loop 1 (SL-1) that comprises the dimerisation initiation signal (DIS), a 
second stem-loop containing the SD (SL-2), a T'-containing stem-loop (SL-3) and a 
stem-loop immediately downstream of the gag AUG (SL-4).
The HIV-1 RNA has also been proposed to contain several long-distance interactions. A 
compactly folded, fast migrating conformer was identified and addition of Mg2+ or NC - 
two factors that promote RNA dimerisation - was found to destabilise it (Berkhout and 
van Wamel, 2000). This conformer contains a long-range base-pairing between the 
Poly(A) and the DIS and was termed the long-distance interaction or LDI structure 
(Huthoff and Berkhout, 2001). Two mutually exclusive alternate conformations were 
subsequently proposed for the HIV-1 5' leader RNA, the LDI and branched multiple 
hairpin (BMH; Figure 1.8A) structures, which differ in their ability to form RNA 
dimers, consistent with the effect of Mg and NC on the LDI stability (Huthoff and 
Berkhout, 2001). A long-range interaction between the gag AUG and a sequence 
upstream of the PBS, referred to as the U5-AUG duplex and first identified in the BMH 
model, was subsequently confirmed by biochemical probing (Abbink and Berkhout, 
2003) and is supported by NMR studies (Spriggs et al., 2008). Interestingly, only the 
full-length genomic RNA can form the dimer-competent BMH structure as the U5- 
AUG duplex only exist in the unspliced RNA, and it has been suggested that alternate 
RNA conformations may help regulate processes such as encapsidation (Abbink and
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Berkhout, 2003). Supporting this hypothesis, analysis of the LDI-BMH equilibrium of a 
large set of HIV-1 mutants showed that a LDI-BMH riboswitch regulated encapsidation 
and dimerisation of HIV-1 RNA (Ooms et al., 2004).
Another intramolecular interaction was identified between the poly(A) loop and 
nucleotides in the matrix coding region (Paillart et al., 2002). Sequences involved in this 
long-range pseudoknot are conserved in HIV-2 and SIV, suggesting that it is 
functionally important. It is worth noting that similarly to the U5-AUG duplex, the 
poly(A)-matrix interaction only exists in the BMH conformer, since the LDI structure 
does not sustain the poly(A) loop.
Phylogenetic analysis of twenty divergent HIV-1 strains, combined with biochemical 
probing, confirmed both the poly(A)-matrix and the U5-AUG long-range interactions 
(Damgaard et al., 2004). Interestingly, the data obtained were consistent with the BMH 
structure but did not support the LDI model. Furthermore, structural probing of HIV-1 
RNA in infected cells and virions confirmed the existence of the dimer-competent BMH 
structure but not that of the LDI, although the LDI conformer may exist as a minor 
transient RNA species (Paillart et al., 2004a).
Finally, high throughput SHAPE analysis of the HIV-1 RNA strongly supported the 
idea that the HIV-1 genomic RNA formed a single predominant structure that included 
the U5-AUG and poly(A)-matrix interaction and fitted the BMH model (Wilkinson et 
al., 2008).
The structure of Psi was shown to be important for encapsidation as HIV-1 packaging 
was severely impaired by disruption of SL1 and SL3 but could be rescued by 
compensatory mutations that restored the base-pairing (McBride and Panganiban, 
1996).
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Figure 1.8: Secondary structure of the HIV-1 and HIV-2 5' RNA leader.
(A) Branched multiple hairpin (BMH) structure of HIV-1LAI 5' leader RNA from Abbink and 
Berkhout (2003). The U5-AUG long-range interaction is indicated by the red box. (B) 
Secondary structure of the HIV-2ROd 5' leader RNA, adapted from Berkhout (1996).
Residue +1 corresponds to the start of the RNA genome. The proposed dimerisation and 
encapsidation signals are highlighted in red and yellow, respectively. TAR, toms-activation 
responsive; PolyA, polyadenylation signal; PBS, primer binding site; PAS, primer activation 
signal; DIS, dimerisation initiation site; SD, splice donor; TVPsi, packaging signal; SL-1/2/3, 
stem-loop 1/2/3.
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Moreover, the base-pairing of the 46 nt located between the SD and gag AUG start 
codon into a stem-loop structure was shown to be crucial for efficient encapsidation 
(Hayashi et al., 1992), confirming the importance of the Psi structure in HIV-1 RNA 
packaging. However, both SL-2 and SL4 appeared dispensable for packaging (McBride 
and Panganiban, 1996).
The structural context of HIV-1 Psi also appears critical for encapsidation. Permutation 
of SL1 and SL3 showed that the individual structures that compose the HIV-1 Psi 
function in a position-dependent manner (McBride and Panganiban, 1997). This 
suggests that the formation of a high-order RNA structure functions to package the full- 
length genomic RNA and exclude subgenomic RNA species.
1.6.3 Trans-acting factors involved in RNA packaging
The role of NC, and in particular of the two CCHC motifs, in retroviral RNA packaging 
was first identified when mutations in NC resulted in a packaging defect (Aldovini and 
Young, 1990; Berkowitz and Goff, 1994; Dorfinan et al., 1993; Gorelick et al., 1988; 
Gorelick et al., 1990; Kaye and Lever, 1999; Meric and Goff, 1989; Meric et al., 1988; 
Schwartz et al., 1997). Even though the zinc fingers were shown to be the main 
requirement for genome encapsidation, flanking basic residues were also found to play a 
role in RNA packaging and binding in vitro (Dannull et al., 1994; Poon et al., 1996; 
Schmalzbauer et al., 1996).
NC was shown to confer the specificity of encapsidation. Chimeric HIV-1 virions 
containing the MLV NC domain preferentially encapsidated MLV RNA and vice-versa 
(Berkowitz et al., 1995; Zhang and Barklis, 1995). MLV-HIV-1(NC) chimera 
selectively packaged unspliced HIV-1 RNA over spliced HIV-1 RNA, while the HIV-1- 
MLV(NC) chimera packaged significantly more non-viral RNAs than wild type HIV-1,
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providing further evidence that NC recognises specifically the genomic RNA during 
encapsidation. Experiments using protease-deficient vectors demonstrated that the Gag 
precursor was able to package HIV-1 RNA irrespective of whether it was processed or 
not (Kaye and Lever, 1996). In addition, HIV-1 Gag (p55) andNC (p i5) fusion proteins 
bind to a ¥  RNA with similar affinities in vitro, suggesting that the NC domain of Gag 
contains all the necessary determinants for efficient ¥  RNA binding (Clever et al., 
1995; Dannull et al., 1994).
A number of in vitro assays have been used to determine the binding affinity of NC for 
the 'F RNA, including electrophoretic mobility shift assay (EMSA), filter binding assay, 
footprinting and NMR (Amarasinghe et al., 2000b; Berkowitz et al., 1993; Clever et al., 
1995; D'Souza and Summers, 2004; De Guzman et al., 1998; Shubsda et al., 2002). 
HIV-1 NC does not bind to SL-1 with high affinity (Lawrence et al., 2003) but is able to 
induce a conformational change during the RNA dimer maturation (Feng et al., 1996b), 
as described in section 1.7.2. Contrary to what has been suggested by mutational 
analyses, SL-2 appears to play some role in HIV-1 packaging as it is able to bind NC 
with high affinity (Amarasinghe et al., 2000a). SL-3, the main HIV-1 packaging 
determinant, also binds NC tightly, as demonstrated by NMR studies (De Guzman et al., 
1998; Zeffman et al., 2000) and footprinting experiments (Damgaard et al., 1998). 
Interestingly, footprinting performed with both HIV-1 Gag and NC revealed differences 
in the binding pattern of the two proteins and even though they both bound to SL-3, Gag 
displayed a much stronger affinity (Damgaard et al., 1998), highlighting the importance 
of using full-length Gag protein in the in vitro binding assays. SL-4 displays only a 
weak affinity for the NC protein when analysed individually (Amarasinghe et al., 2001). 
Importantly, it was noted that even though individual structures could bind recombinant
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Gag and NC proteins, the entire 'F region showed a far greater affinity (Berkowitz and 
Goff, 1994; Clever et al., 1995).
In contrast to HIV-1, few studies have assessed the binding of HIV-2 NC to the *F 
region. HIV-2 NC has been shown to bind to the HIV-2 SL-3 (Matsui et al., 2009) and 
HIV-1 Gag and NC were reported to bind regions of the HIV-2 5' leader RNA both 
upstream and downstream of the major SD (Damgaard et al., 1998).
1.6.4 Genome encapsidation in HIV-2
•  Cis-acting RNA packaging signal
Genome encapsidation in HIV-2 is less well characterised than in HIV-1. Initial reports 
proposed that the HIV-2 cis-acting packaging signal was located between the major SD 
and the gag AUG start codon (Arya et al., 1998; Garzino-Demo et al., 1995; Poeschla et 
al., 1998). However, the deletions introduced were often large and did not allow a 
precise mapping of the Psi region, and mutations upstream of the SD were not fully 
characterised (Arya et al., 1998; Poeschla et al., 1998). Moreover, one study used an 
attenuated HIV-2 strain, H IV -2st, which may differ in its packaging abilities compared 
to infectious HIV-2 isolates (Garzino-Demo et al., 1995). Subsequent mutational 
analyses showed that sequences upstream of the SD were required for efficient 
encapsidation of HIV-2 genomic RNA, while sequences downstream of the SD were 
less important (Griffin et al., 2001; Kaye and Lever, 1999; McCann and Lever, 1997). 
Furthermore, a study of HIV-1 and HIV-2 cross-packaging abilities revealed that an 
HIV-1 helper virus could package HIV-2 vector in trans, but that unspliced and spliced 
HIV-2 RNA were encapsidated in proportion to their cytoplasmic concentrations, 
suggesting that HIV-2 Psi is present on all RNA species (Kaye and Lever, 1998).
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Mapping of HIV-1 NC and Gag binding sites on the HIV-2 5' leader RNA showed 
binding on either side of the SD (Damgaard et al., 1998), confirming the results 
obtained by Kaye and Lever.
The HIV-2 core packaging determinant was subsequently mapped to nucleotides 380- 
408 of the H IV -2rod RNA genome (Figure 1.8B, yellow highlight) and deletion of these 
residues decreased packaging efficiency to approximately 10 % relative to wild type 
HIV-2 (Griffin et al., 2001). Biochemical and free-energy minimisation analyses have 
determined that HIV-2 Psi is partly unstructured and partly folds into the stem of a 
stem-loop termed SL-1 (Baig et al., 2007; Damgaard et al., 1998; Dirac et al., 2001; 
Lanchy et al., 2004), which encompasses a putative DIS (Dirac et al., 2001). Deletion of 
nucleotides 392-434 also resulted in a packaging defect (Griffin et al., 2001; McCann 
and Lever, 1997), suggesting that the structure of SL-1 might play a role in HIV-2 
packaging. A recent study of the HIV-2 Psi region confirmed the relevance of the SL-1 
structure in HIV-2 RNA packaging (Lanchy and Lodmell, 2007) as long-term 
replication of Psi mutants revealed that the formation of an extended SL-1 was 
necessary for viral replication and positively affected RNA encapsidation.
•  Co-translational packaging ofHIV-2 genomes
The location of HIV-2 Psi upstream of the splice donor raises the question of the 
specific encapsidation of unspliced genomic RNA over spliced RNAs. As seen in the 
cross-packaging analysis, HIV-1 Gag preferentially encapsidates HIV-1 unspliced RNA 
but is unable to discriminate between HIV-2 spliced and unspliced RNAs (Kaye and 
Lever, 1998). Interestingly, the HIV-2 helper did not cross-package the HIV-1 vector, 
indicating nonreciprocal packaging and suggesting that the two viruses may use 
different packaging mechanisms. Introduction of HIV-1 NC into HIV-2 Gag was
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sufficient to allow /raws-packaging of an HIV-1-based vector by the HIV-2 helper virus, 
demonstrating that NC is important for the specificity of packaging in HIV-2. It is 
interesting to note that addition of the HIV-1 p2 domain into the chimera enhanced the 
packaging efficiency, suggesting a role for the p2 domain in encapsidation (Kaye and 
Lever, 1998). This implication of p2 in RNA encapsidation has been confirmed by a 
report that the packaging specificity of an HIV-1 DIS mutant incorporating spliced 
RNA could be rescued by a compensatory mutation in p2 (Russell et al., 2003b).
Further mutational analyses showed that efficient packaging of an HIV-2-based vector 
only occurred when the genomic RNA packaged expressed the full-length Gag protein, 
including a functional NC domain with two intact zinc fingers (Kaye and Lever, 1999). 
Truncations of the N-terminus of Gag, introduction of a stop codon in CA and point 
mutations of the two zinc fingers in NC all resulted in the inefficient packaging of the 
vector RNA, and it was proposed that HIV-2 uses a novel type of encapsidation 
initiation mechanism, in which HIV-2 unspliced RNA is captured in cis by the Gag 
protein, hence providing the specificity for full-length genomic RNA (Kaye and Lever, 
1999).
Contrary to what has been observed with HIV-1, HIV-2 cannot efficiently encapsidate 
its genome in trans (Griffin et al., 2001; Kaye and Lever, 1998). However, a helper 
virus that does not harbour a functional Psi sequence can /ra/w-package a vector 
containing a stop codon in Gag, indicating that the HIV-2-based vector is able to 
compete for the Gag protein in trans (Griffin et al., 2001). Encapsidation efficiency of 
wild type HIV-2 was assessed in the presence of Psi mutants that could or could not 
produce functional Gag protein. The packaging efficiency increased only when the wild 
type construct was co-transfected with a Psi mutant that could synthesise Gag, 
suggesting that the Gag protein is a limiting factor for HIV-2 encapsidation (Griffin et
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al., 2001). Therefore, co-translational packaging and competition for the limiting Gag 
protein confer specificity of HIV-2 encapsidation.
•  Similarities and differences with SIV encapsidation
Sequences important for SIV mac packaging have also been mapped to the region 
upstream of the major SD, as sequences on either side of SIV mac239 SD were shown to 
be important for specific encapsidation (Patel et al., 2003; Whitney and Wainberg, 
2006). One study proposed that SIV Psi was located between the SD and the gag start 
codon; however, mutations 3' of the SD were not analysed independently of those 5' of 
the SD, rendering the interpretation of the data difficult (Patel et al., 2003). Other 
reports have proposed that the core packaging signal lie 5' of the SD (Guan et al., 2000; 
Guan et al., 2001b; Strappe et al., 2003) and cross-packaging experiments using HIV-1 
helper viruses showed that deletion 5' of the SD reduced the encapsidation of SIV-based 
vectors (Rizvi and Panganiban, 1993). Deletions of nucleotides 371-397 and 398-418 of 
the SIV mac239 genome reduced packaging efficiency to 21 and 44 %, respectively, 
relative to wild type (Guan et al., 2000; Guan et al., 2001b). Furthermore, deletion of 
nucleotides 397-429 of the SIV mac239 genome resulted in a packaging efficiency less 
than 10 % and a loss of packaging specificity, although neighbouring sequences were 
also shown to affect SIV packaging (Strappe et al., 2003).
Interestingly, the SIV core packaging signal is predicted to fold into a secondary 
structure similar to that of HIV-2 Psi (Guan et al., 2001b; Strappe et al., 2003) and 
sequence analysis revealed almost complete conservation between HIV-2 and SIV Psi 
(HIV sequence compendium 2008). The location of SIV mac Psi upstream of the major 
SD would suggest a packaging mechanism similar to that of HIV-2. However, a 
nonreciprocal packaging mechanism was found to exist between SIVmac and HIV-2,
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with SIV mac being able to deliver an HIV-2-based vector whereas HIV-2 could not 
efficiently encapsidate an SIV-based vector in trans (Strappe et al., 2005). Interestingly, 
HIV-1 could efficiently deliver both SIV mac- and HIV-2-based vectors.
Finally, it is worth noting that not all SIVs are similar regarding their packaging 
mechanisms; for example, SIV agm has been shown to encapsidate its genome 
predominantly in trans (Fu et al., 2007).
1.7 Genome dimerisation in retroviruses
1.7.1 The dimer linkage site
Retroviruses encapsidate two copies of their positive sense RNA genome, non- 
covalently linked at their 5' end through the dimer linkage site (reviewed in Greatorex 
and Lever, 1998; Paillart et al., 2004b).
Deletion analysis of the H I V -I mal 5' leader RNA revealed that a 100 nt sequence 
encompassing the Psi region was necessary and sufficient to promote RNA dimerisation 
in vitro in the absence of protein (Darlix et al., 1990). Similarly, deletion mutagenesis of 
the MLV 5' UTR showed that the cis-acting sequence required for RNA dimerisation in 
vitro overlapped with the packaging signal (Prats et al., 1990). In both studies, the 
addition of NC enhanced dimer formation and the protein was found tightly associated 
with the RNA dimer. Introduction of the MLV Psi sequence into non-viral mRNAs 
resulted in the encapsidation of these RNAs as dimers, supporting the idea that the DLS 
overlaps with Psi (Hibbert et al., 2004). Further analysis confirmed that nucleotides 
311-415 of the HIV-1 mal genome were required for HIV-1 RNA dimerisation in vitro 
in the absence of NC (Marquet et al., 1991). Dimer formation was found to be 
temperature-dependent and stimulated by cations.
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Purine-rich consensus sequences (RGGARA, where R is a purine) have been identified 
in the DLS of many retroviruses and provided an explanation for the heterodimer 
formation and large cation requirements observed (Marquet et al., 1991). However, it 
was shown that HIV-2 RNA transcripts containing only the 5' terminal 255 nt of the 
leader RNA, with no purine-rich motif, could dimerise at 37 °C in high-salt buffer in the 
absence of Gag protein (Berkhout et al., 1993). Similarly, mutational analysis of HIV- 
I lai RNA showed that transcripts that do not contain purine tracts could spontaneously 
dimerise in vitro (Muriaux et al., 1995).
The DLS of MLV and HIV-1, found near the gag AUG start codon, were proposed to 
be multipartite. Supporting this notion, sequences located upstream of the SD and 
outside of the originally identified DLS were shown to be involved in HIV-1 RNA 
dimerisation in vitro (Marquet et al., 1994). In addition, RNAs lacking most of the HIV- 
1 genome were shown to form more stable dimers than wild type RNA (Sakuragi and 
Panganiban, 1997), suggesting the existence of negative regulatory elements.
The primary site of H I V -I mal RNA dimerisation was subsequently identified using 
chemical modification interference, which identifies the nucleotides that are required in 
unmodified form for dimer formation (Skripkin et al., 1994). These nucleotides mapped 
to a region between the PBS and the SD, and centered around a palindromic sequence 
located in a hairpin structure. This corresponds to SL-1, as defined in structural studies 
of the HIV-1 5' UTR (Figure 1.8A; Clever et al., 1995; Harrison and Lever, 1992). A 
model was proposed by which dimerisation occured by annealing of the self- 
complementary sequences, via loop-loop interaction, and the palindrome was therefore 
named the DIS (Paillart et al., 1994; Skripkin et al., 1994). Thermostability analyses 
suggested that the sequences 3' of the SD contributed to the stability of the dimer
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(Skripkin et al., 1994), in particular two purine tracts located near the gag AUG (Paillart 
et al., 1994), confirming the multipartite nature of the DLS.
Similar results were obtained with the HIV-1 l a i  isolate (Clever et al., 1996; Laughrea 
and Jette, 1994; Muriaux et al., 1995). The core dimerisation domain of HIV-1 l a i  i s  
located upstream of the SD, in a stem-loop structure containing an exposed palindrome 
(SL-1) that could initiate dimer formation via loop-loop interaction. The central GC 
residues of the DIS palindrome were shown to be critical for RNA dimerisation and the 
presence of two or three flanking adenine residues were found to increase dimer 
stability (Clever et al., 1996; Paillart et al., 1997). This was confirmed by in vitro 
selection experiments, which also showed that not more than two A-U base-pairs are 
tolerated in the palindrome and that increasing the length of the palindrome above 6 nt 
does not increase dimerisation (Lodmell et al., 2000). Similarly, DIS mutants containing 
four A-U base-pairs were shown to replicate poorly (Laughrea et al., 1999).
Interestingly, duplication of 1000 nt, encompassing the DLS, in an ectopic location of 
the HIV-1 genome caused the appearance of monomeric genomes in virions, a defect 
which could be restored by mutation of the authentic DLS (Sakuragi et al., 2001). These 
results suggested that RNAs containing two DLS self-annealed via intramolecular 
interactions and that the sequences identified in the 5' leader RNA are sufficient to 
promote RNA-RNA interaction.
1.7.2 Formation and maturation of the RNA dimer
•  T h e‘kissing-loop’ complex model
The identification of a self-complementary sequence at the centre of the DIS led to the 
suggestion that dimerisation initiated via symmetrical intermolecular interactions
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between theses sequences, forming a so-called ‘kissing-loop’ complex (Paillart et al., 
1994; Skripkin et al., 1994). Supporting this model, mutations preventing self­
complementarity in the loop resulted in a dimerisation defect in vitro and compensatory 
mutations restored the process (Clever et al., 1996; Muriaux et al., 1996b; Paillart et al., 
1994; Paillart et al., 1996b; Paillart et al., 1997; Skripkin et al., 1994). However, not all 
mutations that maintain self-complementarity are associated with stable dimer 
formation in vitro (Clever et al., 1996; Laughrea et al., 1999; Paillart et al., 1997), 
reflecting the fact that only two major DIS variants are observed among natural HIV-1 
isolates, out of 64 possible sequences. Further evidence for the kissing-loop model was 
provided by a mutational analysis of SL-1, demonstrating that the formation of the stem, 
regardless of its sequence, was required for in vitro RNA dimerisation (Clever et al.,
1996).
Although the formation of the kissing-loop complex has been well documented and is 
supported by structural data (Ennifar et al., 2001; Mujeeb et al., 1998), there have been 
some suggestions that it may not constitute the initiation step of genomic RNA 
dimerisation. Mutations of the SL-1 palindromic sequence were shown to have no effect 
on HIV-1 lai genomic RNA dimer formation or stability, but reduced RNA packaging, 
reverse transcription and viral replication in T-cells (Berkhout and van Wamel, 1996). 
Interestingly, substitution of SL-1 by a wild type or arbitrary 6 nt palindromic sequence 
resulted in a replication defect in T-cells but no decrease in dimer formation or stability 
and replication in PBMCs, suggesting that the requirement for the SL-1 structure is cell 
type-dependent (Hill et al., 2003). The mobility of the RNA was however different from 
that of wild type RNA dimers, suggesting that the SL-1 structure is important for the 
conformation of the dimer.
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These discrepancies between different studies might result from the analysis of dimer 
formation exclusively in vitro or in cell culture based-assays. In particular, the latter 
include cellular and viral factors that may influence the dimerisation process (as 
discussed below) and contain the full-length genomic RNA, which has been shown to 
fold into complex structures, possibly regulating RNA dimerisation (Abbink et al., 
2005). Interestingly, a recent study of HIV-1 genome dimerisation reported that DIS 
mutants packaged monomeric genomes that subsequently dimerised, albeit much slower 
than wild type virus, suggesting that the initiation of dimerisation does occur at the DIS 
(Song et al., 2007b).
It is worth noting that an alternative mechanism was proposed for the initiation of 
dimerisation, involving purine-rich sequences and the formation of purine quartets 
(Awang and Sen, 1993). However, this model was not supported by others and several 
studies of HIV dimerisation have shown that purine tracts are dispensable for this 
process (Berkhout et al., 1993; Fu et al., 1994; Muriaux et al., 1995).
•  Maturation o f the RNA dimer
Transcripts corresponding to the H IV -Im al and MLV 5' leader RNA were shown to 
dimerise in vitro in the absence of protein, yet addition of NC (p i5) greatly enhanced 
dimer formation (Darlix et al., 1990; Prats et al., 1990), suggesting that NC played a 
role in RNA dimerisation. This was confirmed by the observation that a more stable 
HIV-1 RNA dimer, as determined by its thermal stability, is formed in vitro in the 
presence of NC (Feng et al., 1996b; Muriaux et al., 1996a). This stable dimer is thought 
to result from the formation of an extended duplex following the initial loop-loop 
interaction. Despite structural studies supporting the potent formation of an extended 
duplex by interstrand interactions of residues in the SL-1 stem (Ennifar et al., 1999;
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Girard et al., 1999; Mujeeb et al., 1999), it remains uncertain whether an extended 
duplex exists in vivo. Nonetheless, strong evidence supports the transition of a loose 
dimer into a more stable dimer form, both in vitro - in the presence of NC (Feng et al., 
1996b; Muriaux et al., 1996a) or at high temperatures (Laughrea and Jette, 1996; 
Muriaux et al., 1996b) - and in cells (Fu et al., 1994; Fu and Rein, 1993). Importantly, 
this ‘maturation’ of the RNA dimer was shown to correlate with proteolytic processing 
and particle maturation as protease-deficient viruses contained mostly monomeric 
genomes (Fu et al., 1994; Fu and Rein, 1993; Shehu-Xhilaga et al., 2001a; Song et al., 
2007b). In addition, mutations preventing the cleavage at the p2/NC junction inhibit 
dimer maturation in HIV-1 (Shehu-Xhilaga et al., 2001b), further supporting a role for 
the proteolytic cleavage in dimer maturation. Interestingly, the Gag-Pol precursor and 
Pol protein have also been reported to influence the dimer maturation. Increasing the 
Gag/Gag-Pol ratio by overexpressing PR(-) or PR(+) Gag-Pol expression vectors 
progressively reduced the thermal stability of the RNA dimer, the overexpression of a 
PR(-) Gag-Pol vector having a more profound effect on dimer stability (Shehu-Xhilaga 
et al., 2001a). Furthermore, packaging of Pol is required for dimer maturation, as RNA 
dimers isolated from Gag particles produced in the absence of a functional Gag-Pol are 
less stable and show altered mobility compared to wild type dimers (Shehu-Xhilaga et 
al., 2002). Yet, this effect is not solely caused by the lack of PR. While rescue of PR 
expression alone is sufficient to restore the stability of the dimer, it does not restore the 
wild type dimer conformation or correct particle morphogenesis. Co-expression of Vpr- 
RT or Vpr-IN fusion protein does not rescue dimer conformation; however, 
supplementation of a Vpr-RT-IN fusion complex in trans could restore the 
conformation of the RNA dimer as well as the particle morphology, demonstrating that 
the polymerase protein is required for complete dimer maturation and mature core
86
Chapter 1: Introduction
formation. As a result, one might envisage a physical interaction between the mature 
RNA dimer and the RT and IN enzymes. As mentioned previously, these components 
are associated in the PIC, where reverse transcription takes place (see section 1.5.2), and 
it has been proposed that the dimeric state of the RNA genome plays an important role 
during reverse transcription and facilitates recombination (Andersen et al., 2003; 
Balakrishnan et al., 2001; Balakrishnan et al., 2003; Berkhout et al., 1998; Hu and 
Temin, 1990a; Mikkelsen et al., 2000; Temin, 1991). In HIV-1, the first strand transfer 
was shown to be more efficient when the RNA template is dimeric (Berkhout et al., 
1998). Accordingly, the first strand transfer has been shown to occur in a random 
manner, with equal contribution from intramolecular and intermolecular transfer (van 
Wamel and Berkhout, 1998). Furthermore, SL-1 deletion mutants showed a strong 
reduction in second strand transfer (Paillart et al., 1996a), suggesting that dimeric RNA 
is required for efficient strand transfer during reverse transcription.
1.7.3 Dimerisation in HIV-2
In HIV-2, two sequences were shown to be involved in RNA dimerisation in vitro 
(Dirac et al., 2001; Jossinet et al., 2001; Lanchy and Lodmell, 2002). Since the purine- 
rich (PuGGAPuA) motifs initially proposed as dimerisation sites were shown to be 
dispensable for HIV-2 dimerisation (Berkhout et al., 1993), a self-complementary 
sequence flanked by unpaired adenines and similar to HIV-1 SL-1 represented a 
potential dimerisation site. Surprisingly, it was first reported that SL-1 did not mediate 
dimerisation in HIV-2. Instead, a sequence located in the PBS (see Figure 1.8B) was 
identified as being the main site of dimerisation and mutational analysis suggested that 
HIV-2 dimerisation also occurred via formation of a kissing-loop complex (Jossinet et 
al., 2001). The effect of tRNAlys3 annealing on dimerisation was measured and it was
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found to inhibit RNA dimerisation, suggesting that the RNA-RNA complex must 
dissociate to allow tRNA annealing and reverse transcription. However, this is not 
consistent with the proposed role of dimeric RNA in reverse transcription mentioned 
above.
Another detailed mutational analysis of the HIV-2 leader showed that SL-1 mediated 
RNA dimerisation in vitro and that the palindromic sequence in the loop (termed DIS 
and highlighted in red in Figure 1.8B) was essential for dimer formation (Dirac et al., 
2001). Interestingly, the authors observed that even though the palindrome could be 
replaced by other self-complementary sequences, no more than two A-U base-pairs 
were tolerated, consistent with previous findings in HIV-1 (Laughrea et al., 1999; 
Lodmell et al., 2000) and suggesting that this might be a common feature of 
retroviruses. Structural analysis in the context of the entire leader confirmed that the 
DIS palindrome must be exposed to initiate dimerisation (Figure 1.8B; Dirac et al., 
2001, 2002).
In order to determine the exact dimerisation site of HIV-2, Lanchy and Lodmell 
compared the methods used in the two divergent studies and observed that, in vitro, two 
dimerisation sites can be used under different conditions (Lanchy and Lodmell, 2002). 
First, a short sequence at the 5' end of the PBS promotes dimer formation under mild 
conditions (high potassium chloride, high magnesium dimerisation buffer, 
electrophoresis at 4 °C in tris-borate-magnesium buffer) and is therefore considered to 
be a loose-dimer inducing element (Jossinet et al., 2001). Second, a palindrome located 
within the SL-1 structure, similar to the HIV-1 DIS, promotes the formation of a tight 
dimer under more stringent conditions which includes a low sodium chloride, high 
magnesium dimerisation buffer and electrophoresis in tris-borate-EDTA (Dirac et al., 
2001). Interestingly, the facility with which one site could substitute for the other
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suggests a possible switching mechanism that was postulated to be used in the viral 
replication cycle (Lanchy and Lodmell, 2002). Further study of the HIV-2 5' leader 
RNA suggested that it could adopt two alternative conformations, similar to the LDI and 
BMH conformations observed in HIV-1, which could regulate RNA dimerisation (Dirac 
et al., 2002). Dimerisation was proposed to be inhibited when the RNA forms the LDI 
conformer and facilitated in the BMH conformation. As for HIV-1 (Huthoff and 
Berkhout, 2001), the NC protein was postulated to promote the LDI-to-BMH switch 
and to increase dimer formation (Dirac et al., 2002). Another long-distance interaction, 
between the 5' UTR and the gag AUG start codon, was proposed to negatively regulate 
RNA dimerisation by silencing SL-1 (Lanchy et al., 2003a; Lanchy et al., 2003b). 
However, this interaction would be similar to the U5-AUG duplex observed in HIV-1 in 
the dimerisation-competent BMH conformation (Abbink and Berkhout, 2003; Abbink et 
al., 2005). Hence, the exact effect of the long-range interaction and conformational 
switch on HIV-2 dimer formation remains to be confirmed.
Finally, a third palindrome in the HIV-2 Psi region was shown to regulate dimer 
formation in vitro as it could prevent SL-1-mediated dimerisation via SL-1 silencing or 
promote dimerisation itself (Lanchy et al., 2003a). The location of this dimerisation 
signal within the packaging determinant (highlighted in yellow in Figure 1.8B) 
suggested that the two processes may be interconnected.
To date, there has been no confirmation that the DIS or any other palindromic sequence 
in the HIV-2 5' leader RNA is sufficient to promote the dimerisation of HIV-2 genomic 
RNA in the virus.
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1.7.4 Relationship between genome dimerisation and encapsidation
As mentioned in section 1.6.1, the HIV-1 cA-acting packaging signal overlaps with the 
core DIS, leading to the suggestion that the two processes are linked and that 
dimerisation may be necessary for packaging (Paillart et al., 2004b; Russell et al., 
2004). Supporting this hypothesis, several studies have reported that mutations which 
affect dimer formation also reduce genome encapsidation (Berkhout and van Wamel, 
1996; Clever and Parslow, 1997; Harrison et al., 1998; Laughrea et al., 1997; McBride 
and Panganiban, 1996, 1997; Paillart et al., 1996a). Similarly, the HIV-2 packaging 
signal appeared to overlap with sequences that were important for RNA dimerisation 
(Dirac et al., 2001; Griffin et al., 2001; Lanchy et al., 2003a; Lanchy and Lodmell, 
2002).
Interestingly, structural studies revealed that dimerisation of MLV RNA induces a 
conformational change, resulting in the exposure of a conserved UCUG motif that 
bound NC with high affinity (D'Souza and Summers, 2004). Sequestered NC binding 
sites in the monomeric RNA became exposed upon dimerisation, possibly enhancing the 
packaging of a dimeric genome. This led the authors to postulate that a structural RNA 
switch mechanism may be involved in the encapsidation of a diploid genome.
Because of the close proximity of the Psi and DIS elements, it has proven difficult to 
analyse packaging and dimerisation independently of each other and to determine 
whether genome dimerisation is indeed a prerequisite for encapsidation. The exact 
relationship between genome dimerisation and packaging therefore remain poorly 
understood.
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1.8 Aims of research
The aims of this research were to clarify the role of the HIV-2 packaging signal in 
genome dimerisation and virion infectivity in order to elucidate the relationship between 
RNA dimerisation, encapsidation, viral replication and particle morphogenesis.
The approach was to use site-directed mutagenesis to mutate the sequence and alter the 
structure of the HIV-2 packaging and dimerisation signals. The pSVR proviral clone of 
the H IV -2rod isolate was used to analyse the mutations in the context of a fully 
infectious virus. Effects of the mutations on genome encapsidation, RNA dimerisation 
in vitro and in virio, protein expression and viral replication were assessed in transiently 
transfected Cos-1 cells using RNAse protection assay, native northern blot and western 
blot. Viral infectivity was measured in single- and multiple-round assays using a 
reporter cell line and T-cells. The effect of the Psi deletion on particle morphology was 
also evaluated by electron microscopy.
It was hypothesised that identification of the core sequence and structural elements 
required for HIV-2 genome dimerisation would lead to further investigation into their 
requirement for RNA packaging and viral infectivity with respect to characterising the 
relationship between dimerisation and viral replication in HIV-2. In addition, the 
emergence of potential revertants in the long-term replication study might provide 
further insight into the elements required for HIV-2 infectivity and indicate new targets 
to block viral replication.
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2 Materials and methods
2.1 Materials
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich. Ethanol, 
methanol and isopropanol were purchased from Fisher Scientific. Distilled/deionised 
water was generated using a Millipore filtration system.
Oligonucleotides were obtained from Sigma-Genosys. Standard oligonucleotides were 
synthesised at 0.025 pinole and desalted. Mutagenic oligonucleotides used in 
oligonucleotide-cloning site-directed mutagenesis were synthesised at 0.05 pmole and 
purified by high performance liquid chromatography (HPLC).
Unless specified in the text, all enzymes, including restriction endonucleases, and their 
associated buffers were purchased from New England Biolabs (NEB), Roche or 
Promega.
Commercial reagents and enzymes utilised for RNA work were obtained from Promega 
or Ambion. Water and prepared reagents required to be RNase-free were treated with 
0.1 % (v:v) diethylpyrocarbonate (DEPC) at 37 °C for 12 h prior to autoclaving. 
Radiochemicals were purchased from Amersham-GE Healthcare and Perkin Elmer.
Cell culture reagents and media were obtained from Gibco-Invitrogen and PAA. Cell 
lines already in use in the laboratory were obtained from the American Type Culture 
Collection (ATCC), the European Collection of Cell Cultures (ECACC) and the Centre 
for AIDS Reagent (CFAR) at the National Institute for Biological Standards and 
Controls (NIBSC).
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General laboratory plasticware was obtained from Coming, Greiner Bio-One and 
Starlab. Plastics used in tissue culture were purchased from Coming and Greiner Bio- 
One.
2.2 Cloning procedures/manipulation of DNA
2.2.1 Digestion of plasmid DNA by restriction endonucleases
Restriction digests were carried out in the appropriate reaction buffer and at the 
recommended temperature, typically 37 °C, according to the manufacturer’s 
instructions. Bovine semm albumin (BSA) was added to a final concentration of 100 
pg/ml when required. Restriction analysis of recombinant plasmid DNA was performed 
on 1 pg of DNA using 10 Units of enzyme in a total volume of 20 pi and incubated for 
1 h. Digestion of DNA subsequently used in ligation was achieved by incubation of 5 
pg of DNA and 40 Units of enzyme in a total volume of 50 to 100 pi for 2 h. 
Simultaneous digestion by Aatll and Xhol or Aatll, Xhol and Xmnl were carried out in 
NEB buffer 4 in the presence of 1 x BSA.
2.2.2 Dephosphorylation of digested plasmid DNA
Vector plasmid DNA to be used in compatible end ligations was dephosphorylated 
using 10 Units of Shrimp Alkaline Phosphatase (Roche) for 15 min at 37 °C prior to gel 
purification.
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2.2.3 Polymerase Chain Reaction (PCR)
PCR was performed using either the Taq DNA polymerase from NEB or the BioMix 
Red reagent from Bioline. Typically, 20 to 100 ng of DNA was used and each primer 
was added to a final concentration of 0.4 pM.
When the NEB Taq DNA polymerase was used, the standard Taq reaction buffer 
provided was diluted to a final concentration of 1 x (10 mM Tris-HCl, 50mMKCl,
1.5 mM MgCb, pH 8.3). Each deoxyribonucleotide triphosphate (dNTP; Promega) was 
added separately to a final concentration of 0.2 mM. When using the 2 x BioMix Red, 
the DNA and primers were mixed with H2O and the BioMix Red was added to the final 
concentration of 1 x.
Reactions were carried out in a Labnet MultiGene II, a Techne Touchgene or a Perkin 
Elmer Cetus DNA thermal cycler. When using the latter, the PCR mixture was overlaid 
with a drop of sterile mineral oil. The hybridisation temperature (TH) was adjusted for 
each primer pair as follows: melting temperature (TM) of the primer (provided by the 
manufacturer) minus 5 °C. The time of the polymerisation step was calculated as 
follows: 1 min per kb of DNA to amplify.
A typical PCR amplification comprised a 2 min denaturation step at 95 °C, 30 cycles of 
1 min denaturation at 95 °C, 1 min hybridisation at Th = TM - 5 °C and 1 min/kb 
polymerisation at 72 °C followed by a final extension of 5 min at 72 °C.
2.2.4 Purification of DNA
Digested vector and insert DNAs used in cloning were separated by agarose gel 
electrophoresis in 1 x TBE (90 mM Tris-borate, 2 mM EDTA) and purified by gel 
extraction using the Qiagen “Gel Extraction Kit”, according to the manufacturer’s 
instructions.
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PCR products were purified using the Qiagen “PCR Purification Kit”, according to the 
manufacturer’s instructions.
2.2.5 DNA ligation
Vector and insert DNA were ligated using 2 to 6 Units of T4 DNA ligase (Promega) in 
1 x reaction buffer (30 mM Tris-HCl pH 7.8, 10 mM MgCl2, 10 mM DTT and 1 mM 
ATP). Vector to insert ratio ranged from 1:5 to 1:1 and the final volume of the ligation 
did not exceed 20 pi. Reactions were incubated at 16 °C overnight and 2 to 5 pi of the 
reaction was subsequently transformed into a 50 pi aliquot of frozen competent 
Escherichia coli (E. coli) bacteria.
2.2.6 Site-directed mutagenesis
Site-directed mutagenesis was performed using the QuickChange II mutagenesis kit 
(Stratagene) following the manufacturer’s instructions. For each reaction, 1 pi of 
plasmid DNA template (20 to 50 ng) was mixed with 1 pi of each mutagenic primer (10 
ng), 1 pi of 10 x reaction buffer, 1 pi of dNTP mix, 4 pi of H2O and 1 pi of Pfu high 
fidelity polymerase. The PCR-based amplification was programmed as follow: 30 sec at 
95 °C, 16 cycles of 30 sec at 95 °C, 1 min at 55 °C and 1 min/kb of template at 68 °C. 
Samples were subsequently treated with 1 pi of Dpnl for 1 h at 37 °C, followed by 
transformation in XL-10 Gold ultracompetent cells (Stratagene).
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2.2.7 Sequencing
All the mutations introduced were verified by sequencing of the plasmid preparation, 
which was performed off-site by GeneService Ltd. When using plasmid DNA, 100 
ng/pl of DNA purified with the Maxiprep or Miniprep commercial kits (Qiagen) was 
used. When PCR-amplified DNA was used, 10 ng/pl of DNA purified using the Qiagen 
“PCR Purification Kit” was sent. All primers were diluted to 3.2 pM. Chromatograms 
were visualised using the Chromas Lite software (www.technelysium.com.au). Analysis 
and alignments were performed with CLC Free Workbench 4.0 software 
(www.clcbio.com).
2.3 Plasmid construction and PCR templates
All of the following plasmid constructs generated for the present study had their 
sequence verified by digestion with restriction endonuclease where possible and by 
sequence analysis.
2.3.1 Proviral constructs with packaging deletions and substitutions
pSVR is an infectious molecular clone of the ROD strain of HIV-2 (H IV -2rod; 
GenBank accession number M15390) (Clavel et al., 1986a; Guyader et al., 1987), which 
derives from pRODIO (Ryan-Graham and Peden, 1995) and contains a simian virus 40 
(SV40) origin of replication inserted in an EcoRl site in the vector DNA, 200 bp 5' of 
the 5' LTR (McCann, 1996; McCann and Lever, 1997). The replication characteristics 
of this clone and proviral construct pSVRDM, containing a 28 nt deletion in the 5' 
leader between nucleotides 380 and 408 of H IV -2rod, have been previously described
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(Griffin et al., 2001; McCann and Lever, 1997). Restriction sites and nucleotide 
numbering, where given, are relative to the first nucleotide of the viral RNA genome. 
Mutations in the 5' leader of HIV-2 were introduced by site-directed mutagenesis into a 
subclone of HIV-2, pGRAXS (Kaye and Lever, 1998). The mutagenic oligonucleotides 
used for the introduction of the Pal, SMI, SM2, SM4, SM5, SM6 and SM7 mutations 
are listed in Table 1. Subclone pGRAXS-SM2 was mutated using oligonucleotides SMI 
or SM6 to create pGRAXS-SM3 and pGRAXS-SM8, respectively. Subclone pGRAXS- 
SM6 was mutated using oligonucleotide SM4 to create pGRAXS-SM9. Sequences from 
the resulting subclones pGRAXSPal, pGRAXS-SMl, pGRAXS-SM2, pGRAXS-SM3, 
pGRAXS-SM4, pGRAXS-SM5, pGRAXS-SM6 , pGRAXS-SM7, pGRAXS-SM8 and 
pGRAXS-SM9 were introduced into the provirus by exchanging an AatlI (position - 
1384) - Xhol (position 2032) fragment, generating proviral constructs pSVRPal, 
pSVRSMl, pSVRSM2, pSVRSM3, pSVRSM4, pSVRSM5, pSVRSM6 , pSVRSM7, 
pSVRSM8 and pSVRSM9 respectively.
2.3.2 Envelope-deleted proviral constructs
The envelope-deleted proviral constructs pSVRANB and pSVRANBDM, which contain 
a 550 nt deletion in the env ORF between position 6369 and 6919, have been described 
elsewhere (Griffin et al., 2001). pSVRANBSMl, pSVRANBSM2 and pSVRANBSM3 
were generated by replacing the Aatll (position -1384) - Xhol (position 2032) fragment 
of pSVRANB with that of pGRAXS-SMl, pGRAXS-SM2 and pGRAXS-SM3, 
respectively. A proviral construct carrying a reversion of the DM mutation was also 
created in order to control for the absence of second-site mutations in pSVRANBDM 
which might have been introduced during the cloning process. The pSVRANBDM
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plasmid was mutated by site-directed mutagenesis using mutagenic oligonucleotide DM 
Rev (Table 1), creating construct pSVRANBDMrev.
Table 1: Mutagenic oligonucleotides used to introduce packaging signal deletion 
and substitutions by site-directed mutagenesis.
Mutagenic oligonucleotides
Name Sequence
Pal 5' GAACAAACCACGACTAGAAAGGCGCGGG 3’
SMI 5' GGCGCGGGCCGACCAACCAAAGGCAGCGTGTGG 3’
SM2 5' GGAACAAACCACGACCCTCTGCTCCTAGAAAGGCG 3’
SM4 5' CAAACCACGACGGAGTGGAGGTAGAAAGGCGCGGG 3'
SM5 5' GAAACCACGACCCTCGTGAGGTAGAAAGGCGCGGG 3’
SM6 5' CCAAAGGCAGCGTGTCCTCCGGGAGGAGAAGAGG 3'
SM7 5' CGACGGAGTGCTCCACACGCGGGCCGAGGTAC 3'
DM Rev
5' GGGCGGCAGGAACAAACCACGACGGAGTGCTCCTAGAAAGGCGCGG 
GCCGAG 3'
2.3.3 Envelope expressor constructs
pCMV-VSVG was a gift from Nijsje Dorman (Dorman, 2000) and contains the coding 
sequence of the vesicular stomatitis virus (VSV) G glycoprotein in the context of the 
pCDNA3 expression vector (Invitrogen). Expression of the VSV-G protein is controlled 
by the hCMV immediate early promoter.
2.3.4 Constructs for protein expression
The pGEXGag2 plasmid used for the expression of the Glutathione-S-transferase (GST) 
tagged HIV-2 Gag protein in E. coli bacteria culture has been described previously 
(Myers and Allen, 2002).
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2.3.5 Constructs used as templates for riboprobes in northern blot and 
RNase protection assay
Plasmids KS2VFKE and KS2VFEP have been previously described and contain HIV-2 
sequences from positions 306 to 751 and (-107) to 306 of pSVR, respectively, cloned 
into the polylinker of the pBluescript KSII(+) transcription vector (Stratagene) (Griffin 
et al., 2001; Kaye and Lever, 1998).
A glyceraldehyde-3-phosphate dehydrogenase (GAPDH) riboprobe template was 
created by reverse transcription-PCR (RT-PCR) amplification of the sequence from 
position 61 to 346 of the human GAPDH using 5' GGTGAAGGTCGGAGTCAACG 3' 
and 5? AATTAACCCTCACTAAAGGACTCCACGACGTACTC 3' primers. Total 
cytoplasmic RNA extracted from Jurkat T-cells served as template for the reaction.
2.3.6 PCR-derived templates for in vitro transcription
For the in vitro dimerisation assay, WT and mutant DNA templates were produced by 
PCR amplification of the corresponding proviral plasmid using HIV-2 Psi F 5' 
TAATACGACTCACTATAGGCTGAGTGAAGGC 3’ and Psi R 5’ AGGTACTT- 
ACCTTCACCC 3'.
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2.4 Preparation of plasmid DNA from bacterial cultures
2.4.1 Strains of Escherichia coli
•  DH5a
For general cloning, the DH5a strain of E. coli [F‘ cp80dlacZAM15 A(lacZYA- 
argF)U169 deoR recAl endAl hsdR17(rk', mk+) phoA supE44 X  thi-1 gyrA96 relAl] 
was used. Competent DH5a were prepared as described in section 2.4.2 from an 
original stock of frozen chemically competent bacteria purchased from Invitrogen.
•  ToplOF'
For the transformation of proviral plasmid DNA, the ToplOF' strain of E. coli [F' (laclq 
TnlO(TetR)) mcrA A(mrr-hsdRMS-mcrBC) (p80dlacZAM15 AlacX74 deoR recAl 
araD139 A(ara-leu)7697 galU galK rpsL (StrR) endAl nupG] (Invitrogen) was used. 
ToplOF' E. coli are deficient for Recombinase A l (recAl) to reduce occurrence of non­
specific recombination in cloned DNA and contain an F' episome, which carries the 
tetracycline resistance gene and allows isolation of single-stranded DNA from vectors 
that have an fl origin of replication. Chemically competent ToplOF' E. coli were 
obtained from Invitrogen.
2.4.2 Preparation of frozen competent E. coli
Frozen competent bacteria were prepared based on the method developed by Inoue 
(Inoue et al., 1990). Using a sterile loop, competent DH5a (Invitrogen) were plated on 
Luria Bertani (LB)-agar (10 g/1 tryptone, 5 g/1 yeast extract, 10 g/1 NaCl, pH 7.0, 15 g/1 
agar) and grown at 37 °C overnight. A single colony was picked with a sterile toothpick,
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resuspended in 10 ml of SOB medium (20 g/1 tryptone, 5 g/1 yeast extract, 10 mM NaCl,
2.5 mM KC1, 10 mM MgCl2, 10 mM MgSC>4, pH 7.0) and grown overnight at 37 °C, 
225 rpm in a shaking incubator. 500 pi of the overnight culture was used to inoculate 
250 ml of SOB medium and the bacteria were grown at room temperature (rt) with 
gentle rotation until an optical density (OD) at 600 nm of 0.6 was obtained. The bacteria 
were then incubated on ice for 10 min followed by pelleting at 2500 x g at 4 °C for 10 
min in a Sorvall RC3C-Plus centrifuge. The pellet was gently resuspended in 80 ml ice- 
cold TB (10 mM PIPES, 15 mM CaCl2, 250 mM KC1, pH adjusted to 6.7, then MnCl2 
added to 55 mM). The suspension was incubated on ice for 10 min followed by 
centrifugation as above. The pellet was resuspended in 20 ml ice-cold TB supplemented 
with 7 % (v:v) dimethyl sulfoxide (DMSO), swirled gently and incubated on ice for 10 
min. The bacteria were frozen in liquid nitrogen and stored in 50 pi aliquots at -80 °C.
2.4.3 Transformation of competent E. coli
A frozen aliquot of competent E. coli was thawed on ice for 5 to 10 min. Approximately 
100 ng of plasmid DNA was added to the cells. The reaction was mixed by taping the 
tube gently and immediately placed back on ice. The cells were incubated on ice for 30 
min to 1 h before being heat shocked for 45 sec at 42 °C. The cells were put back on ice 
for 2 min before addition of 500 pi preheated LB medium (10 g/1 tryptone, 5 g/1 yeast 
extract, 10 g/1 NaCl, pH 7.0). The cells were allowed to recover at 37 °C for 1 h with 
shaking at 200 rpm. The cells were then spun at 1000 x g for 5 min in a benchtop 
microcentrifuge and resuspended in 100 pi LB medium prior to plating on LB-agar 
containing 100 pl/ml ampicillin (Sigma-Aldrich). Plates were incubated at 37 °C for 24 
h. When ToplOF' bacteria were transformed with proviral plasmids, plates were 
incubated at 30 °C for 24 to 36 h to reduce the risk of recombination.
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2.4.4 Growth of bacterial culture
All strains of E. coli transformed with standard plasmids carrying the Ampicillin 
resistance (ampR) gene were grown in LB supplemented with 100 pg/ml ampicillin. 5 
ml cultures were grown in 30 ml universal tubes for small scale preparations of plasmid 
DNA and 500 ml cultures were grown in 2 1 Erlenmeyer flask for large scale 
preparations. DH5a E. coli were incubated at 37 °C whereas ToplOF' E. coli 
transformed with proviral constructs were incubated at 30 °C to prevent recombination.
2.4.5 Small scale preparation of plasmid DNA
A single colony was picked from a plate of transformed E. coli (see section 2.4.3) and 
resuspended in 5 ml of LB containing 100 pg/ml ampicillin (LB-Amp). The culture was 
incubated at 37 °C, 225 rpm overnight. If ToplOF' transformed with proviral DNA were 
used, the incubation temperature was decreased to 30 °C. 1 ml of the culture was then 
spun at 9500 x g for 5-10 min in a Heraeus Biofuge pico microcentrifuge and plasmid 
DNA was extracted by the alkaline lysis method using the Qiagen “Qiaspin Miniprep” 
kit. The manufacturer’s instructions were followed with the exception that plasmid 
DNA was resuspended in water instead of elution buffer EB which contains EDTA and 
may inhibit subsequent enzymatic reactions.
Integrity of the plasmid DNA was verified by agarose gel electrophoresis before either 
sequencing or large scale preparation. Where possible, a test restriction digest was 
performed to analyse the presence of the introduced mutation.
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2.4.6 Large scale preparation of plasmid DNA
250 to 500 jlxI  of the 5 ml culture used for small scale preparation was added to 250 to 
500 ml of LB-Amp in a 2 L Erlenmeyer flask and incubated at 37 °C (or 30 °C for 
ToplOF'), 225 rpm overnight. The culture was spun at 4500 x g for 20 min at 4 °C in a 
Sorval Evolution RC  centrifuge (rotor SLA-3000). Plasmid DNA was prepared by the 
alkaline lysis method using the “Qiagen Maxiprep” kit following the manufacturer’s 
instruction with the exception that plasmid DNA was resuspended in 500 pi water 
instead of buffer EB.
Integrity of the plasmid DNA was verified by agarose gel electrophoresis. The 
concentration and the level of proteins in the sample were determined by measuring the 
OD at 260 nm and the OD260nm/OD280nm ratio using a NanoDrop ND-1000 
spectrophotometer (Thermo Fisher), respectively.
All plasmids prepared by Maxiprep had their sequence verified (see section 2.2.7).
2.5 Cell culture techniques
2.5.1 Cell lines
•  Cos-1 cells
Cos-1 cells were obtained from the ECACC (catalogue number: 88031701). Cos-1 cells 
are derived from African Green Monkey kidney fibroblasts (CV-1 cells) transformed 
with an origin-defective mutant of Simian virus 40 (SV40) which encodes the wild type 
T antigen (Gluzman, 1981). Cos-1 cells were maintained in complete Dulbecco’s 
modified Eagle’s medium (DMEM; see section 2.5.2). DEAE-dextran transfection of 
pSVR-derived proviral DNA (section 2.5.7), which carries a SV40 origin of replication,
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into Cos-1 cells yielded a high level of HIV-2 particle release as measured by a reverse 
transcriptase (RT) assay (see section 2.8.5).
•  GHOST indicator cell line
The GHOST indicator cells, engineered by Drs. Littman and Kewal Ramani (Trkola et 
al., 1998), were obtained from the CFAR at NIBSC (catalogue number: ARP084). 
GHOST cells are human osteosarcoma (HOS) CD4 positive cells expressing the CCR5 
and CXCR4 chemokines on their surface and containing an HIV-2 LTR linked to a 
green fluorescent protein {gfp) gene, each under a specific selection (see section 2.5.3). 
GHOST cells were maintained in complete DMEM supplemented with antibiotics (see 
sections 2.5.2 and 2.5.3). Upon infection with HIV-2, the Tat protein frvms-activates the 
HIV-2 promoter and triggers the expression of GFP, which can be detected by 
fluorescence activated cell sorting (FACS) as described in section 2.6.2.
•  C33-A cells
C33-A cells, a human cervical carcinoma cell line (Auersperg, 1964), were obtained 
from the ATCC (catalogue number HTB-31) and were tested negative for human 
papilloma virus (Yee et al., 1985). C33-A cells were maintained in complete DMEM 
(see section 2.5.2) and transfected using the Calcium-phosphate method (see section 
2.5.7).
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•  Jurkat cells
Jurkat cells (Jurkat Clone E6-1) were obtained from the CFAR at NIB SC (catalogue 
number: ARP027). Jurkat cells are a CD4 positive human T-cell leukemia cell line 
expressing high levels of interleukin-2 (IL-2) after stimulation (Weiss et al., 1984). 
Jurkat cells were maintained in complete Roswell Park Memorial Institute media 
(RPMI-1640; see section 2.5.2). HIV-1 and -2 can establish persistent infection in 
Jurkat cells, with sustained levels of virus replication for prolonged periods.
•  PM1 cells
PM1 cells were a gift from Dr. Truus Abbink and can be obtained from the CFAR at 
NIBSC (catalogue number: ARP057). PM1 cells are a clonal derivative of HUT78, a 
human cutaneous T-cell lymphoma from peripheral blood of a patient with Sezary 
Syndrome (Lusso et al., 1995). PM1 cells were maintained in complete RPMI-1640 (see 
section 2.5.2). PM1 cells have the unique characteristic of supporting infection by a 
wide range of HIV-1 isolates, including primary and biologically pure macrophage- 
tropic isolates (Lusso et al., 1995).
•  SUP-T1 cells
SUP-T1 cells were a gift from Dr. Truus Abbink and can be obtained from the CFAR at 
NIBSC (catalogue number: ARP024). SUP-T1 cells are Non-Hodgkin’s T-cell 
lymphoma which express high levels of CD4 (Smith et al., 1984). SUP-T1 cells were 
maintained in complete RPMI-1640 (see section 2.5.2).
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2.5.2 Passage of cell lines
All media were completed with 10 % (v:v) fetal bovine serum (FBS; Gibco BRL) and 1 
% penicillin-streptomycin solution (10000 U/ml penicillin, 10 mg/ml streptomycin; 
Gibco BRL). All cells were grown in humid incubators at 37 °C in the presence of 5 % 
C 02.
Cos-1 and GHOST cells were grown in complete DMEM (Gibco BRL) to 80 % 
confluency. Additional antibiotics, as detailed in section 2.5.3, were used to passage the 
GHOST cells. Cells were split 1/10 twice a week. Cells grown in 75 cm2 flasks were 
washed in pre-waimed phosphate buffered saline (PbS; 137 mM NaCl, 2.7 mM KC1, 10 
mM Na2HP0 4 , 2 mM KH2P04 ) and detached by addition of 2.5 ml 1 x trypsin-EDTA 
solution (Gibco BRL). Trypsin was inactivated by addition of 7.5 ml serum-containing 
DMEM before 1 ml of cells was transferred to a new 75 cm2 flask.
Jurkat, PM1 and SUP-T1 cells were grown in complete RPMI-1640 (Gibco BRL) and 
split 1/10 with fresh media twice a week.
2.5.3 Antibiotic selection
GHOST cells were maintained and stored under selection for the expression of CD4, co­
receptors (CCR5 and CXCR4) and the HIV-2 LTR controlling expression of the gfjp 
gene by supplementing the DMEM with 100 pg/ml hygromycin (Invitrogen), 500 pg/ml 
geneticin (PAA) and 1 pg/ml puromycin (Sigma-Aldrich).
2.5.4 Cell viability and counting
A 10 pi aliquot was removed from thoroughly mixed cell suspensions and added to 10 
pi of a trypan blue solution (Sigma-Aldrich). The solution was homogenized by
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repeated pipetting prior to loading of 10 pi onto each chamber of an improved Neubauer 
haemocytometer. An average of two counts of the appropriate area of the grid was used 
to determine the cell density.
2.5.5 Freezing of cell stocks
Adherent cells were washed in PbS and detached by addition of 1 x trypsin-EDTA for 5 
min. Trypsin was inactivated by fresh serum-containing media and the cells were 
pelleted by centrifugation at 300 x g for 5 min in a MSE Falcon 6/300 centrifuge. 
Suspension cells were pelleted as before directly from the medium. Cell pellets were 
resuspended in 10 ml of the appropriate media supplemented with 20 % FBS and 10 % 
DMSO and 1 ml aliquots were placed at -80 °C overnight prior to storage in liquid 
nitrogen to allow for slow cooling down of the cells.
2.5.6 Resuscitation of cell stocks
Cells that were stored in liquid nitrogen were thawed at rt and added to 10 ml of pre­
warmed medium. Residual DMSO was removed by centrifugation at 300 x g for 5 min. 
The pelleted cells were resuspended in 10 ml of fresh pre-warmed media and incubated 
in a 25 cm2 flask at 37 °C, 5 % C 02.
2.5.7 Transfection techniques
•  DEAE-Dextran method
For the transfection of Cos-1 cells, the DEAE-dextran method was adapted from 
Mortlock (Mortlock et al., 1993). The day prior to transfection, 1.5 x 106 Cos-1 cells
107
Chapter 2: Materials and methods
were seeded into a 10 cm dish in fresh DMEM. The following day, 5 to 10 jug of 
plasmid DNA were mixed with 1.9 ml of pre-warmed PbS and 100 pi of DEAE-dextran 
(10 mg/ml in 1M Tris-HCl pH 7.5). The cells were washed twice with PbS before the 
DNA mixture was added. Cells were incubated for 30 min at 37 °C, 5 % CO2. The cells 
were then covered with 5 ml of 80 pM chloroquine diphosphate (prepared in serum-free 
DMEM media) prior to a further 2.5 h at 37 °C. The mixture was removed and the cells 
were shocked for 2 min with serum-free DMEM containing 10 % DMSO. Following 
two washes in serum-free DMEM, the cells were incubated in 10 ml of fresh complete 
DMEM for 48 h at 37 °C, 5 % C 02.
•  Calcium-phosphate method
C33-A cells were transfected using the calcium-phosphate method. The day prior to 
transfection, 1.5 x 106 C33-A cells were seeded into a 10 cm dish in fresh complete 
DMEM. The following day, 30 pg of plasmid DNA were diluted in 645 pi of H20  and 
mixed with 733 pi of 2 x HBS (50 mM HEPES pH 7.1, 250 mM NaCl, 1.5 mM 
Na2HP04 ) in a glass vial. 88 pi of 2M CaCl2 were added and the mixture was incubated 
at room temperature for 20 min. The mixture was then added dropwise to the cells and 
these were incubated at 37 °C for 24 h. After 24 h, the culture medium was removed, 
the cells were washed twice with warm PbS and fresh complete DMEM was added 
before incubation at 37 °C for a further 24 h.
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2.6 Virus culture and analysis
2.6.1 Preparation of concentrated virus supernatants
Virus-containing supernatant from transfected or infected cells was collected and 
filtered through a 0.45 pm filter. If the virus was isolated from suspension cells, the 
supernatant was first spun at 300 x g for 5 min to pellet the cells. Filtered viruses were 
precipitated in 0.5 V of 30 % (w:v) polyethylene glycol (PEG)-8000 (MW) in 0.4 M 
NaCl overnight at 4 °C. Precipitates were spun at 500 x g for 40 min at 4 °C and the 
supernatant was discarded. Following a second 5 min spin to remove any traces of PEG, 
the virus-containing pellet was resuspended in 500 pi of TNE (10 mM Tris-HCl pH 7, 
150 mM NaCl, 1 mM EDTA pH 8) and layered onto 500 pi of TNE-20 % (w:v) 
sucrose. The virus preparation was spun at 71550 x g in a Beckman Optima MAX 
Ultracentrifuge (Rotor TLA-55) for 2 h at 4 °C. The supernatant was removed and the 
virus was resuspended in the appropriate medium depending on the downstream 
application (see sections 2.6.2, 2.6.3, 2.6.5 and 2.7.5).
The few remaining microliters of virus-containing TNE were used to determine the RT 
activity of the preparation as described in section 2.8.5.
2.6.2 Infectivity assay using the GHOST cells
For each virus to be analysed, two 10 cm dishes of Cos-1 or C33-A cells (1.5 x 106 cells 
per dish) were transfected with 5 pg of proviral DNA as described in section 2.5.7 and 
incubated for 48 h.
The day prior to infection, 2 x 105 GHOST cells were seeded in 6 -well plates in 
selection medium (see section 2.5.3).
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At 48 h post-transfection, the viruses were concentrated as described above, 
resuspended in 500 pi DMEM supplemented with 1 x penicillin/streptomycin, 10 % 
FBS and 8 pg/ml polybrene (hexadimethrine bromide, Sigma-Aldrich) and pooled. The 
RT activity of each virus preparation was determined as described in section 2.8.5 and 
used to calculate the virus input. Increasing amounts of virus were used to infect the 
GHOST cells in a total volume of 1 ml DMEM supplemented with 1 x 
penicillin/streptomycin, 10 % FBS and 8 pg/ml polybrene. The cells were incubated at 
37 °C, 5 % CO2 for 16 h. The medium was then replaced with fresh DMEM 
supplemented with 1 x penicillin/streptomycin, 10 % FBS, hygromycin (100 pg/ml), 
geneticin (500 pg/ml) and puromycin (1 pg/ml) and the cells were incubated at 37 °C, 5 
% CO2 for a further 48 h.
The cells were next washed with PbS and detached using 400 pi of 1 x trypsin-EDTA 
prior to addition of 600 pi of DMEM. The cells were spun at 300 x g for 5 min and 
resuspended in 200 pi of a freshly prepared 2 % (w:v) paraformaldehyde (Sigma- 
Aldrich) solution to fix the cells and inactivate the virus. The expression of GFP was 
measured by FACS using a BD FACSCalibur system (BD Biosciences) and the results 
were analysed with the WinMDI software (http://facs.scripps.edu/software.html).
2.6.3 T-cell replication assay
For the long-term study of viral replication, Jurkat T-cells were infected with HIV-2 
produced from transfection of Cos-1 cells and passaged over a period of approximately 
3 months. For each virus to be analysed, two 10 cm dishes of Cos-1 (1.5 x 106 cells per 
dish) were transfected with 5 pg of proviral DNA as described in section 2.5.7 and 
incubated for 48 h. The viruses were concentrated as described in section 2.6.1, 
resuspended in 500 pi complete RPMI-1640 and pooled. The RT activity of each virus
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preparation was determined as described in section 2.8.5 and used to calculate the virus 
input. Typically, an equivalent of 10000 cpm was used to infect 1 x 106 Jurkat cells in 2 
ml complete RPMI-1640 supplemented with 10 pg/ml DEAE-dextran. The cells were 
incubated overnight at 37 °C, 5 % CO2 before being transferred into a 25 cm2 flask 
containing 8 ml of complete RPMI-1640. The cells were returned to the incubator for a 
further 4 to 6 days, at which point the first sample was taken. Two 10 pi samples were 
used to determine the RT activity (see section 2.8.5). The cells were then split lA every 8 
days and viral replication was followed by measuring the RT activity of the culture 
every 4 days.
For the short-term study of viral replication and the analysis of revertants, SUP-T1 and 
PM1 cells, which produce a higher titre of HIV-2 than Jurkat cells, were used. Viruses 
were produced by transfection of Cos-1 cells (section 2.5.7) and purified as described in 
section 2.6.1. The RT activity of each virus preparation was determined as described in 
section 2.8.5 and used to calculate the virus input required. Typically, 5000 to 10000 
cpm was used to infect 1 x 106 PM1 or SUP-T1 cells in a total of 5 ml complete RPMI- 
1640. Cells were maintained at 37 °C, 5 % CO2 and split 1/5 twice a week. Viral 
replication was followed by measuring the RT activity of two 10 pi samples every 2 to 
4 days.
2.6.4 Passage of viruses
Viruses cultured in PM1 cells were passaged in order to study the evolution of the 
mutant viruses. Following infection of PM1 cells as described above and once the peak 
of infection was reached as determined by RT activity, 500 pi of virus-containing cell- 
free supernatant was used to infect 1 x 106 PM1 cells in 5 ml RPMI-1640 supplemented 
with antibiotics and FBS. The same aliquot of virus was frozen at -20 °C and the cell
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pellet was used for sequencing analysis. The cell pellet was resuspended in 500 pi of 
PbS followed by addition of 100 pi of lysis buffer (10 mM Tris-HCl pH 8 , 1 mM 
EDTA, 0.5 % Tween-20) and 6 pi of 20 mg/ml Proteinase K (Ambion). The mixture 
was mixed gently and incubated at 56 °C for 1 h to inactivate any residual virus. After 
inactivation of the proteinase K for 10 min at 95 °C, 1 pi of the genomic DNA 
preparation was used in a 50 pi PCR using different sets of HIV-2 specific primers (see 
Table 2) to amplify the leader region (IF and 751R), the gag ORF (514F and 1440R; 
122IF and 2144R; 1800F and 2627R) and the U3 promoter region (NEF2F and 300R; 
RODU3 and 300R; -107F and 300R). Amplifications were performed as described 
previously (section 2.2.3) except that the number of cycles was increased to 40 due to 
the low amount of template present in the sample. The PCR amplicons were purified 
using the Qiagen “PCR purification kit” and sent for sequencing in order to determine if 
reversion had occurred.
2.6.5 Electron microscopy of purified virus particles
Envelope-deleted viruses were produced by transfection of pSVRANB and 
pSVRANBDM into Cos-1 cells as described in section 2.5.7. Viruses were purified on a 
20 % sucrose-cushion as detailed above and washed three times in 50 pi 100 mM NaCl, 
50 mM MOPS (pH 7) buffer by centrifugation at 6000 x g for 8 min at 4 °C. Pelleted 
virions were resuspended in 10 pi of the same buffer at 4 °C for 24 h prior to negative 
staining. 0.8 pi of virion preparation was applied to a carbon coated grid and stained 
with a few drops of 1 % uranyl acetate. Micrographs were recorded on a Philips 
EM208S at a nominal magnification of x 20,000. Electron microscopy was performed 
in the Structural Studies division at the Laboratory of Molecular Biology, in 
collaboration with R.A. Crowther.
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Table 2: Sequences of HIV-2 specific oligonucleotides used for the sequencing of 
potential revertants in the evolution study.
Primer names Primer sequences
IF 5’ GGTCGCTCTGCGGAGAGGCTGG 3’
751R 5’ GGTACCATTGGATCTAAAACTG 3’
514F 5s CCTACCTTTAGACAGGTAG 3’
1440R 5’ CATAGCTTTGGAACGGC 3’
1221F 5’ GCGGGGCAGCTTAGAGAGCC 3’
2144R 5’ CTACTGGCTGACCCTC 3’
1800F 5’ GGACACATCATGACAAACTGC 3’
2627R CCTTGTTTAGTTCTCTG 3’
NEF2F 5’ GTGGAGGTATTGGAACG 3’
RODU3 5’ GGAAGGGATGTTTTACAG 3’
-107F 5’ CTGCAGGGACTTTCCAGAAGG 3’
300R 5’ TCCCTGTTCAGGCGCCAACC 3’
2.7 Synthesis, preparation and analysis of RNA
2.7.1 In vitro transcription
RNA used in the in vitro dimerisation assays was produced as follows. 5 pi of PCR- 
derived template (see section 2.3.6) was mixed with 5 pi of 10 x transcription buffer 
(Ambion), 1.5 pi RNasin (40 U/pl; Promega), 2 pi each of 10 mM ATP, GTP and CTP 
(Promega), 6 pi of 100 pM UTP (Promega), 2 pi [a-32P] UTP 800 Ci/mmol (20 
mCi/ml; GE Healthcare or Perkin Elmer), 22 pi H2O and 2.5 pi T7 RNA Polymerase 
(Ambion). The reaction was incubated at 37 °C for 1 to 2 h before addition of 2 pi of 
TURBO DNase (Ambion) and incubation at 37 °C for 15 to 30 min. RNAs were 
purified as described in section 2.7.2.
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Antisense riboprobes used in the ribonuclease protection assays (RPAs) were 
synthesised using the T3 RNA polymerase (Promega). 2 pi of linearised template (0.5 
mg/ml) was mixed with 4 pi of 5 x transcription buffer (Promega), 2 pi of 100 mM 
DTT, 0.5 pi RNasin (40 U/pl), 1 pi of each 10 mM ATP, GTP and CTP, 2.4 pi of 100 
pM UTP, 2.5 pi [a-32P] UTP 800 Ci/mmol (20 mCi/ml), 1 pi of T3 RNA Polymerase 
and 2.6 pi of H2O. The reaction was incubated at 37 °C for 1 to 2 h before addition of 1 
pi of TURBO DNase and incubation at 37 °C for 15 min. 21 pi of 2 x loading buffer II 
(Ambion) were added and the probes were gel-purified as described below.
Antisense riboprobes used in the northern blot were synthesised as follow. 10 pi of 
linearised DNA template (0.5 mg/ml) was mixed with 5 pi of 10 x Biotin RNA 
labelling mix (Roche), 10 pi of 5 x transcription buffer (Promega), 5 pi of lOOmM 
DTT, 1.5 pi of RNasin (40 U/pl), 13.5 pi of H20  and 5 pi of T3 RNA Polymerase 
(Promega) and incubated at 37 °C for 1 h. 5 pi of RQ DNase I (Promega) were added 
and the reaction was incubated at 37 °C for a further 15 min. Following purification 
through a G-50 sephadex column, riboprobes were aliquoted and stored at -20 °C.
2.7.2 Purification of in vitro transcribed RNA
Radiolabelled RNAs used in the in vitro dimerisation assay were quantified by TCA 
precipitation (see section 2.7.3) and purified as follow. One volume of 25:24:1 (v:v:v) 
phenol:chloroform:isoamyl alcohol (IAA) at pH 4.7 (Sigma-Aldrich) was added to the 
transcription reaction, thoroughly mixed by vortexing and spun for 2 min at 16000 x g. 
The top layer was transferred into a clean tube containing one volume of 24:1 (v:v) 
chloroform-LAA (Sigma-Aldrich), mixed by vortexing and spun for 2 min at 16000 x g. 
The top layer was transferred into a clean tube containing 0.1 V 5 M NH4OAC and 2.5 
V 100 % EtOH, mixed by vortexing and precipitated at - 80 °C for at least 30 min. The
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RNA was pelleted by centrifugation at 16000 x g for 15 min at 4 °C, and resuspended in 
the appropriate volume of DEPC-treated water.
Riboprobes used in the RPA were gel-purified on an 8 M urea 5 % acrylamide gel run 
in 1 x TBE at 250 Volts for 30 min. After electrophoresis, the gel was wrapped and 
exposed to X-ray film for 1 to 3 min. The riboprobe bands were cut out and eluted in 
350 pi of probe elution buffer (Ambion) at 37 °C overnight.
Riboprobes used in the northern blot were purified through a G-50 sephadex column 
(Roche) following the manufacturer’s instructions.
2.7.3 TCA precipitation
Radiolabelled RNAs used in in vitro dimerisation assays were quantified by the TCA 
precipitation method. After incubation with DNase, 1 pi of radiolabelled RNA was 
removed from the reaction and diluted in 10 pi of H2O. 1 pi of the dilution was mixed 
with 10 pi of 10 mg/ml yeast tRNA, 89 pi of H2O and 500 pi of 5 % trichloroacetic acid 
(TCA) and incubated on ice for 10 min. The reaction mixture was passed onto a glass 
microfibre filter previously equilibrated with 5 % TCA. The filter was washed once 
with 5 % TCA, once with acetone and air dried. As a control for incorporation, 1 pi of 
the original dilution was spotted onto another filter and air dried. Both filters were 
placed into scintillation vials, covered with 1 ml of OptiPhase HiSafe 2 scintillant and 
the percentage of incorporation was determined using a TRI-CARB 2100 TR liquid 
scintillation analyser (Packard).
2.7.4 Isolation of cytoplasmic RNA
Cytoplasmic RNA was extracted using the Qiagen “RNeasy mini kit”.
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Adherent cells were washed once in cold PbS, lysed directly in the dish by addition of 
600 |j,l of buffer RLT from the “RNeasy mini kit” and the cytoplasmic RNA was 
extracted following the manufacturer’s instructions.
If suspension cells were used, the cells were pelleted by centrifugation at 300 x g for 5 
min, washed in cold PbS once and the cell pellet was resuspended in 600 pi of buffer 
RLT. The cytoplasmic RNA was subsequently extracted following the manufacturer’s 
instructions and eluted in 40 to 50 pi of RNase-free H2O.
2.7.5 Isolation of virion RNA
Virion RNA was extracted using the Qiagen “QiAamp Viral RNA mini Kit”, following 
the manufacturer’s instructions. Virions were pelleted as described in section 2.6.1 and 
resuspended in 140 pi of RPMI-1640 prior to extraction. The RNA was eluted in 40 to 
50 pi of buffer AVE.
2.7.6 DNase treatment of RNA samples used in the RPA
RNA samples used in the RPA were DNase treated to remove any trace of plasmid 
DNA carried over during the purification process. Cytoplasmic and virion RNA samples 
purified using commercial kits were eluted in 40 pi of H2O and buffer AVE, 
respectively. 5 pi of 10 x TURBO buffer and 5 pi TURBO DNase (Ambion) were 
added and the reactions were incubated at 37 °C for 30 min. RNAs were then extracted 
once with phenol-chloroform and once with chloroform as described above and 
precipitated with 0.1 V 5 M NH4OAC and 2.5 V 100 % EtOH at -80 °C for at least 30 
min. Samples were spun at 16000 x g for 15 min and resuspended in 50 pi of RNase- 
free H20 .
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2.7.7 RNase Protection Assay
RPAs were performed using the “RPA III kit” from Ambion as recommended by the 
manufacturer. Riboprobes were synthesised and purified as described in sections 2.7.1 
and 2.7.2. Following overnight elution of the probe in the probe elution buffer 
(Ambion), a 10 pi aliquot was removed, added to 2 ml OptiPhase HiSafe 2 scintillant 
and counted in the liquid scintillation analyser (Packard). 2 x 105 cpm was used for each 
riboprobe tested. Cytoplasmic RNA inputs were normalised on concentration, typically 
0.5 pg. Virion RNA inputs were normalised on RT activity as determined by a RT assay 
(see section 2.8.5), with an equivalent of 2500 cpm being used. Cytoplasmic and virion 
RNAs were first co-precipitated with the KS2XPKE, KS2'FEP or GAPDH riboprobes. 
The probes were allowed to anneal at 42 °C overnight prior to digestion of single 
stranded RNA using a 1:100 dilution of RNaseA/Tl provided in the kit for 30 min at 37 
°C. The protected RNA fragments were precipitated using the RNase 
inactivation/precipitation solution, resuspended in 10 pi of loading buffer II (Ambion) 
and separated on an 8 M urea, 5 % polyacrylamide gel alongside radiolabelled “Century 
Plus” RNA size markers (Ambion). The gels were run at 1100 Volts for approximately 
2 h, dried and autoradiographed. RNAs were quantified using an Instant Imager 
(Packard) or by densitometry using the ImageJ software (http://rsb.info.nih.gov/ij/). The 
GAPDH probe was used to correct the level of cytoplasmic RNA for loading variations, 
with the mock transfected lane set at 100 %. Plasmid DNA contamination was 
accounted for using the KS2VFEP probe, which allows differential detection of DNA 
(protected fragment of 413 nt) and RNA (protected fragment of 306 nt). The packaging 
efficiency was determined as follows: [(viral RNA)/(cyto RNA)]Mutant / [(viral 
RNA)/(cyto RNA)]Wt.
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2.7.8 Northern blot
Northern blots were performed using the “NorthemMax-Gly kit” and “BrightStar 
Biodetect kit” from Ambion, following the manufacturer’s instructions.
Cytoplasmic and virion RNA samples were normalised on concentration and RT 
activity as before, with a typical amount of 2 pg cytoplasmic RNA and an equivalent of 
2500 cpm virion RNA used. The samples were electrophoresed at room temperature on 
a non-denaturing 0.8 % agarose-LE (Ambion) gel in 1 x gel prep/running buffer 
(Ambion) for 4 h at 60 to 80 Volts. The Biotinylated Millenium RNA size markers 
(Ambion) were run alongside the samples. The RNA was transferred onto a positively 
charged nylon membrane (BrightStar membrane; Ambion) overnight using the supplied 
transfer buffer. The membranes were cross-linked by baking at 80 °C for 15 min and 
pre-hybridised in UltraHyb for 30 min at 68 °C. Biotinylated KS2VFKE (0.4 nM final 
concentration) was hybridised overnight at 68 °C in UltraHyb. The membrane was 
washed once in 2 x standard sodium citrate (300 mM NaCl, 30 mM sodium citrate, pH 
7; SSC), 0.1 % SDS for 10 min at rt and twice in 0.1 x SSC, 0.1 % SDS for 15 min at 
68 °C. The blot was detected using the BrightStar Biodetect kit from Ambion following 
the manufacturer’s protocol. The blot was analysed by densitometry using the ImageJ 
software and the percentage of dimer was calculated.
2.7.9 In vitro dimerisation assay
The in vitro dimerisation assay was adapted from the method previously described by 
Dirac and co-authors (Dirac et al., 2001). 20 to 40 nM of radiolabelled Psi RNAs 
(position 350 to 450) were incubated in 10 pi of dimer buffer (10 mM Tris-HCl pH 7.5, 
40 mM NaCl and 5 mM MgCb) for 10 min at 65 °C, followed by slow cool down to 
room temperature. Dimers were stabilised on ice for 2 min and 2 pi of native loading
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buffer containing 30 % glycerol were added. Samples were analysed on a 1.5 % agarose 
gel run in 0.25 x TBE for 1 h 30 at room temperature at 30 to 40 mAmp. Gels were 
fixed in 40 % MeOH, 10 % acetic acid, dried and autoradiographed. RNA was 
quantified by densitometry using the ImageJ software.
2.7.10 RT-PCR
For the amplification of viral sequences from the HIV-2 genome, viral RNA was 
extracted from a known amount of purified virions, as determined by RT activity, using 
the Qiagen “QIAamp Viral RNA mini kit” as described above. To control for loss of 
RNA during the extraction, 1 pg of in vitro transcribed GAPDH RNA (pos. 61 to 346, 
see section 2.3.5) was added to the virions prior to extraction. For the HIV-2 specific 
RT-PCR, 10 pi of neat or diluted viral RNA was mixed with 25 pi of 2 x BioMix Red 
(Bioline), 1 pi of 20 pM HIV-2 Psi F, 1 pi of 20 pM HIV-2 Psi R, 12 pi of H20  and 1 
pi of AMV RT (Promega). The GAPDH control RT-PCR was performed similarly 
using primers 5’ GGCACCGTCAAGGCTGAG 3’ and 5' AATTAACCCTCAC- 
TAAAGGACTCCACGACGTACTC 3'. A no RT control was set up in parallel. 
Reactions were reverse-transcribed and amplified in a one-step RT-PCR using the 
following program: 47 °C for 1 h, 95 °C for 2 min, [95 °C for 30 sec, 45 °C for 30 sec, 
72 °C for 30 sec] for 45 cycles and a final extension at 72 °C for 5 min. RT-PCR 
products were separated by agarose gel electrophoresis in 1 x TBE.
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2.7.11 Computer analysis of nucleic acids
RNA secondary structures were predicted using the version 3.2 of the free energy 
minimisation algorithm mfold (Mathews et al., 1999; Zuker, 2003) available at 
http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/ma-forml.cgi.
Nucleotide alignments were performed using the basic local alignment search tool or 
BLAST (Altschul et al., 1997) available at http://blast.ncbi.nlm.nih.gov/Blast.cgi.
2.8 Preparation and analysis of proteins
2.8.1 Preparation of proteins from transfected cells
Transfected cells were washed once with ice-cold PbS, trypsinised using 1 x trypsin- 
EDTA solution and pelleted by centrifugation at 300 x g for 5 min. The cell pellet was 
resuspended in 100 pi PbS and 100 pi of 2 x protein loading buffer (100 mM Tris-HCl 
pH 6 .8, 200 mM p-mercaptoethanol, 4 % (w:v) SDS, 0.2 % bromophenol blue and 20 % 
(v:v) glycerol) was added. The cells were sonicated five times for 1 min at 50 % power 
using a XL2020 sonicator (Heat Systems) prior to analysis by SDS-polyacrylamide gel 
electrophoresis (PAGE) as described below.
2.8.2 Preparation of proteins from virions
Virions were purified through 20 % sucrose cushion as described in section 2.6.1 and 
resuspended in 100 pi PbS. 100 pi of 2 x protein loading buffer was added and virions 
proteins were analysed by SDS-PAGE.
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2.8.3 SDS-PAGE
SDS-PAGE was used to analyse proteins levels. Samples were heat-denatured at 95 °C 
for 3 min prior to loading on 10 to 15 % polyacrylamide gel prepared as described in 
Molecular Cloning (Sambrook and Russell, 2001). Prestained protein markers (GE- 
Healthcare) were run in parallel for size determination. When a broad range resolution 
was required, 4-20 % gradient gels (Pierce) were used according to the manufacturer’s 
instructions.
2.8.4 Western blot analysis
Following separation on a SDS-PAGE, the proteins were transferred onto nitrocellulose 
membrane (Hybond-C extra, GE Healthcare) in 1 x transfer buffer (25 mM Tris-HCl, 
200 mM glycine, 20 % (v:v) MeOH) overnight at 20 Volts or for 2 h at 60 Volts. 
Membranes were blocked in PbS, 0.05 % Tween-20, 5 % milk for at least 30 min at rt 
prior to incubation with the primary antibody. Antibodies were diluted as recommended 
by the manufacturer in the blocking solution. Following incubation at rt for 1 h with 
gentle agitation, the blot was washed three times for 10 min in PbS, 0.05 % Tween-20 
and incubated with the horseradish peroxidase (HRP)-conjugated secondary antibody 
for 1 h at rt. The blot was washed three times in PbS, 0.05 % Tween-20, developed 
using the ECL reagents (Pierce) and exposed to X-ray film.
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2.8.5 Reverse Transcriptase assay
The reverse transcriptase assay was first described by Potts (Potts, 1990). 10 pi of 
sample was mixed with 50 pi of RT solution (80 mM Tris-HCl ph 7.8, 120 mM KC1,
3.2 mM DTT, 7.92 mM MgCk, 80 pg/ml Poly(A), 2.52 pg/ml oligo dT (12-18), 4 % 
Nonidet-P40, 0.05 pCi [a-32P] dTTP) and incubated at 37 °C for 1 h 30 min. 5 pi were 
spotted on chromatography paper (DE81 anion exchanger, Whatman), air dried for 15 
min and washed four times in 2 x SSC and twice in 96 % EtOH. The paper was dried 
and radioactivity was counted on a Matrix 96 direct beta counter (Packard).
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3 Relationship between genomic RNA dimerisation, 
packaging and viral infectivity in HIV-2
3.1 Introduction
Retroviruses encapsidate two copies of positive sense single-stranded genomic RNA. 
Encapsidation is very specific, as the virus has to select and package the full length 
genomic RNA in preference to the vast excess of cellular and viral subgenomic RNA 
species. In HIV-1, the Gag structural protein interacts with a highly structured RNA 
motif located downstream of the splice donor, ensuring specificity of encapsidation for 
full length RNAs (Aldovini and Young, 1990; Baudin et al., 1993; Berkowitz et al., 
1995; Clever et al., 1995; Dannull et al., 1994; Gorelick et al., 1990; Harrison and 
Lever, 1992; Hayashi et al., 1992; Lever et al., 1989; Luban and Goff, 1994; McBride 
and Panganiban, 1996).
In the case of HIV-2, the process is less well understood. Although some reports have 
suggested that sequences downstream of the splice donor are required for RNA 
packaging (Arya et al., 1998; Garzino-Demo et al., 1995; Poeschla et al., 1998), the 
main packaging determinant (Psi) was shown to be located upstream of the major splice 
donor (Griffin et al., 2001; McCann and Lever, 1997). As a result, HIV-2 has been 
shown to preferentially package its genome in a cis rather than a trans manner in order 
to specifically encapsidate the unspliced genomic RNA (Kaye and Lever, 1999). The 
structural Gag protein is therefore translated from the full length unspliced RNA and 
encapsidates genomic RNAs present in the same pool of RNAs that were translated.
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This cis mechanism, combined with a limited availability of the Gag polyprotein,
provides specificity (Griffin et al., 2001; Kaye and Lever, 1999). It has also been
proposed that the formation of an extended stem-loop 1 (SL-1) structure in the HIV-2 5'
leader, which overlaps with the packaging signal, is required for efficient genome
encapsidation and viral replication (Lanchy and Lodmell, 2007), providing evidence
that specific RNA structures are implicated in HIV-2 RNA packaging.
Retroviruses are unique amongst other viruses as they have a diploid genome. In HIV-1,
genome dimerisation has been shown to occur by loop-loop interaction via a
palindromic sequence termed the dimer initiation site (DIS) and subsequent formation
of a ‘kissing-loop’ complex (Clever et al., 1996; Haddrick et al., 1996; Laughrea and
Jette, 1994, 1996; Mujeeb et al., 1998; Muriaux et al., 1996b; Paillart et al., 1994;
Paillart et al., 1996b; Paillart et al., 1997; Skripkin et al., 1994).
In HIV-2, the sequence initiating dimerisation has not been clearly identified. A 
palindromic sequence (pal) within the encapsidation signal was shown to be important 
for the regulation of the dimerisation process in vitro (Baig et al., 2007; Lanchy et al., 
2003a). In addition, several in vitro studies proposed that a palindrome located in the 
loop of SL-1, immediately downstream of Psi, and structurally analogous to the HIV-1 
DIS (Laughrea and Jette, 1994; Skripkin et al., 1994), could act as the DIS for HIV-2 
(Dirac et al., 2001; Lanchy and Lodmell, 2002). Additional sequences in the PBS were 
suggested to act as dimerisation signals (Jossinet et al., 2001) but subsequently shown 
only to promote the formation of a weak dimer in contrast to studies implicating the 
putative DIS (Lanchy and Lodmell, 2002). To date, the presence of RNA dimers in 
HIV-2 virions has not been demonstrated.
Since the cA-acting RNA elements required for retroviral RNA dimerisation and 
encapsidation are often located in close proximity in the 5' RNA leader, it has been
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suggested that these two processes may be interdependent (Lanchy et al., 2003a; Paillart
et al., 1996a; Russell et al., 2003a; Russell et al., 2004; Sakuragi et al., 2003; Torrent et
al., 1994; Whitney and Wainberg, 2006). In addition, the nucleocapsid domain of the
Gag polyprotein of several retroviruses has been proposed to act as a trans-acting factor
involved in both genome encapsidation (Aldovini and Young, 1990; Berkowitz et al.,
1995; Fu et al., 2007; Gorelick et al., 1988; Gorelick et al., 1990; Meric and Spahr,
1986; Rein et al., 1994; Schwartz et al., 1997) and dimerisation (Bonnet-Mathoniere et
al., 1996; Darlix et al., 1990; Feng et al., 1999; Feng et al., 1996b; Lanchy et al., 2003b;
Laughrea et al., 2001; Muriaux et al., 1996a; Prats et al., 1990). In MLV too,
dimerisation and packaging are linked since mRNA molecules containing the packaging
signal were shown to be encapsidated as dimers (Hibbert et al., 2004).
Interestingly, several in vitro studies have shown that long-range interactions can
regulate RNA dimerisation in HIV-1 and HIV-2 (Berkhout et al., 2002; Dirac et al.,
2002; Huthoff and Berkhout, 2001; Lanchy et al., 2003a) and it has been proposed that
RNA packaging may also be regulated through alternative RNA conformations (Lanchy
et al., 2003a; Paillart et al., 2002).
However, in HIV-2, a clear relationship between genome dimerisation and 
encapsidation has not been established and it remains to be demonstrated whether the 
dimerisation of the genome is a prerequisite for its encapsidation, as proposed for HIV-1 
(for review see Russell et al., 2004).
Efficient genome dimerisation and encapsidation have been shown to be important for 
HIV infectivity. Mutations that impair RNA packaging often result in a delay or defect 
in replication and a reduced infectivity in HIV-1 (Aldovini and Young, 1990; Clavel 
and Orenstein, 1990; Clever and Parslow, 1997; Gorelick et al., 1990; Lever et al., 
1989). Similarly, genomic RNA dimerisation has been shown to influence viral
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infectivity, as HIV-1 mutants with a reduction in genome dimerisation also had a
decreased infectivity (Clever and Parslow, 1997; Laughrea et al., 1997; Russell et al.,
2003b). Interestingly, a mutation that disrupted the HIV-1 DIS base-pairing did not
affect genome dimerisation but resulted in a decrease in the level of RNA packaged in
the virions and a delay in viral replication (Berkhout and van Wamel, 1996). While
efficient RNA packaging has been shown to be required for HIV-2 replication (Griffin
et al., 2001; Lanchy and Lodmell, 2007; McCann and Lever, 1997), it has not been
determined whether the same is true for genome dimerisation.
In this study, the relationship between genome dimerisation, packaging and viral 
infectivity in HIV-2 was investigated. The roles of the Psi and putative DIS palindromes 
in HIV-2 genome dimerisation and viral infectivity were analysed. Using site-directed 
mutagenesis, deletions and substitutions were introduced in Psi and the putative DIS 
palindrome and genomic RNA packaging and dimerisation, protein production and viral 
infectivity were assessed. It was shown that deletion of Psi rendered the genomic RNA 
monomeric in virion produced in cell culture {in virio) as well as in vitro. Furthermore, 
the results demonstrated that the putative DIS palindrome was not required for genomic 
RNA dimerisation. Instead, mutations of the Psi palindrome pal resulted in a significant 
reduction in the amount of dimeric genome present in the virions and a decrease in 
packaging efficiencies. In addition, replication in T-cells was impaired in all 
dimerisation-deficient mutants. Nonetheless, viral infectivity was found to be affected 
independently of the reduction in RNA packaging and despite normal Gag protein 
production and processing.
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3.2 Deletion of the main packaging determinant renders the RNA 
monomeric in cell-culture as well as in vitro
The main HIV-2 packaging determinant was identified upstream of the major splice 
donor (Griffin et al., 2001), at position 380-408 of the H IV -2rod genome (Figure 3.1 A 
and B ). Deletion of this 28 nt sequence (DM mutant, Figure 3.1 A and C) was found to 
greatly reduce genomic RNA packaging (Griffin et al., 2001). Since dimerisation and 
encapsidation of the genome have been proposed to be linked in HIV-1 and HIV-2, it 
was decided to analyse the native state of the wild type and DM mutant RNA transcripts 
as well as genomic RNAs (Figure 3.2). First, the level of dimeric RNA was analysed in 
an in vitro dimerisation assay. This kind of assay had been successfully used to identify 
the sequences required for HIV-1 genome dimerisation (Laughrea and Jette, 1994; 
Skripkin et al., 1994) and to predict a putative DIS in HIV-2 (Dirac et al., 2001; Lanchy 
and Lodmell, 2002). Using the conditions described by Dirac and co-workers (Dirac et 
al., 2001) and detailed in section 2.7.9, the deletion of the DM sequence was found to 
reduce the in vitro dimerisation of a 130 nt RNA transcript comprising nucleotides 350 
to 480 of the H IV -2rod genome by approximately twofold (Figure 3.2A and B ). 
Similarly, when the genomic RNA from purified virions was analysed by native 
northern blot (Figure 3.2C), the amount of dimeric genome in the DM mutant was 
significantly decreased from 80 % (wild type) to 30 % (Figure 3.2D).
This was the first evidence of dimeric genomes in HIV-2 virions and confirmed that 
HIV-2 genomic RNA, like that of all exogenous retroviruses studied to date, is dimeric 
within viral particles. In addition, these results implied that the HIV-2 packaging signal 
may contain sequences that are important for RNA dimerisation.
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Figure 3.1: Genomic and structural context of the HIV-2 Psi deletion mutant.
(A) Schematic genetic organisation of the HIV-2ROd molecular clone, pSVR. LTR, long 
terminal repeat; packaging signal (Psi); SD, splice donor; RRE, Rev responsive element; U3, 
unique 3'; R, repeat; TAR, Tnms-activation responsive; PA, Poly A; PBS, Primer binding site; 
DIS, Putative dimer initiation site; WT, wild type; DM, DM deletion mutant. The packaging 
signal and putative DIS are indicated in red and blue respectively. (B) Structure of the WT HIV- 
2 5' RNA leader (from position 370 to 490) based on biochemical analysis (Baig et al., 2007; 
Damgaard et al., 1998; Dirac et al., 2001; Lanchy et al., 2004) and minimal free-energy 
modelling using mfold (Mathews et al., 1999; Zuker, 2003). The packaging signal Psi is 
indicated in red and the putative DIS in blue. (C) Structure of the DM mutant 5' RNA leader 
(position 370 to 462) predicted by minimal free-energy modelling using mfold. The putative 
DIS is in blue.
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Figure 3.2: Deletion of the HIV-2 packaging signal significantly reduces genomic 
RNA dimerisation.
(A) Representative in vitro dimerisation assay using wild type (WT) and DM mutant (DM) 
RNA transcripts (position 350-480 of the HIV-2ROd genome). The positions o f the dimeric and 
monomeric RNA species are indicated. (B) Quantification of monomeric and dimeric RNA 
species for the WT and DM transcripts using the ImageJ software. Average and standard 
deviation (sd) from three independent experiments are shown. (C) Native northern blot analysis 
of WT and DM genomic RNA. 2000 cpm of viral RNA extracted from purified virions and 
normalised on RT activity was analysed by native northern blot using the biotinylated KS2VFKE 
riboprobe. The positions of the RNA dimers and monomers are indicated. (D) Quantification of 
the monomeric and dimeric RNA genomes for the WT and DM viruses using ImageJ. Average 
and sd of three independent experiments are shown. *, two-tailed unpaired Student t test p value 
<0.05.
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Interestingly, the reduction in RNA dimerisation was greater when analysed in the
context of the whole genome, where factors such as long-range interactions and the viral
NC protein are present which have been shown to influence genome dimerisation in
several retroviruses (Abbink et al., 2005; Clever et al., 1995; Darlix et al., 1990; Dirac
et al., 2002; Lanchy et al., 2003b; Prats et al., 1990).
3.3 The Psi palindrome pal, but not the putative DIS palindrome, is 
required for RNA dimerisation in virio
Although we had established that deletion of the HIV-2 encapsidation determinant 
affected genome dimerisation, the exact location of the cis-acting element required for 
genomic RNA dimerisation remained unknown. Whilst the Psi sequence was partly 
unstructured, it also extended into the SL-1 structure which contained the putative DIS 
(Figure 3.IB). Hence, deletion of the Psi sequence in the DM mutant was predicted to 
result in an alteration of the SL-1 structure which might prevent a loop-loop interaction 
through occluding the putative DIS palindromic motif and because of its closer 
proximity to the PBS stem-loop structure (Figure 3.1C). The predicted structure of the 
dimerisation-deficient DM mutant did however leave intact the putative dimerisation 
site in the loop of SL-1, suggesting that the putative DIS palindrome may not be critical 
for genome dimerisation in virio. The DM region also contained a palindrome (pal) that 
had been shown to promote RNA dimerisation in vitro (Lanchy et al., 2003a).
Hence, in order to determine which palindromic sequence was necessary and sufficient 
to promote RNA dimerisation in HIV-2, both palindromic sequences were mutated by 
site-directed mutagenesis (Figure 3.3A). The mutant Pal carried a deletion of the 10 nt 
Psi palindrome pal (Figure 3.3A, green residues). In SMI, the first three bases of the
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terminal palindrome (putative DIS) were substituted so that it was no longer a self-
complementary sequence (Figure 3.3A, blue residues, yellow highlight). SM2 was a
similar substitution of the first four bases of pal (Figure 3.3 A, green residues, yellow
highlight). SM3 corresponded to a double mutation combining SMI and SM2 (Figure
3.3A, green and blue residues, yellow highlights).
The minimal free-energy structures of the 5' RNA leader of these mutants were 
predicted using the algorithm mfold (Figure 3.3B-D). Deletion of pal was predicted to 
diminish the length of SL-1 and prevent the formation of the bulge in SL-1 (Figure 
3.3B). However, unlike in the DM mutant (Figure 3.1C), the distance between the PBS 
stem-loop and SL-1 was predicted to be maintained by the presence of a single-stranded 
region (Figure 3.3B, red). The SMI mutation was not predicted to affect the structure 
since the mutated residues were located in the loop of SL-1 (Figure 3.3C). Substitution 
of the residues 392-395 in SM2 altered the conformation of SL-1 with the formation of 
an extended SL-1 and the disappearance of the neighbouring ¥1 stem-loop (Figure 
3.3D). The formation of stem B, which was proposed to be necessary for viral 
replication (Lanchy and Lodmell, 2007), was however maintained.
First, the impact of these mutations on in vitro RNA dimerisation was analysed using 
the in vitro assay used for the DM mutant and described in section 2.7.9 (Figure 3.4A 
and B). The wild type RNA transcript was approximately 60 % dimeric in this assay. 
Deletion or substitution of pal in the mutants Pal and SM2 reduced the proportion of 
dimeric RNA by approximately twofold (Figure 3.4B), but this reduction was not 
statistically significant as assessed by a Student t test and assuming a normal 
distribution of the data. More striking however was the effect of the SMI mutation, 
which completely abrogated dimerisation of the RNA in vitro (Figure 3.4A and B). This 
phenotype appeared dominant as the SM3 double mutant displayed a phenotype similar
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to that of SMI. The dimerisation of the genomic RNA in virions was then assessed in 
order to confirm whether the putative DIS was indeed the main requirement for HIV-2 
dimerisation (Figure 3.4C and D). As for the DM mutant, viral RNA extracted from 
purified virion was analysed by native northern blot where RNA input was normalised 
on the RT activity of the purified virions (Figure 3.4C). Whilst the wild type genomic 
RNA appeared 80 % dimeric within the virions, a significant decrease in the level of 
dimeric genomes was observed when the palindrome pal was mutated in the Pal and 
SM2 mutants (Figure 3.4D), suggesting that pal plays a role in genomic RNA 
dimerisation. Surprisingly, in contrast with the data obtained in vitro, the SMI mutation 
had no effect on genome dimerisation and the SM3 double mutant had a phenotype 
similar to that of the SM2 mutant (Figure 3.4C and D). These results suggested that 
even though the putative DIS can promote the in vitro dimerisation of a short RNA 
transcript, in the context of the whole viral genome, it is not required to initiate the 
dimerisation process. Interestingly, northern blot analysis of the genomic RNA from 
HIV-1 DIS mutants also revealed that the HIV-1 DIS was not essential for genome 
dimerisation (Berkhout and van Wamel, 1996), whilst in vitro studies proposed the DIS 
as being the primary dimerisation site for HIV-1 (Laughrea and Jette, 1994; Skripkin et 
al., 1994).
These discrepancies between the in vitro and the cell culture-based assays may be due in 
part to the different structure adopted by the RNA in the context of a 130 nt transcript as 
compared to the full-length genomic RNA. Long-range interactions in the HIV-1 and 
HIV-2 5' RNA leader have been demonstrated to influence the dimerisation process, at 
least in vitro (Abbink et al., 2005; Dirac et al., 2002; Lanchy et al., 2003b), and the size 
of the RNA transcripts used has been shown to greatly influence the outcome of in vitro 
dimerisation assays (Lanchy and Lodmell, 2002).
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Figure 3.3: Genomic and structural context of the Psi and putative DIS palindrome 
mutations.
(A) Genomic context of the mutations of the pal and putative DIS palindromes. LTR, long 
terminal repeat; ¥ ,  packaging signal (Psi); SD, splice donor; RRE, Rev responsive element; U3, 
unique 3'; R, repeat; TAR, 7><ms,-activation responsive; PA, PolyA; PBS, Primer binding site; 
DIS, Putative dimer initiation site; WT, wild type. (B-D) Predicted structures o f the 5' RNA 
leader (position 370 to 490) for mutants Pal (B), SMI (C) and SM2 (D) using mfold. The Psi 
region, Psi palindrome pal and putative DIS are indicated in red, green and blue respectively. 
The mutated residues are highlighted in yellow (A) or underlined (C-D).
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Figure 3.4: The Psi palindrome pal, not the putative DIS palindrome, is required 
for dimerisation of the HIV-2 genomic RNA.
(A) In vitro dimerisation assay using a 130 nt RNA transcript (pos. 350-480 of HIV-2R0D). The 
positions of the monomer and dimer bands are indicated. (B) Quantitative analysis o f the in 
vitro dimerisation assay using the ImageJ software. Average and sd of three independent 
experiments are plotted. (C) Native northern blot analysis of viral RNA extracted from purified 
virion, using 2000 cpm of viral RNA as normalised on RT activity. The positions o f the 
monomer and dimer RNA species are indicated. (D) Quantification of the dimer and monomer 
RNA species in the northern blot using ImageJ. Average and sd of three independent 
experiments are represented. *, two-tailed unpaired Student t test p value < 0.05. (A-D) WT, 
wild type; mock, mock transfected cells.
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In addition, the presence of the NC domain of the Gag polyprotein was proposed to 
affect dimer formation in HIV-1 (Darlix et al., 1990; Feng et al., 1996b; Fu et al., 1994; 
Muriaux et al., 1996a) and HIV-2 (Dirac et al., 2002; Lanchy et al., 2003b).
Even though a role for the putative DIS palindrome in the stabilisation or maturation of 
the dimer cannot be excluded, as the stability of the dimers in the mutant viruses has not 
been assessed, the palindrome pal appeared to represent the critical sequence for HIV-2 
genome dimerisation.
3.4 The putative DIS palindrome is dispensable for replication in T- 
cells
In HIV-1, the DIS has been shown to mediate dimerisation (Laughrea and Jette, 1994; 
Skripkin et al., 1994), yet whether it is required for viral replication remains unclear 
(Berkhout and van Wamel, 1996; Hill et al., 2003; Jones et al., 2008; Laughrea et al., 
1997). The HIV-1 DIS was shown to be dispensable for replication in PBMCs (Hill et 
al., 2003) but was required in SUP-T1 T-cells (Berkhout and van Wamel, 1996; Hill et 
al., 2003), suggesting a cell type-dependent mechanism. Deletions and substitutions of 
the HIV-1 DIS also reduced the infectious titres by at least twofold in two T-cell lines, 
SUP-T1 (Paillart et al., 1996a) and MT-4 cells (Laughrea et al., 1997).
Since the current study showed that the Psi palindrome pal, not the putative DIS 
palindrome, was necessary for HIV-2 genome dimerisation and considering that 
mutations affecting HIV-2 genome encapsidation also affect viral replication (Griffin et 
al., 2001; Lanchy and Lodmell, 2007; McCann and Lever, 1997), it was important to 
measure the viral infectivity of the mutant viruses (Figure 3.5).
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A single-round infectivity assay was performed using a reporter cell line, termed
GHOST cells. This clonal derivative of HUT78 cells is a human osteosarcoma cell line,
constitutively expressing CD4, CXCR4 and CCR5. It contains the green fluorescent
protein (gfp) gene, the expression of which is controlled by an HIV-2 promoter (Trkola
et al., 1998). Upon infection by HIV-2, the Tat protein ^raws-activates the expression of
GFP, which can be detected by FACS.
Wild type and mutant viruses were first produced by transfection of Cos-1 cells and 
harvested at 48 h post-transfection. An increasing amount of virus, as determined by an 
RT assay, was added to the GHOST cells. At 72 h post-infection, the percentage of 
GFP-expressing cells, which represents the percentage of infected cells, was determined 
by FACS (Figure 3.5A). For safety reason, VSV-G pseudotyped viruses were used in 
this experiment. VSV-G pseudotyped wild type HIV-2 and SMI viruses appeared fully 
infectious, with up to 90 % of infected cells at the highest input tested. However, viruses 
containing mutations within the Psi region (DM, Pal, SM2 and SM3) all failed to 
efficiently infect the reporter cells, with a maximum of 30 % to 50 % of cells being 
infected. A reversion of the DM mutation was introduced into the pSVRANBDM 
molecular clone and the infectivity of the resulting virus (DM rev) was determined. The 
DM rev virus was able to infect cells as efficiently as wild type virus (Figure 3.5A) 
demonstrating that the infectivity defect observed for the DM mutant was the sole result 
of the DM deletion and not due to the introduction of another mutation in the proviral 
backbone during the cloning process. As a control, each individual plasmid was 
transfected alone. Neither the envelope-deleted proviral construct, nor the VSV-G 
plasmid, triggered expression of GFP in the reporter cells.
The assay was repeated once using a different cell line to produce the viruses, C33-A, 
which is a human carcinoma cell line (Figure 3.5B), since it had been shown that for
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certain viruses, such as hCMV, the producer cell line could affect the cellular response
to infection by influencing the mode of entry of the virus (Wang et al., 2007). Although
there was no evidence of such a producer cell type-dependent mode of entry for HIV, it
was decided to test an alternative cell line.
A similar pattern was observed when viruses were produced in C33-A or Cos-1 cells, 
even though the percentage of infected cells was lower when C33-A cells were used 
(compare Figure 3.5A and B). This difference was likely due to the difference in 
number of passage of the GHOST cells and the level of expression of the CD4 receptor 
and CCR5 and CXCR4 co-receptors as it was observed that the percentage of infected 
cells was higher when the cells had been grown for at least five weeks in selection 
media prior to use.
The results obtained in C33-A cells showed that the decrease in infectivity of the Psi 
mutant viruses observed using Cos-1 cells represented a genuine defect of the mutated 
virus.
To confirm these findings in a system that allows the virus to replicate, T-cells were 
infected with equal amounts of wild type and mutant viruses and the replication kinetics 
of the viruses were established (Figure 3.6). Viruses were produced by transfection of 
Cos-1 cells with the appropriate proviral clones and normalised on RT activity prior to 
the infection of Jurkat T-cells (Figure 3.6A). The replication was followed by measuring 
the RT activity in the culture supernatant every 4 days, when the cells were passaged 
one in two. Following an initial peak of infection at 15 days post-infection, the wild 
type virus continued to replicate in the Jurkat cells up to 50 days post-infection. The 
replication of the SMI mutant was comparable to that of the wild type, with an initial 
peak of infection at day 15 and a second one at day 50 post-infection, demonstrating 
that the SL-1 terminal palindrome was dispensable for HIV-2 replication in T-cells.
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Figure 3.5: Infectivity of wild type and mutant HIV-2 produced in Cos-1 and C33- 
A cells.
Single round infectivity assay using the GHOST reporter cell line, a CD4+ CXCR4+ CCR5+ 
human osteosarcoma cell line expressing the gfp gene under the control of the HIV-2 promoter. 
(A) VSV-G pseudotyped viruses were produced by co-transfection of 1.5 x 106 Cos-1 cells with 
5 pg of envelope-deleted proviral construct and 1 pg pCMV-VSVG (DEAE-dextran method). 
Virions were purified through sucrose cushion and normalised on RT activity. 2 x 105 GHOST 
cells were infected with increasing amounts o f virus. At 72 h post-infection, the percentage of 
GFP-expressing cells, representing the proportion of infected cells, was determined by FACS. 
WT, wild type; DM rev, cloned reversion of the DM mutation. Average and sd o f three 
independent experiments is plotted. (B) Full-length viruses were produced by transfection o f 1.5 
x 106 C33-A cells with 30 pg of proviral construct using the calcium-phosphate transfection 
method. GHOST cells were infected as described above. Data from a single experiment are 
shown.
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Figure 3.6: Replication of wild type and mutant HIV-2 in T-cells.
1 x io 6 Jurkat (A) and 1 x 106 PM1 (B) cells were respectively infected with 10000 cpm and 
2500 cpm of purified virions produced by Cos-1 cells transfection. (C) 1 x 106 Jurkat, PM1 and 
SUP-T1 cells were infected with 7000 cpm of purified wild type HIV-2 produced by 
transfection of Cos-1 cells. (A-C) Viral replication was followed by measuring the RT activity 
in a 10 pi aliquots of culture supernatant in duplicate. WT, wild type; mock, mock transfected 
cells. Data from a single (B and C) or two (A) independent experiments are shown.
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In contrast, deletion of the packaging signal (DM), deletion (Pal) and substitution (SM2)
of pal and double mutation of the putative DIS and pal (SM3) all impaired viral
replication of HIV-2.
The replication of two mutant viruses and the wild type was also measured in PM1 T- 
cells (Figure 3.6B) as it was observed that these cells could support HIV-2 replication 
more effectively than Jurkat or SUP-T1 cells (Figure 3.6C). Similar results were 
obtained in PM1 cells compared to Jurkat cells, with the wild type and SMI viruses 
being able to replicate while the SM2 mutant could not.
Taken together, these data suggested that viruses bearing mutations in the Psi region are 
non-infectious. Interestingly, the SM2 substitution of the GGAG motif at position 392- 
395 resulted in the same phenotype as the 28 nt deletion in the DM mutant, suggesting 
that this purine motif plays an important role in HIV-2 replication.
3.5 Correlation between HIV-2 RNA packaging, dimerisation and 
replication
Since the mutations were introduced in the 5' RNA leader, a highly structured region 
involved in numerous stages of the HIV-2 life cycle, several hypotheses could explain 
the replication defect observed with the Psi mutants.
The translation of the Gag polyprotein might for example be affected. In their initial 
analysis, Griffin and colleagues analysed the protein production of the DM mutant by 
metabolic labelling and found no significant difference with the wild type virus (Griffin 
et al., 2001). To verify that the other mutations introduced did not affect protein 
synthesis, viral proteins were harvested from Cos-1 transfected cells and purified virions 
at 48 h post-transfection and protein synthesis was analysed by western blot using a
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panel of HIV-2 positive patient sera (Figure 3.7). No differences in the level of Env
proteins (gpl25 and gp36) could be detected at 48 h post-transfection between the wild
type and mutant viruses. The level of the Gag (p57) polyprotein and cleavage products
MA-CA-p2 (~p41) and CA (p26) also appeared mostly similar between the wild type
and mutant viruses. Some variations were observed between the RT (p66) and Gag
(p57) levels in the wild type and SMI compared to the rest of the mutants, but this
result was not consistent amongst repeat experiments. It is interesting to note that two of
the three isoforms of the Gag polyprotein proposed to be synthesised, namely p57 and
p50 (Herbreteau et al., 2005), could be detected in the virion fraction. The ratio of these
isoforms was also maintained between the wild type and mutant viruses.
Since the dimerisation-deficient mutants (DM, Pal, SM2 and SM3) failed to replicate in
T-cells in spite of a normal protein production, it was of interest to determine whether
their packaging efficiencies had been affected by the mutations. Indeed, the inability to
replicate in T-cells could result from either a lack of genomic RNA in the incoming
virion or the absence of stable dimers in those virions. An RNase protection assay
(RPA) was performed to assess the level of HIV-2 genomic and spliced RNA present in
the cytoplasm of Cos-1 cells and released virions at 48 h post-transfection. The sizes of
unspliced RNA fragments protected by the KS2lPKE riboprobe are indicated in Figure
3.8A. DNase treated cytoplasmic and virion RNA samples were normalised on the
concentration of total cytoplasmic RNA and RT activity of the virus preparation
respectively. A representative RPA probing with KS2XFKE is shown in Figure 3.8B. A
GAPDH riboprobe was used to control the loading of the cytoplasmic RNA samples
and plasmid DNA contamination was detected using a vector backbone-specific
riboprobe (KS2'FEP).
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Figure 3.7: Protein expression of WT and m utant viruses.
Cos-1 cells were transfected with WT and mutant proviral constructs and cells and virions were 
harvested at 48 h post-transfection. 15 pi o f the cytoplasmic fraction (top panel) and 500 cpm of 
the virion fraction (middle panel) were analysed by SDS-PAGE using a 4-20 % gradient gel 
(Pierce). Protein synthesis was analysed using a 1:1000 dilution of a panel of HIV-2 positive 
sera (ARP501, NIBSC, UK). Loading was controlled for by probing for P-actin (bottom panel) 
using a 1:5000 dilution of a mouse monoclonal anti-P-actin (Abeam). 1:1000 dilutions o f rabbit 
anti-human-HRP or goat anti-mouse-HRP conjugated secondary antibodies (Dako) were used. 
WT, wild type; mock, mock transfected cells. The sizes o f the protein markers (full-range 
Rainbow; GE Healthcare) are indicated on the left. The positions of the HIV-2 proteins are 
indicated on the right: Gag-Pol (p i60), Env SU (gpl25) and TM (gp36), RT (p66), Gag (p57), 
MA-CA-p2 (~p41), CA-p2 (~p26) and CA (p26). The multiple bands seen for Gag are thought 
to represent the different isoforms of the polyprotein (p57, p50 and p44) depending on the 
initiation codon usage, as described by Herbreteau et al. (2005).
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Figure 3.8: Packaging efficiencies of the HIV-2 mutants.
(A) Size of the protected fragments for wild type and mutant genomic RNA using the KS2VFKE 
riboprobe. (B) Representative RPAs using the KS2VPKE riboprobe. 0.5 pg of cytoplasmic RNA 
and 2500 cpm virion RNA were used with 2 x 105 cpm of 32P-labelled riboprobe. WT, wild 
type; mock, mock transfected cells; Y+, yeast RNA + RNase; Input 1:10, 1:10 dilution of yeast 
RNA - RNAse; C+, Century Plus RNA markers (Ambion). The positions of the main protected 
fragments are indicated on the left. Detection of plasmid DNA with KS2VPEP (413 nt protected 
fragment) and GAPDH internal control (285 nt protected fragment) are shown below. (C) 
Relative packaging efficiency of the mutants, taken as the ratio o f virion RNA to cytoplasmic 
RNA, relative to that of the wild type. Average and sd o f at least two independent experiments 
is shown. *, two-tailed unpaired Student t test p value < 0.05.
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The position of wild type and mutant genomic RNA protected fragments are indicated 
on the side of the autoradiograph. The packaging efficiency of each virus relative to 
wild type was calculated and is shown in Figure 3.8C. In accordance with previous 
findings, deletion of the DM sequence resulted in a significant, yet not as marked, 
decrease in packaging efficiency compared to wild type. In their initial analysis, Griffin 
and co-workers described a packaging efficiency of 5.7 ± 1.6 % for the DM mutant 
(Griffin et al., 2001), whereas in this study, the figure was 40 ± 15 %. The decrease in 
the relative packaging efficiency was still significant with a Student t test p value less 
than 0.05. Mutations of pal also resulted in a significant decrease of the packaging 
efficiencies of these viruses, with two- to threefold reduction for Pal and SM2. The SMI 
mutation of the putative DIS had however no effect on the packaging efficiency of the 
virus. The SM3 double mutant displayed a phenotype similar to that of SM2 with a two- 
to threefold reduction in encapsidation compared to the wild type virus. These results 
showed a correlation between the ability of the virus to form a dimeric genome, its 
ability to encapsidate that genome and its replicative fitness.
3.6 Viral infectivity is independent of the amount of genomic RNA 
packaged
A correlation was observed between the dimerisation, encapsidation and infectivity 
defect, suggesting that these three processes are closely linked. However, the exact 
nature of their relationship remained unknown. In particular, it was unclear whether the 
encapsidation of the genome required dimerisation and if the reduced infectivity 
resulted from a decrease in RNA packaging, dimerisation or both.
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If the diminution in encapsidation, i.e. a lack of genomic RNA, was the sole factor 
responsible for the reduction in viral infectivity, the targeting of an equivalent amount 
of genomes onto the cells would elicit a similar infectivity for the packaging mutant and 
wild type virus. The DM virus showed a two- to threefold decrease in RNA packaging 
relative to the wild type virus (Figure 3.8). Hence, a DM virus input three times larger 
than that of the wild type would be expected to contain as many copies of the genomic 
RNA as the wild type virus input. Following this assumption, a single-round infectivity 
assay was performed using three times more DM virus than wild type virus (Figure 
3.9A). The virus inputs were normalised on the RT activity of the virus preparation, an 
equivalent of 62.5 and 250 cpm being used for the wild type virus and 187.5 and 750 
cpm for the DM virus. Semi-quantitative RT-PCR was used to estimate the genomic 
RNA level for each input tested. A control with no reverse transcriptase was performed 
to ensure that no plasmid DNA contaminated the RNA samples. For each input tested, 
the genomic RNA content was equivalent for the wild type and DM virus. Yet, the DM 
virus still showed a statistically significant diminution in infectivity suggesting that 
factors other than RNA packaging were affecting the infectivity of the DM mutant. 
These results were corroborated by the replication kinetic of the viruses in T-cells. In 
this experiment, the input of wild type virus was reduced by threefold to approximately 
3000 cpm, as determined by an RT assay, while the DM virus input was 9000 cpm. This 
approach was necessary due to the limited amount of DM virus produced by the 
transfection of Cos-1 cells. A normal input of wild type virus (9000 cpm) was used in 
parallel. Jurkat cells were infected with wild type and DM virus and viral replication 
was followed for three weeks by measuring the RT activity in the culture supernatant 
(Figure 3.9B).
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Figure 3.9: The infectivity defect of the DM virus is independent of its packaging 
defect.
(A) Pseudotyped viruses were produced by co-transfection of 1.5 x  106 Cos-1 cells with 5 pg of 
pSVRANB (WT) or pSVRANBDM (DM) and 1 pg pCMV-VSVG, purified through sucrose 
cushion and normalised on RT activity. 2 x  105 GHOST cells were infected with 62.5 and 250 
cpm of WT virus and 187.5 and 750 cpm or DM virus. At 72 h post-infection, the percentage of 
GFP-positive cells was determined by FACS. In the meantime, the viral RNA from an 
equivalent fraction of virions as used to infect the cells was extracted for RT-PCR analysis. 10 
pi of undiluted, 1:10 and 1:100 dilution of viral RNA were reverse transcribed and amplified 
using HIV-2 specific primers as described in section 2.7.10. A control reaction without RT was 
carried out in parallel. Statistical significance was assessed by a two-tailed unpaired Student t 
test. *, p value < 0.05, **, p value < 0.01. (B) 1.5 x  106 Jurkat cells were infected with either 
9000 cpm of purified WT and DM viruses or 3000 cpm of purified WT virus (WT 1/3), as 
measured by RT activity. At day 7, 10, 19 and 25, two 10 pi aliquots were removed to measure 
RT activity in duplicate. Mock, mock transfected cells. Average and sd from two independent 
experiments are shown.
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As previously observed, the DM virus failed to replicate in T-cells. Diminishing the
input of wild type virus, so that it would have an amount of targeting genome equivalent
to that of the DM sample, did not significantly affect the ability of the virus to replicate
in Jurkat cells.
3.7 Discussion
The relationship between genome dimerisation, encapsidation and viral replication was 
investigated. Using native northern blot analysis of the HIV-2 full-length genomic 
RNA, it was shown that sequences within the HIV-2 packaging signal were involved in 
the dimerisation of the genome. Deletions of Psi and deletion or substitution in the 
palindrome pal resulted in a significant reduction in the amount of dimeric genomes 
present in the virions, suggesting that pal is the main requirement for HIV-2 genome 
dimerisation.
On the contrary, mutation of the palindrome located in the loop of SL-1 (putative DIS) 
had no effect on genomic RNA dimerisation, in spite of abrogating in vitro dimerisation 
of a short RNA transcript and presenting similarities with the HIV-1 DIS. Previous in 
vitro studies on HIV-2 dimerisation had proposed that the putative DIS mediated 
dimerisation (Dirac et al., 2001; Lanchy and Lodmell, 2002). Here, we have shown that 
discrepancies exist between in vitro and in virio data and that, in the context of the full- 
length genome, the putative DIS palindrome was dispensable for HIV-2 RNA 
dimerisation. A similar disparity has also been reported in HIV-1 (Sakuragi and 
Panganiban, 1997). The differences observed between the in vitro and in virio data may 
be due to the presence of trans-acting factors such as the NC protein, which has been 
shown to enhance dimerisation of HIV-1 and HIV-2 RNA transcripts in vitro (Darlix et
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al., 1990; Dirac et al., 2002; Lanchy et al., 2003b) and induce a change of conformation, 
called ‘maturation’, of HIV-1 RNA dimers in vitro (Feng et al., 1996b; Mujeeb et al., 
2007; Muriaux et al., 1996a; Takahashi et al., 2001). In addition, the viral protease PR 
has been reported to be essential for the maturation of the dimer following particle 
budding in both HIV-1 and MLV and the stability of dimer isolated from PR" viruses 
was found to be similar to that observed in immature particles (Fu et al., 1994; Fu and 
Rein, 1993; Shehu-Xhilaga et al., 2001b; Song et al., 2007b). Furthermore, several long- 
range interactions have been described in the HIV-1 and HIV-2 leader RNAs (Abbink 
and Berkhout, 2003; Dirac et al., 2002; Huthoff and Berkhout, 2001; Paillart et al., 
2002) and some of them have been implicated in the regulation of dimerisation (Abbink 
et al., 2005; Dirac et al., 2002; Lanchy et al., 2003b).
Interestingly, HIV-1 with a mutated DIS was found to contain dimeric genomes, yet this 
virus had a delayed replication kinetic in SUP-T1 cells and a reduced level of dimeric 
genomes packaged (Berkhout and van Wamel, 1996). Several studies confirmed that the 
DIS was required for HIV-1 infectivity in T-cells (Laughrea et al., 1997; Paillart et al., 
1996a), however, this requirement appeared to be cell-type dependent, as PBMCs could 
support replication of DIS mutants over the course of 40 days (Hill et al., 2003). A 
similar cell-type dependency might exist in HIV-2 and it would be interesting to assess 
whether it is the case. Furthermore, one might envisage that the palindrome pal, as the 
main dimerisation site in HIV-2, would act like the HIV-1 dimerisation site and 
therefore be required for replication in a cell-type dependent manner. This hypothesis 
has not yet been explored. However, the replication of the dimerisation-deficient viruses 
in T-cells was assessed and it was found that these viruses could not replicate. Several 
hypotheses could explain such a replicative defect. The mutations introduced might 
affect the translation of the Gag polyprotein, possibly by introducing an additional
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structure in the leader RNA and further reducing the efficiency of ribosomal scanning, 
as has been shown in HIV-1 (Miele et al., 1996). However, it was suggested that HIV-2 
could translate the Gag polyprotein using an IRES located downstream of the Gag 
authentic start codon at position 545 of H IV -2rod (Herbreteau et al., 2005). This would 
therefore not be affected by the mutations introduced in the RNA leader. Gag 
polyprotein synthesis and its proteolytic cleavage were analysed at 48 h post­
transfection by western blot analysis and were found to be unaffected by the mutations. 
This does not exclude the possibility that the mutations could affect Gag synthesis at 
earlier time points. Moreover, it has not been fully evaluated whether the sequence and 
ratio of the proteolytic processing of the Gag polyprotein might have been disturbed. 
The proteolytic processing of the Gag protein as well as the ratio of Gag/Gag-Pol have 
been shown to influence RNA dimerisation in HIV-1 (Shehu-Xhilaga et al., 2001a; 
Shehu-Xhilaga et al., 2001b). The reverse is also true and mutations near the 
dimerisation signal of HIV-1 were found to result in the delayed processing of the p2 
peptide from the CA-p2 precursor (Liang et al., 1999a).
All non-replicative mutant viruses showed a dimerisation and encapsidation defect. The 
packaging defect alone could be responsible for the reduction in infectivity as it would 
result in the release of more empty particles. The reduction in the proportion of dimeric 
genomes in the mutant virions could also impair viral replication, as seen in HIV-1 and 
MLV, by affecting reverse transcription and reducing the recombination rate, for 
example by preventing the use of the alternative template in intermolecular first-strand 
transfer or, in the case of strand breakage, in intramolecular first-strand transfer 
(Berkhout et al., 1998; Chin et al., 2008; Hu and Temin, 1990a; Jones et al., 2008; 
Mikkelsen et al., 2000; Mikkelsen et al., 2004; Moore et al., 2007; Paillart et al., 1996a; 
Panganiban and Fiore, 1988; Shen et al., 2000). The efficiency of reverse transcription
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in the dimerisation-deficient viruses was assessed by measuring the level of strong-stop 
cDNA synthesis. However, due to technical difficulties, the assay was inconclusive and 
it was not possible to determine whether this stage of reverse transcription was affected. 
It would be interesting to further investigate this aspect of the virus life cycle and 
determined whether the initial stages of reverse transcription are affected when the RNA 
genomes are less dimeric, and in particular to measure the efficiency of the first-strand 
transfer.
Since the cis-acting signals involved in dimerisation and encapsidation are in close 
proximity, it was difficult to discriminate if one or both defects are responsible for 
inhibiting viral replication. To determine if reduced genome encapsidation restricted the 
replication of the Psi mutant, its packaging defect was accounted for by increasing the 
amount of genome targeted onto the cells in an infectivity assay. Interestingly, this did 
not restore the infectivity of the mutant. Similarly, reducing the amount of wild type 
genomes to the same level as the mutant virus had no impact on wild type HIV-2 
replication. Altogether, these data implied that the reduction in viral RNA encapsidation 
was not the sole factor responsible for the fall in viral infectivity observed with the Psi 
mutant. Furthermore, it seemed unlikely that a two- to threefold reduction in genome 
encapsidation could completely abrogate viral replication. Similarly, a two- to fourfold 
decrease in genome dimerisation alone might not be sufficient to inhibit viral 
replication. Hence, it appeared probable that a combination of defects, including - but 
not exclusively - dimer formation and genome packaging, were responsible for the 
block in viral replication.
It has also been suggested that the presence of the RNA genome may contribute to 
particle morphogenesis (Campbell and Rein, 1999; Campbell and Vogt, 1995; Muriaux 
et al., 2001). This would imply that the Psi mutants, which packaged less RNA, would
150
Chapter 3: Relationship between genomic RNA dimerisation, packaging and viral
infectivity in HIV-2
produced more empty particles or particles with an aberrant morphology than the wild 
type virus. This could trigger the replication defect observed. This hypothesis has been 
tested and will be detailed in Chapter 5.
Nonetheless, from these data emerged a correlation between RNA dimerisation, 
packaging and viral replication. Such a link has been observed in HIV-1 (reviewed in 
Greatorex, 2004; Paillart et al., 2004b) and is supported by the close proximity of the 
elements required for RNA dimerisation and packaging. Furthermore, a recent study of 
the HIV-2 packaging signal proposed that genome encapsidation and viral replication 
required the presence of an extended SL-1, as depicted in Figure 3.IB, that includes the 
formation of a lower stem, termed stem B (Lanchy and Lodmell, 2007). The DM and 
Pal mutations of the packaging signal both disrupted the SL-1 structure, including stem 
B, and this alteration of the SL-1 structure might explain the inhibition of viral 
replication observed. However, in the SM2 and SM3 mutants, which also failed to infect 
and replicate in T-cells, stem B remained unaffected by the mutation and it appeared 
that SL-1 was further extended due to the substitution of the GGAG residues at position 
392-395 (see Figure 3.3). The structural context of the dimerisation and packaging 
elements and its implication for HIV-2 infectivity has been further explored and is 
detailed in Chapter 4.
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4 Sequence and structural context of stem-loop 1 and 
its implication for HIV-2 replication
4.1 Introduction
It has been demonstrated that the 5' RNA leader of HIV-1, comprising the RNA 
elements required for genome dimerisation and encapsidation, is highly structured 
(Baudin et al., 1993; Clever et al., 1995; Harrison and Lever, 1992; McBride and 
Panganiban, 1996; Sakaguchi et al., 1993). As part of the encapsidation process, the NC 
domain of the Gag polyprotein recognises and binds to specific motifs within the HIV-1 
RNA leader via its two zinc fingers (Aldovini and Young, 1990; Gorelick et al., 1990), 
and the exact nature and affinity of this binding has been extensively studied using a 
range of methods (Amarasinghe et al., 2000a; Amarasinghe et al., 2001; Bacharach and 
Goff, 1998; Berkowitz and Goff, 1994; Berkowitz et al., 1993; Clever et al., 1995; 
Damgaard et al., 1998; Dannull et al., 1994; De Guzman et al., 1998; Hagan and Fabris, 
2003; Zeffman et al., 2000). Specific RNA structures are also critical for genome 
dimerisation. The position of the HIV-1 DIS in a stem-loop structure favours loop-loop 
interaction and formation of the ‘kissing-loop’ complex that was shown to be essential 
for dimerisation (Clever et al., 1996; Haddrick et al., 1996; Laughrea and Jette, 1994, 
1996; Mujeeb et al., 1998; Muriaux et al., 1996b; Paillart et al., 1994; Paillart et al., 
1996b; Paillart et al., 1997; Skripkin et al., 1994). As for HIV-1 packaging, NC has 
been proposed to enhance HIV-1 RNA dimerisation by promoting maturation of the 
RNA dimer from a weak dimer to a more stable form (Feng et al., 1996b; Mujeeb et al.,
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2007; Muriaux et al., 1996a; Takahashi et al., 2001). Protease-dependent proteolytic 
processing of the Gag protein appears to be required for this ‘maturation’ of the dimer 
(Fu et al., 1994; Shehu-Xhilaga et al., 2001b; Song et al., 2007b), although it has been 
suggested that Gag processing alone is not sufficient (Fu et al., 2006).
In HIV-1, it has been shown that the structural context of stem-loop 3 (SL-3) and SL-1 
is important for HIV-1 genomic RNA encapsidation (Clever and Parslow, 1997). 
Similarly, altering the structural context of the HIV-1 DIS, in particular a lower stem 
structure part of SL-1 and termed stem B, has a critical effect on dimerisation (Clever 
and Parslow, 1997; Clever et al., 1996; Laughrea et al., 1997; Laughrea et al., 1999; 
Muriaux et al., 1996b; Russell et al., 2003a; Sakuragi et al., 2003).
The HIV-2 RNA leader has been shown to contain a stem-loop structurally equivalent 
to HIV-1 SL-1 (Baig et al., 2007; Damgaard et al., 1998; Dirac et al., 2001; Lanchy et 
al., 2004). Interestingly, long-term culture and phenotypic reversions of pal-mutated 
HIV-2 have suggested the existence of an extended SL-1, including formation of a 
lower stem structure (stem B), and it was suggested that the integrity of this stem is 
necessary for HIV-2 replication and RNA packaging (Lanchy and Lodmell, 2007).
The 3' end of pal is involved in the formation of stem B. However, mutation of the 5' 
end of pal (SM2), which is not part of stem B, significantly reduced infectivity and 
impaired viral replication (see Chapter 3). Hence, the precise sequence and structural 
elements required for HIV-2 replication are not yet resolved.
In this study, we aimed to clarify this and to identify the sequence and structure 
requirements for the individual processes of HIV-2 genome dimerisation, packaging and 
viral infectivity. Using a mutagenesis approach, the SL-1 of the HIV-2 leader RNA was 
mutated to disrupt the previously implicated motifs, pal and stem B. Compensatory 
mutations were also created to distinguish the relative importance of the structural
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elements over nucleotide sequence alone. A GGAG motif corresponding to the 5' end of 
the palindrome pal was shown to be critical for both genome dimerisation and viral 
replication. Surprisingly, RNA encapsidation could be affected independently of 
genome dimerisation. However, it was found that dimerisation-deficient viruses fail to 
replicate in T-cells. The data obtained suggested that stem B was not required for viral 
infectivity and clearly identified the GGAG motif at position 392-395 as essential for 
HIV-2 replication.
4.2 Role of the SL-1 sequence and structural motifs in genomic RNA 
dimerisation and encapsidation
4.2.1 Stem-loop 1 mutants
To investigate the importance of the postulated structure termed stem B, located at the 
base of SL-1 and involving part of the Psi palindrome pal, a series of substitution 
mutants (SM4 to SM9; Figure 4.1) that affected the formation of the stem B structure 
and the bulge of SL-1 were created (Figure 4.2A). The SM4 and SM5 mutations both 
led to the disruption of stem B (Figure 4.2B and C), with SM4 also disrupting pal while 
SM5 retained a palindromic sequence (Figure 4.1 A). In SM6, the 3' end of SL-1 was 
mutated to disrupt stem B but leaving pal unaffected (Figure 4.1 A and B, residues 439- 
442 shown in green; Figure 4.2D). To assess the relative importance of the stem B 
structure compared to its constituent sequences, a double mutant of SM4 and SM6 
(SM9) was created (Figure 4.1 A). This mutant restored a stem B structure using 
alternative sequences (Figure 4.2G).
There are several GGAG motifs present in the palindrome pal and stem B. The 
previously described SM2 was a substitution of the GGAG motif at position 392-395 of
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the H IV -2rod genome and caused a dramatic decrease in viral infectivity and genome 
dimerisation (see Chapter 3). SM6 affected the second GGAG motif, at the 3' end of 
SL-1 (Figure 4.IB). Similar purine tetrads have been implicated in RNA packaging and 
Gag binding in both HIV-1 (Aldovini and Young, 1990; Clavel and Orenstein, 1990; 
Damgaard et al., 1998; Lever et al., 1989; Shubsda et al., 2002) and HIV-2 (Damgaard 
et al., 1998; Garzino-Demo et al., 1995; McCann and Lever, 1997; Poeschla et al., 
1998), hence a double mutant of SM2 and SM6 was created to analyse the effect of 
substitutions in both GGAG motifs (SM8; Figure 4.1 A and Figure 4.2F).
Computer generated predictions and biochemical studies (Baig et al., 2007; Damgaard 
et al., 1998; Dirac et al., 2001; Lanchy et al., 2004) all suggested that SL-1 was a 
discontinuous helix (see Figure 4.IB). Thus, the nucleotides involved in the bulge of 
SL-1 (position 402-409) were substituted in SM7 (Figure 4.1 A), resulting in the 
formation of an extended and highly stable SL-1 (Figure 4.2E).
The effects of each mutant on stem B, the palindrome pal and the bulge structure are 
summarised in Figure 4.1C.
To ensure that the mutation introduced did not severely affect protein production, the 
level of viral proteins in transfected Cos-1 cells and newly released virions was assessed 
by western blotting using a panel of HIV-2 positive patient sera (Figure 4.3). At 48 h 
post-transfection, the level of the Env glycoproteins gpl25 and gp36 appeared 
maintained across the range of mutants. The level of RT (p66), Gag (p57) and 
proteolytic cleavage products MA-CA-p2 (p41) and CA (p26) was equivalent in the 
wild type and mutant transfected cells and subsequently released particles. The slight 
reduction in the level of p57 Gag observed in the SM7 virions was not consistent in 
between experiments.
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Figure 4.1: Genomic and structural context of the stem-loop 1 mutations.
(A) Genomic organisation of the HIV-2ROd molecular clone (pSVR) and localisation o f the SL-1 
mutations. The main functional elements of the 5 ’ leader region are indicated: TAR, Tat 
response element; PA, PolyA signal; PBS, Primer binding site; SL-1, Stem-loop 1; SD, Splice 
donor. The main packaging determinant Psi (¥ ) is indicated. WT, wild type; SM4 to SM9, 
Substitution Mutant 4 to 9. The palindrome pal (392-401) is denoted by the red shadowing in 
the WT sequence and the 3' end o f SL-1 involved in the formation of stem B (439-442) is 
shown in green. The mutated nucleotides are indicated in red. All numberings refer to the start 
of the HIV-2ROd genome. (B) Structure o f WT SL-1 as determined by biochemical analysis 
(Baig et al., 2007; Damgaard et al., 1998; Dirac et al., 2001; Lanchy et al., 2004) and free- 
energy minimisation using mfold. The packaging signal Psi (380-408) and pal (392-401) are 
shown in red and shadowed red respectively. The residues involved in the formation o f stem B 
(439-442) appear in green. The bulge mutated in SM7 is indicated. (C) Presence (+) or absence 
(-) of pal (392-401), stem B (397-401/439-442) and bulge (402-408) in the WT and mutated 
viruses.
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Figure 4.2: Predicted structures of the SL-1 mutants.
Predicted structure of SL-1 (nt 380-444 of H I V - 2 r o d )  of wild type (WT; A), SM4 (B), SM5 (C), 
SM6 (D), SM7 (E), SM8 (F) and SM9 (G) using the algorithm mfold. The Psi region is 
indicated in red and the mutated residues in green.
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Figure 4.3: Gag protein level in wild type and mutant HIV-2.
Cos-1 cells were transfected with wild type (WT) and SM4 to SM9 mutant pro viral constructs. 
Cells (top panel) and virions (middle panel) were harvested 48 h later and analysed by western 
blot using HIV-2 positive patient sera (ARP501, NIBSC; 1:1000) and a rabbit anti-human-HRP 
antibody (Dako; 1:1000). An equal volume of the cytoplasmic fraction (15 pi) was used and the 
virion fraction was normalised on the RT activity o f the virus preparation. Equal loading o f the 
cytoplasmic protein fraction was verified using a mouse anti-actin antibody (Abeam; 1:5000, 
bottom panel) and a goat anti-mouse-HRP antibody (Dako; 1:1000). WT, wild type; mock, 
mock transfected cells. The sizes of the protein markers (full-range Rainbow; GE Healthcare) 
are indicated on the left. The position of the Gag-Pol polyprotein (p i60), Env gpl40 and gp36 
proteins, RT (p66), Gag polyprotein (p57) and Gag cleavage products MA-CA-p2 (p41) and 
CA (p26) is indicated on the right. The multiple bands seen for the Gag protein represent the 
different isoforms (p57, p50 and p44) depending on the initiation codon usage, as described by 
Herbreteau et al. (2005).
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4.2.2 Substitution of the GGAG motif at position 392-395 negatively affects 
genome dimerisation
Previous data link elements located within the HIV-2 packaging signal with in vitro 
dimerisation (Lanchy et al., 2003b). In addition, the results obtained in the present study 
showed that the HIV-2 Psi region was involved in genomic RNA dimerisation in virio 
and that it was associated with viral infectivity. Hence, the ability of the SL-1 mutant 
viruses to dimerise in virio was analysed (Figure 4.4). Wild type and mutant virions 
were purified following transfection of Cos-1 cells and the genomic viral RNA was 
analysed by native northern blot, with RNA inputs normalised on the RT activity of the 
virion preparation.
As shown in Figure 4.4, disruption of stem B by mutation of the 3' end of pal in SM4 or 
by mutation of the GGAG motif at position 439-442 in SM6 resulted in decreased 
genome dimerisation (left panel). However, on a longer exposure of the blot (Figure 4.4, 
right panel), dimeric genomes are still easily identifiable, indicating that genome 
dimerisation could occur in the absence of stem B. Interestingly, SM9, a combination of 
SM4 and SM6 which restored stem B but disrupted pal, had a high level of dimeric 
genomes (Figure 4.4), suggesting that pal was dispensable for dimerisation; yet, 
mutations of pal resulted in a decrease in dimerisation in the Pal and SM2 mutants (see 
Figure 3.4). When comparing the dimerisation of the two pal substitution mutants, SM2 
and SM4 (Figure 3.4 and Figure 4.4), with that of the pal deletion mutant Pal (Figure
3.4), it appeared that the 5' end of pal (residues 392-395) was essential. Indeed, 
mutation of the 5' end of pal in SM2 triggered the same dimerisation defect as deletion 
of the whole palindrome (Pal), whereas mutation of the 3' end of pal in SM4 (residues 
397-401) had a less marked reduction in the level of dimeric genome present in the 
virions.
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Analysis of SM5 confirmed that a palindromic sequence in Psi was not a critical factor 
for dimerisation as this mutant contained a substitute palindromic sequence at the same 
position as wild type pal but failed to dimerise (Figure 4.4).
SM8, a combination of SM2 (nt 392-395) and SM6 (nt 439-442), also failed to dimerise 
(Figure 4.4). Since SM2 did not dimerise (Figure 3.4), but SM6 could, albeit at a lower 
efficiency than wild type, the GGAG motif at position 392-395 appears to be dominant 
for genome dimerisation.
SM7 dimerised almost to wild type level, indicating that the bulge in SL1 is dispensable 
for genome dimerisation (Figure 4.4). The minor defect observed may be due to a more 
stable stem impairing the transition from the initial duplex to the extended dimer.
These data, together with the previous analysis of the SM2 mutant, indicated that 
neither stem B, nor merely a non specific palindromic sequence in the Psi region, was 
critical for genome dimerisation. The sole factor in common between the mutants which 
failed to dimerise was the absence of the GGAG motif at position 392-395 (see Figure 
4.1C and Figure 3.3).
4.2.3 The reduction in genome dimerisation does not correlate with a 
packaging defect
Genome dimerisation and packaging are frequently described as interdependent (for 
review see Russell et al., 2004). In HIV-2, the main packaging determinant (Griffin et 
al., 2001; McCann and Lever, 1997) overlaps with sequences shown to be involved in 
RNA dimerisation in vitro (Baig et al., 2007; Lanchy et al., 2003b) and in virio (present 
study). In order to further investigate this relationship in HIV-2, the packaging 
efficiencies of the SL-1 mutants were measured by RPA (Figure 4.5).
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Figure 4.4: Dimerisation of the HIV-2 genome requires the presence of a GGAG 
motif at position 392-395.
Native northern blot analysis of wild type (WT) and mutant genomic RNA. WT and mutant 
pro viral constructs were transfected into Cos-1 cells and virions were harvested after 48 h. The 
genomic RNA was normalised by RT activity and analysed by native northern blot. The right 
panel shows a longer exposure (15 minutes) of the blots presented in the left panel (1 minute 
exposure), mock: mock transfected cells. Representative blot from three independent 
experiments is shown.
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Figure 4.5: Packaging efficiencies of the SL-1 mutants.
(A) Size o f the genomic RNA fragments protected by the KS2VFKE riboprobe. (B) 
Representative RPA of wild type (WT) and mutant HIV-2 RNAs. Pro viral constructs were 
transfected into Cos-1 cells and virions were harvested after 48 h. Cytoplasmic and virion RNAs 
were extracted and subjected to an RPA with riboprobes KS2VPKE, KS2XPEP and GAPDH. 1 pg 
of cytoplasmic RNA and an equivalent of 2500 cpm of virion RNA, as measured by RT assay, 
were used. C+, Century Plus RNA markers (Ambion). (C) Packaging efficiencies o f the mutant 
viruses relative to WT. The average and sd of three independent experiments is shown. 
Significant difference relative to WT packaging efficiency was assessed using a two-tailed 
unpaired Student t test. *, p value < 0.05; **, p value < 0.001.
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The protected fragments generated by hybridisation of the KS2VFKE riboprobe to wild 
type and mutant genomic RNAs are indicated in Figure 4.5A and a representative RPA 
using the KS2PKE riboprobe is shown in Figure 4.5B. The level of cytoplasmic RNA 
was adjusted by probing for GAPDH and plasmid DNA contamination was accounted 
for using the KS2PEP riboprobe, which recognises sequences between the U3 region 
and the PBS. Packaging efficiencies relative to wild type are presented in Figure 4.5C. 
Contrary to what was observed with the Psi mutants, there was no interdependent 
relationship between the ability of the genome to dimerise and the efficiency with which 
it was packaged. While the dimerisation-competent SM4 mutant packaged as efficiently 
as the wild type virus, the SM6, SM7 and SM9 mutants packaged at approximately 50 
% of wild type, despite being able to dimerise. Similarly, the dimerisation-deficient 
mutants SM5 and SM8 both showed reduced packaging, even though the intensity of 
the defect was variable. These data suggest that the HIV-2 genome dimerisation and 
encapsidation processes may not be as interdependent as initially thought. It is 
interesting to note that there seems to be a nonreciprocal relationship between genome 
dimerisation and packaging in HIV-2. While all mutants that failed to dimerise showed 
a packaging defect, the reverse is not true. Therefore, one might conclude that RNA 
dimerisation is important for encapsidation and that the GGAG motif at position 392- 
395 is required; however, there must be an alternative mechanism to explain the case of 
those mutants with a normal level of RNA dimer but a reduced RNA content.
Although these results did not corroborate the ‘apparent’ level of genomic RNA present 
in the virions analysed by northern blot (Figure 4.4), the RPA remained the most 
appropriate and sensitive method to calculate packaging efficiencies. The sensitivity of 
the technique is reported to be at least ten times greater than for northern blot (Ambion 
technical bulletin #500) and most importantly, the level of viral RNA present in
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the cytoplasm of the cells as well as the contamination of the sample by plasmid DNA 
are taken into account. In addition, breakage of the genomic RNA has little impact on 
an RPA as it is based on the detection of short protected fragment as compared to full- 
length genome of approximately 9500 nt in the northern blot. Finally, an RPA allows 
the visualisation and quantification of any spliced RNA being incorporated into virions. 
The transfection of Cos-1 cells results in the over-expression of the viral genomes and 
one might envisage that this high-level expression might suppress the effect of 
otherwise disruptive mutations, as suggested previously (Luban and Goff, 1994).
4.3 Effect of the mutations on viral replication and infectivity
4.3.1 Mutations of the 392-395 GGAG motif reduce infectivity and impair 
viral replication in T-cells
Mutations within the HIV-2 packaging signal and SL-1 region have been reported to 
affect HIV-2 replication (Griffin et al., 2001; Lanchy and Lodmell, 2007; McCann and 
Lever, 1997). To determine whether the dimerisation-deficient SL-1 mutants were 
infectious, a single-round infectivity assay using the GHOST reporter cell line was 
performed. Increasing amounts of virus, normalised on RT activity, were inoculated 
onto the cells and the percentage of infected cells was determined by FACS analysis. 
The results obtained for the highest virus input were representative of the data set and 
are shown in Figure 4.6A. Disruption of stem B in SM4 and SM6 resulted in a 
significant decrease in the percentage of infected cells, while the SM9 double mutant 
appeared fully infectious, suggesting that stem B may be important for infectivity. 
Analysis of the SM5 and SM8 mutants showed a correlation between the ability to 
dimerise and viral infectivity. These SM5 and SM8 mutants failed to dimerise and
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demonstrated the most striking reduction of infectivity, at least fivefold lower than wild 
type, while SM4 and SM6, which had a small decrease in virion dimers, showed a less 
dramatic reduction of viral infectivity (Figure 4.6B). It is interesting to note that SM8, 
which lacked two GGAG motifs, showed the strongest decrease in infectivity, 
suggesting that these purine-rich motifs may be important for viral replication. On the 
other hand, dimerisation-competent mutants SM7 and SM9 were fully infectious 
(Figure 4.6A and B).
To confirm these findings in a system allowing viral replication, PM1 T-cells were 
infected with wild type and mutant viruses and the replication kinetics of the viruses 
were followed by measuring the RT activity in the culture supernatants (Figure 4.6C). 
The correlation between genome dimerisation and viral replication was clearly 
reproduced. Replication patterns for the SM4, SM7 and SM9 viruses were similar to 
that of wild type virus, demonstrating that both stem B and the SL-1 bulge are 
dispensable for HIV-2 replication. The SM6 virus was replication-competent but 
showed a delay, which could be explained by the reduced infectivity observed in the 
single-round infectivity assay and correlated with a small decrease in RNA dimerisation 
and packaging. This result suggested that the second GGAG motif may be involved in 
viral replication, possibly acting as a Gag binding site. Finally, the SM5 and SM8 
viruses did not replicate detectably in PM1 cells over a 15 to 20 day monitoring period, 
suggesting that the original palindromic sequence pal but not the alternative palindrome 
may be essential for viral replication. Comparison of the replication fitness of SM5 and 
SM8 with the previously analysed SM2 and Pal mutants highlighted the 5' end of pal as 
being required for viral replication.
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Figure 4.6: The infectivity of the viruses correlates with their ability to dimerise 
their genome.
(A) Single-round infectivity assay. 2000 cpm of vims, as measured by RT activity, was used to 
infect 2 x io 5 cells. Infected cells were harvested 72 h later and GFP expression was analysed 
by FACS. WT, wild type. The average and sd of four independent experiments is plotted.*, two- 
tailed unpaired Student t test p value < 0.01. (B) Viral infectivity from (A) expressed as fold 
reduction in infectivity for the mutant vimses compared to WT vims. A fivefold reduction over 
WT is indicated by the red line. Average and standard error o f at least four experiments are 
shown. (C) Replication kinetics of WT and mutant vimses in PM1 T-cells. 10000 cpm o f vims, 
as measured by RT activity, was used to infect 1 x 106 cells and replication followed by 
measuring RT activity in the culture supernatant every 4 days. Mock, mock infected cells.
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In particular, and again consistent w ith the capacity to dim erise the genom e, the 
presence o f  the GG A G  m o tif at position 392-395 appeared to be critical for viral 
replication, being present in all replication-com petent viruses and absent in all non- 
infectious viruses m utants (Table 3). This w as further supported by  phylogenetic 
analysis, w hich revealed that this m o tif was 100 % conserved in all HIV-2 subtypes and 
m ost o f  the related SIVs, nam ely SIVsm , SIV stum p-tailed m acaque (S IV stm ), SIV p ig ­
tailed m acaque (SIV m ne) and SIV m ac, as show n on Figure 4.7 (H IV  sequence 
com pendium  2008).
Table 3: Correlation between viral infectivity and the sequences and structural 
elements of the HIV-2 leader.
Virus Infectivity" Sequence elem ents Structural elem ents
Psi
L
Palindrom e
GGAG
(392-395)
Stem B Psi l c Splice 
d o n o rc
Psi 2 C Psi 3 c
W T + + + + + + + +
SM4 + - + - + + + +
SM6 + + + - - + + +
SM7 + + + + + + + +
SM9 + - + + + - + +
SM2 - - - + - + - +
SM5 - + - - + + - -
SM8 - - - - - + +
Pal - - - + + + +
a, Replication kinetics in PM1 T-cells (measure of RT activity) based on 3 independent 
experiments.
h, Palindrome pal at position 392-401 of the HIV-2ROd genome.
c, Stem-loop structures previously described by Dirac and co-workers (Dirac et al., 2001) and 
predicted by the mfold program.
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HIV-2 Accession
isolate number
ROD M15390 380
MCR35 AY509260 381
MCN13 AY509259 381
BEN M30502 936
CRIK147 DQ307022 682
ALI AF0 823 39 931
SBLISY J 0 4 4 9 8 381
PEI2 U22047 904
NNVA EU980602 930
mho Z48731 380
X52223 381
D194 U38293 935
UC2 M31113 382
STGH1 M30895 376
96FR12034 AYS3 0 8 8 9 427
A b t 9 6 AF20 8027 307
CAM2CG D00835 1136
Sequence
ACAAACCACGAC GGAGTGCTCCTAGAAAG
. . T ........................
408
409 
409 
964 
710 
959 
409  
932 
957 
407
962
40 9
403
449
332
1157
Figure 4.7: Phylogenetic analysis of the HIV-2ROd packaging signal.
The packaging signal of HIV-2ROd (nt 380-408) was aligned against sequences o f fifteen other 
HIV-2 isolates using the basic local alignm ent search tool or BLA ST (Altschul et al., 1997; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). The GGAG motif at position 392-395 is indicated by 
the red box. The name and GenBank accession number of each isolate is indicated.
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4.3.2 Partial characterisation of revertant viruses
Mutations of SL-1 that affected the GGAG motif at position 392-395 of the H IV -2rod 
genome resulted in an absence of detectable viral replication in PM1 T-cells as 
measured by the RT activity of the culture supernatant (see Figure 4.6). Some of the 
mutations introduced only affected a few nucleotides, leaving the possibility for the 
virus to revert. Yet, no reversion event was observed in the first 20 days of the 
experiment. In order to analyse whether the replication of some mutant viruses could be 
rescued by a reversion of the mutation or a second site mutation, the replication of SM5 
and SM8 in PM1 cells was followed for a longer period of time (Figure 4.8A). The 
replication of the DM and Pal mutants was also measured, as PM1 cells were shown to 
support HIV-2 replication more efficiently than Jurkat cells (see Figure 3.6) and the 
absence of reversion event in Jurkat cells might have been due in part to a low 
replication efficiency of the virus.
Interestingly, while RT activity could not be detected for DM after 30 days, the SM5, 
SM8 and Pal viruses showed detectable viral replication when cultured for more than 20 
days in PM1 cells (Figure 4.8A). In order to determine whether the replication in a 
particular culture was due to a reversion of the mutation or was simply a delayed 
replication phenotype, cell-free culture supernatant was added to fresh PM1 cells and 
the replication of the viruses was followed by measuring the RT activity in the culture 
supernatant (Figure 4.8B). The passage of each virus was performed at day 25 post­
infection, when the RT activity detected was significantly above background level. 
Unfortunately, this time point did not correspond to the peak of infection for Pal and 
SM5.
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Figure 4.8: Analysis of the revertant viruses reveals second site mutations in Gag.
(A) 10000 cpm of wild type (WT) and mutant viruses, as measured by RT activity, was used to 
infect 1 x 106 PM1 cells and replication followed by measuring the RT activity in the culture 
supernatant every 2 to 4 days. Mock, mock infected cells. (B) At day 25 post-infection, Pal, 
SM5 and SM8 viruses were passaged onto fresh cells. 1 ml of culture was spun at 300 x  g  for 5 
min and 500 pi of cell-free supernatant was added to 1 x  106 PM1 cells. Viral replication was 
followed by measuring the RT activity in the culture supernatant. (C) Schematic o f the sequence 
analysis of the revertant viruses. The cell pellet from (B) was resuspended as described in 
section 2.6.4. The integrated provirus was amplified by PCR and analysed by sequencing. The 
sites of the original mutations (X) and second site reversions (X) are indicated. The sequencing 
data for SM5 were obtained from two independent virus cultures. TAR, /nms-activation 
responsive; PA, PolyA; PBS, primer binding site; Psi; SD, splice donor; MA, matrix; CA, 
capsid; NC, nucleocapsid; p6, late domain; PI and P2, spacer peptides 1 and 2. Schematic not to 
scale.
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In the case of Pal and SM8, it seemed clear that the viruses had mutated as the 
replication kinetics of the passaged viruses were faster than those of the original viruses 
(compare Figure 4.8A and B). The situation was not as clear for SM5 as the passaged 
virus did not start to replicate properly until day 15 post-infection on two independent 
occasions. This may in part be due to the fact that the virus was passaged before it had 
reached the peak of infection. Nevertheless, there was still an improvement in the 
replication kinetic as compared to the original virus.
To confirm whether these mutants had reverted, the integrated pro viruses were 
amplified by PCR using specific primers for the 5' leader, the U3 promoter region and 
the gag ORF and analysed by sequencing as described in section 2.6.4. Sequencing of 
Pal and SM8 was performed on a single culture of passaged virus, while two 
independent cultures of SM5 were used. However, it is important to note that the 
method used does not allow linking the sequencing data to individual viral clones. A 
schematic of the sequence analysis results is presented in Figure 4.8C. In all cases, the 
original mutation had been retained, implying that a second site mutation was 
responsible for the amelioration in viral replication. Sequencing of the U3 promoter 
region did not yield any results. However, when the gag ORF was sequenced, several 
mutations were found. Most notably, a T70I mutation in MA occurred in two 
independent occasions, in SM5 and SM8, and Pal showed a similarly located mutation 
at amino acid 68 (V68E). Other second site mutations were observed in CA (T98A and 
V26I) and the late domain p6 (E35K). Surprisingly, no mutations occurred in NC, 
which corresponds to the RNA-binding domain of the Gag polyprotein.
These compensatory mutations may have an effect at the nucleic acid or at the amino 
acid level. At the nucleic acid level, one might envisage that the reversion could restore 
or disrupt a long range RNA interaction or a protein-RNA interaction. However, this
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region of MA has not been previously linked with such protein-RNA or RNA-RNA 
interactions.
Regarding the modifications introduced in the protein sequence, while the V26I 
mutation in CA may not result in a change in the charge or function of the protein, as 
both amino acids are aliphatic and hydrophobic, other substitutions could have an 
impact on the function or charge of the protein.
The T70I mutation, a replacement of a threonine (slightly polar, uncharged and 
hydrophobic) with an isoleucine (aliphatic and hydrophobic), represents a relatively 
neutral mutation as both amino acids are hydrophobic and carbon-beta branched, a 
feature that results in more restriction in the conformation of the main chain (Betts and 
Russell, 2003). On the other hand, the V68E mutation of an aliphatic and hydrophobic 
valine substituted with a glutamate (negatively charged, acidic and hydrophilic) did not 
correspond to a favoured substitution. Interestingly, these two mutations occurred in a 
region of MA that is possibly quite restricted regarding the conformation of the main 
chain due to a sequence rich in isoleucine, threonine, valine and proline (60- 
ILT VLDPM VPT-70).
The T9 8A mutation in CA, corresponding to the replacement of a threonine with an 
alanine (hydrophobic), represents a neutral substitution. Finally, in the E35K 
substitution in p6, a negatively charged acidic amino acid (glutamate) is replaced with a 
positively charged basic residue (lysine), possibly triggering important changes in the 
function of the protein even though this substitution is neutral in intracellular proteins 
and favoured in membrane-associated proteins (Betts and Russell, 2003).
The method used in this study did not allow the analysis of individual clones and it is 
not possible to determine whether the second site mutations observed were sufficient to 
rescue viral replication on their own or whether a combination of these mutations was
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required. Previous examination of SIV revertants have suggested that sets of several 
compensatory mutations were required for a full rescue of infectivity, yet, each 
individual reversion was found to improve the replication of the mutated virus (Guan et 
al., 2001a). The fact that the SM8 revertant showed only one compensatory mutation 
(MA T70I) would suggest that it is sufficient to rescue, at least in part, viral replication. 
However, the presence of further mutations in the genome of these revertant viruses 
could not be determined due to technical difficulties during the PCR-based 
amplification and the sequencing steps and it is possible that more second site mutations 
are present on the genome of these revertant viruses. Therefore, although studies of 
HIV-1 and SIV mutants impaired for RNA packaging and viral replication have 
reported compensatory mutations in Gag and the leader region only (Guan et al., 2001a; 
Liang et al., 1998; Liang et al., 1999b; Liang et al., 2000; Rong et al., 2001; Rong et al., 
2003; Whitney et al., 2002), it is impossible to exclude the possibility that other 
reversions have occurred and played a role in restoring viral replication.
4.4 Discussion
HIV-2 infectivity correlates with genome dimerisation and the presence o f the 392- 
395 GGAG motif
Using a series of mutations, the role of the SL-1 sequence and structure in genome 
dimerisation, packaging and viral replication was investigated. The results obtained 
demonstrated that a correlation existed between the ability of the virus to dimerise its 
genome and its replicative fitness. In particular, it was observed that a purine-rich motif 
at position 392-395  of the H IV -2rod genome was absolutely critical for viral infectivity. 
Removal of that GGAG motif systematically resulted in the production of non-
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infectious virions that could not replicate in T-cells and contained mostly monomeric 
genomes. This result was in agreement with another study that reported a GGRG motif 
(where R is a purine) at the same position as being important for HIV-2 replication 
(Baig et al., 2009). Consistent with its essential role in the virus life cycle, that purine- 
rich motif is well conserved in all HIV-2 and SIVsm subtypes as well as in related SIV 
species (HIV sequence compendium 2008).
Interestingly, mutation of a second GGAG motif at position 439-442 also had some 
effect on genome dimerisation and resulted in a delayed replication in T-cells. This 
suggested that this motif might play a role in viral replication. The HIV-1 Gag 
polyprotein has been shown to bind purine-rich motifs, which constitute the packaging 
signal (Berkowitz et al., 1993; Clever et al., 1995). Hence, one might envisage that these 
motifs could act as a Gag binding site in HIV-2 as well. Consistent with this hypothesis, 
mutation of the second GGAG motif resulted in a twofold reduction in RNA packaging. 
It is also interesting to note that whilst most Psi/SL-1 mutants showed some reduction in 
RNA packaging, the SM4 mutant, which contained an additional GGAG sequence, was 
the only one to display a packaging efficiency of 90 %, apart from the SMI mutation of 
the terminal SL-1 palindrome (see Chapter 3).
The binding affinity of Gag to the mutated RNAs was assessed in vitro using EMSA 
and RNA-protein GST-pull down. Unfortunately, due a lack of sensitivity and 
reproducibility, these experiments were inconclusive.
Contrary to what was observed with the Psi mutants in Chapter 3, encapsidation did not 
absolutely correlate with dimerisation. This difference could be explained by the fact 
that a much greater number of mutations were analysed in the second set of 
experiments. Furthermore, the Psi mutations DM and Pal both corresponded to rather
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large deletions (28 and 10 nt respectively) and could affect dimerisation and 
encapsidation simultaneously due to the overlap of the RNA elements required for each 
process. Specifically, these two mutations of the packaging signal also removed the 
GGAG motif at position 392-395 that was important for genomic RNA dimerisation; 
hence, one would expect both their dimerisation and packaging abilities to be affected. 
It would be interesting to test non-radioactive-based methods to assess the packaging 
efficiencies of the mutant viruses to confirm the results of the RPAs as the use of 
radioactive methods presents the major problem of the decay of the radioisotope. The 
use of radioactivity in RNA-protein binding experiments also posed difficulties. 
Quantification of the RNA input in the EMSA using TCA precipitation did not prove 
the most reproducible method and it was difficult to perform each experiment on an 
equivalent amount of RNA, rendering the results impossible to interpret. Similarly, 
measure of the RNA bound to GST-Gag in the GST pull-down experiment suffered 
from a lack of reproducibility due to variation in both the RNA input and the output 
reading of the experiment by scintillation counting. Methods based on real-time RT- 
PCR are ideal candidates to replace the use of radioactivity in the packaging assays, as 
the concentration of the RNA input could be measured precisely using a Nanodrop 
spectrophotometer. Besides, real-time RT-PCR is an extremely sensitive method, 
allowing detection of minimal amounts of RNA.
However, despite apparent discrepancies between the results obtained with the two sets 
of mutants (presented in Chapters 3 and 4) regarding the connection between genome 
dimerisation and packaging, a nonreciprocal relationship is observed between the two 
processes. When the set of data is analysed as a whole (Table 4), one can note that all 
mutants that failed to efficiently form RNA dimers also showed a packaging defect, yet
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the reverse is not true. This suggests that genome dimerisation is important for 
encapsidation and it implies that RNA dimer formation occurs prior to packaging.
Recent work by the Lodmell group has shown that a GGRG sequence in the HIV-2 Psi 
region was important for packaging as well as replication (Baig et al., 2009). Our data 
did not corroborate this finding and mutants that contained an intact GGAG motif failed 
to package their genomes to wild type level (e.g. SM6, SM7 and SM9). In their study, 
Baig and co-authors used an in vivo SELEX (selected evolution of ligands by 
exponential enrichment) method, in which randomised 5'pal sequences were introduced 
into a pool of genomes and selected through serial passages of the viruses. Sequencing 
of the surviving viruses revealed a consensus towards a GGRGN sequence at position 
392-396, suggesting that a purine-rich motif was indeed critical for viral replication. 
Analysis of the packaging ability of two pyrimidine-rich mutants, TTB16 (5'-ACCUG- 
3') and the SM2 mutant described in this study (5'-CCUCU-3') and previously published 
(L'Hemault et al., 2007), as well as a purine-rich mutant, TTB78 (5-GGGGU-3'), 
showed that only the pyrimidine-rich mutants had a reduction in packaging, two- to 
threefold compare to the wild type virus, leading to the conclusion that a purine-rich 
motif was critical for encapsidation. In the present study, six mutants were analysed for 
their ability to dimerise and encapsidate their genomes and replicate in T-cells and a 
careful comparison between the sequences and structural elements present in each 
mutant and the experimental data obtained for each of them was carried out. Extending 
this comparative analysis to the Psi mutants presented in Chapter 3 (see Table 4), it was 
confirmed that the ability to form RNA dimers correlated with the packaging efficiency 
and the replicative fitness of HIV-2 and that the presence of the GGAG motif at position 
392-395 was essential for HIV-2 infectivity. In our study, genome encapsidation did
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not, how ever, depend upon the presence o f  this purine-rich m otif. Further analysis will 
be required to clarify the requirem ent for a purine-rich m otif - such as G G RG  - in HIV- 
2 RN A  packaging.
Table 4: Comparative analysis of the Psi and SL-1 mutants.
Virus Dimerisation
in virio a
Packaging b Replicationc pal DIS Stem
Bf
392-395
GGAG
439-442
GGAG
WT +++ 1 + + + + + +
SMI -HH- 0.9 + + - + + +
SM7 +-1- 0.5 + + + + + +
SM9 ++ 0.5 + - + + -
SM4 + 0.9 + - + - + +
SM6 + 0.5 + + - + -
DM - 0.4 - - + - - +
Pal - 0.4 - - + - - +
SM2 - 0.5 - - + + - +
SM3 - 0.4 - - - + - +
SM5 - 0.6 - + e + - - +
SM8 - 0.4 - - + - - -
a, genomic RNA dimerisation as measured by native northern blot.
b, packaging efficiency determined by RPA. Wild type (WT) is set as 1.
c, Replication in PM1 T-cells, followed by measuring the RT activity in the culture supernatant. 
Presence (+) or absence (-) of detectable RT activity over a 20 days monitoring period.
d, a 2-days delay in replication was observed prior to wild type-like replication.
e, alternative palindromic sequence in place of wild type pal.
f, base-pairing between residues 397-401 and 439-443.
g, alternative sequences restoring the base-pairing forming in stem B.
Purine-rich sequences are involved in a wide range o f  cellular processes 
Purine-rich m otifs can be found in a variety o f  organism s and have been proposed to 
p lay a role in post-transcriptional control, m RN A  splicing, translation, pro tein-R N A  
interactions and RN A  packaging.
177
Chapter 4: Sequence and structural context o f stem-loop 1 and its implication fo r  HIV-2
replication
For example, in the bacteriophage T4, GGAG motifs are involved in post- 
transcriptional control as early mRNAs are cleaved by the endoribonuclease RegB, 
mostly at GGAG sites located in intergenic regions - including Shine-Dalgamo 
sequences - resulting in their inactivation (Jayasena et al., 1996; Sanson and Uzan, 
1995).
In humans, members of the serine/arginine-rich (SR) family of proteins such as splicing 
factor 2 (SF2/ASF) and SRp30, which are involved in pre-mRNA splicing, mRNA 
export and translation, have been shown to bind to purine-rich sequences - mainly 
located in exons - resulting in the enhancement of splicing (Sanford et al., 2008; Tian 
and Kole, 2001). Interestingly, the N-terminal region of HIV-2 Gag has been shown to 
specifically interact with a serine-threonine kinase from the SR family of splicing 
factors, PRP4, resulting in the inhibition of SF2/ASF phosphorylation (Bennett et al., 
2004). However, this interaction, which was demonstrated by yeast-two-hybrid, did not 
appear to involve an RNA intermediate.
Another splicing factor, SFRS1, was shown to recognise a purine-rich octamer (Sanford 
et al., 2009), similar to the sequence located between SL-1 and the SD stem-loop in 
HIV-2.
In higher eukaryotes, proteins are translocated through the RER membrane during their 
synthesis where they undergo a range of post-translational modifications. To achieve 
this, the signal recognition particle SRP, a cytoplasmic ribonucleoprotein complex, 
directs the ribosome to the RER membrane and facilitates the insertion of the nascent 
polypeptide into the membrane (reviewed in Lutcke, 1995). Assembly of the human 
SRP has been shown to include the specific binding of the SRP 19 protein on the SRP 
RNA, at a site that comprises a central GGAG loop (Sakamoto et al., 2002).
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In vivo footprinting carried out in infected T-cells also showed that several purine-rich 
sites in the HIV-1 promoter region, sharing the common sequence 5 '-GGAGAGA-3', 
were prime protein binding sites (Demarchi et al., 1992), suggesting that these purine- 
rich motifs are also involved in DNA-protein interaction and might play a role in HIV-1 
mRNA transcription.
Finally, purine-rich motifs have been found to be key players in protein-RNA 
interactions in several viruses, including HIV-1. Interestingly, it was shown that the coat 
protein of Cauliflower Mosaic virus interacts with purine-rich sequences on the pre- 
genomic RNA via its zinc finger motif and basic residues (Guerra-Peraza et al., 2000). 
This mechanism displays extreme similarities with the NC-RNA interaction observed in 
retroviruses during genome packaging. The zinc fingers in HIV-1 and MLV NC and the 
flanking basic amino acid residues in HIV-1 NC have indeed been reported to be 
required for this interaction (Aldovini and Young, 1990; Berkowitz and Goff, 1994; 
Dannull et al., 1994; De Guzman et al., 1998; Gorelick et al., 1988). The NC domain of 
the HIV-1 Gag polyprotein binds to a sequence in the 5' leader RNA located close to the 
Gag start codon (SL-3) which corresponds to the main packaging determinant and 
contains a GGAG motif exposed in a loop (Aldovini and Young, 1990; Bacharach and 
Goff, 1998; Berkowitz and Goff, 1994; De Guzman et al., 1998; Lever et al., 1989; 
Luban and Goff, 1994). Interestingly, a GA-rich sequence located immediately 
downstream of SL-3 was also found to be involved in HIV-1 RNA packaging and 
dimerisation (Russell et al., 2003a) and in vitro footprinting experiments confirmed that 
purine-rich sequences were amongst the preferred binding sites for HIV-1 Gag and NC 
(Damgaard et al., 1998).
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Possible roles o f the HIV-2 rod 392-395 GGA G motif
The position of the 392-395 GGAG motif in the 5' untranslated region of the HIV-2 
genome and the similarities with other retroviruses, including HIV-1, suggest a role in 
protein-RNA binding and RNA packaging. Indeed, a function in regulation of mRNA 
splicing seems less likely as the purine-rich splicing regulatory elements described 
above appear to be primarily located in exons. Besides, the binding site of the splicing 
enhancer SFRS1 shares strong homology with the GA-rich stem-loop located between 
SL-1 and the SD stem-loop in the HIV-2 leader RNA, but not with SL-1 itself.
With regards to a role in mRNA translation, there is no evidence so far to support this 
hypothesis, as the translation of the GGAG mutants appeared normal. Nonetheless, this 
possibility cannot be completely excluded since the rate of protein synthesis and 
processing of the mutants has not been measured. One might envisage that similarly to 
what is observed in HIV-1, where the Gag protein modulates its own translation partly 
through binding of NC to the RNA leader (Anderson and Lever, 2006), the HIV-2 Gag 
protein also has some self-regulatory function involving sequences in the RNA leader. 
In HIV-1, the translation of Gag is stimulated when the protein is present at low 
concentrations and inhibited at high concentrations, probably corresponding to a switch 
between the need for the structural protein synthesis and the need for packaging and 
assembly. The matrix domain appeared to stimulate Gag translation - independently of 
RNA binding - while binding of the NC domain to the packaging signal seemed to 
cause the inhibition of translation (Anderson and Lever, 2006). In HIV-2, only the 
inhibitory effect is seen and it appears that the matrix domain does not stimulate Gag 
translation (Emma Anderson, personal communication). This may be due to the 
inability of HIV-2 MA to efficiently bind to the eukaryotic initiation factor 5B or eIF5B 
(Andrew Lever, personal communication) as one hypothesis to explain the stimulatory
180
Chapter 4: Sequence and structural context o f stem-loop 1 and its implication for HIV-2
replication
effect of HIV-1 MA on Gag translation is that HIV-1 MA, which was shown to interact 
with eIF5B (Andrew Lever, personal communication; Wilson et al., 1999), could act as 
a guanine exchange factor for eIF5B (Emma Anderson, personal communication). If 
HIV-2 Gag also modulates its own translation through the binding of NC to the 5' leader 
RNA, mutation of a Nucleocapsid binding site would result in a shift in the balance 
between translation and packaging. In particular, considering that HIV-2 packages its 
genome in a co-translational manner and that the limited availability of the Gag 
polyprotein ensures the specificity of packaging, one could envisage that prevention of 
the NC-mediated inhibition of Gag translation would affect HIV-2 genome 
encapsidation. This might provide an explanation for the reduced packaging and 
delayed replication of the SM6 virus that bears a mutation at a second GGAG motif at 
position 439-442, another putative NC binding site. It would be interesting to test this 
hypothesis by measuring the effect of HIV-2 NC on Gag translation in the context of the 
SL-1 mutants described in this study.
Potential implications o f the compensatory mutations in the gag coding sequence 
While all mutations that removed the 392-395 GGAG motif resulted in an absence of 
detectable replication in PM1 cells over the course of 20 days, prolonged culture of 
these non-infectious viruses resulted in the emergence of revertants for SM5, SM8 and 
Pal. All revertants retained the original mutations, suggesting that the rescue of viral 
replication was triggered by second site compensatory mutations. The promoter region, 
5' leader and gag ORF of Pal, SM5 and SM8 revertants were sequenced and several 
mutations were identified in the gag coding region. Each virus carried a mutation in MA 
at position 68 or 70. Pal displayed a V68E substitution and SM5 and SM8 both had a 
T70I substitution. Interestingly, the MA T70I mutation has been observed previously in
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a SIVmac239 packaging mutant bearing a deletion at position 398-418 (termed SD2) in 
combination with a mutation in RT (Ml 84V) that delays reversion (Whitney et al., 
2002). Residues 398-418 of SIVmac239, which are almost 100 % conserved with 
nucleotides 397-417 of H IV -2rod and predicted to fold into a structure similar to SL-1 
in H IV -2rod, appeared to be required for viral replication in SIV (Guan et al., 2000). 
The T70I reversion conferred a replicative advantage to the SD2-M184V virus but did 
not restore replication to wild type level (Whitney et al., 2002), similarly to what can be 
seen with the SM5 and SM8 revertants. The impact of this reversion on the replication 
of the SD2 mutant in the absence of the Ml 84V mutation was unfortunately not 
assessed.
The T70I compensatory mutation was also identified in HIV-1 MA mutants bearing 
substitutions at residues 4 and 6 and presenting defects in particle assembly and release. 
In HIV-1, the T70I reversion was found to induce a modest increase in the rate of Gag 
p55 processing, but had no effect on the kinetics of replication (Ono et al., 1997).
The MA protein has been implicated in RNA dimerisation in RSV as mutations that 
altered the localisation of MA were found to disrupt dimer formation (Garbitt et al., 
2001). It has also been proposed that HIV-1 MA is involved in the proteolysis of the 
Gag precursor during assembly (Lee and Linial, 1994; Ono et al., 1997). Furthermore, 
Gag multimerisation, which is required for the assembly of retroviral particle and is 
enhanced by the presence of RNA, has been shown to require the capsid-dimer interface 
and the basic residues in MA in the absence of NC (Bumiston et al., 1999). This 
suggests that protein-protein and protein-RNA interactions may be involved in the 
assembly process and that MA might be involved in some of these protein-RNA 
interactions via its basic residues. In addition, HIV-1 MA has been shown to play a role 
in the targeting of the Gag polyprotein to the plasma membrane as part of the assembly
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process (Facke et al., 1993; Ono and Freed, 1999; Ono et al., 2000) and in the 
incorporation of the Env glycoprotein into virions (Dorfman et al., 1994b; Freed and 
Martin, 1996; Ono et al., 1997). HIV-1 MA, but not HIV-2 MA, has also been shown to 
stimulate Gag translation when Gag is present at low concentration, possibly via 
interaction of the N-terminus of matrix with eIF5B (Anderson and Lever, 2006; Lever, 
personal communication). The region between residues 32 and 57 of HIV-1 MA was 
shown to be required for the interaction with eIF5B (Lever, personal communication). 
Finally, these mutations are located immediately downstream of the second Gag AUG, 
proposed to promote the translation of the p50 isoform of Gag (Herbreteau et al., 2005), 
and could affect the production of the p50 isoform and/or the ratio of the three Gag 
isoforms produced. Unfortunately, the Gag protein synthesis of the revertant viruses 
was not assessed.
Interestingly, at the nucleic acid level, part of the matrix coding region also appears to 
be involved in a long-range pseudoknot RNA-RNA interaction with sequences 
downstream of the PolyA signal (Paillart et al., 2002). Sequences required for this 
interaction were found to be conserved in HIV-2 and SIV isolates, supporting its 
functional importance; yet, the exact role of this interaction has not been elucidated. It 
was suggested that it could act as a repressor of the polyadenylation signal, regulate 
steps of the life cycle such as Gag translation and/or facilitate the selection of the 
genomic RNA during packaging.
In addition to the reversions in MA, mutations in CA (V26I and T98A) and p6 (E35K) 
were observed for the HIV-2 SM5 and Pal mutants.
In a previous study of the SIVmac239 SD 2 mutant, which showed the same T70I 
reversion in MA as SM5 and SM8, two sets of three compensatory mutations were 
found, including mutations in CA and p6 (Guan et al., 2001a). In each case, an A423G
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substitution in the terminal palindrome of SL-1 was observed. This mutation disrupted 
the putative DIS and would have prevented self-complementarity (GGUACC to 
GGUGCC). In addition to this mutation, two mutations in CA (K197R) and p6 (E49K) 
were identified when the virus was grown in C8166 cells. Using CEMxl74 cells, in 
which the replication kinetic of the viruses was much faster, two mutations in NC 
(E18G and Q3 IK) were found. For each set, the three mutations were required to restore 
full replication, even though each individual reversion on its own was able to provide a 
replicative advantage. Similar studies of HIV-1 SL-1 and SL-3 deletions mutants 
impaired for RNA dimerisation and packaging also found compensatory mutations in 
Gag. The SL-1 mutant reverted in MA (V35I), CA (I91T), p2 (T12I) and NC (T24I), 
while the SL-3 mutant mutated p2 (Al IV) and NC (I12V) (Liang et al., 1999b; Rong et 
al., 2003). Importantly, the T24I mutation in NC appeared first and contributed most to 
the rescue of viral replication. While it seems probable that mutations in NC would 
rescue the replication of a mutant virus with a defect in viral RNA packaging, as NC 
plays a major role in RNA selection during the encapsidation process, it is less clear 
what effects the compensatory mutations in CA and p6 had.
Capsid is the major component in particle assembly and the presence of RNA has been 
shown to enhance VLPs assembly in vitro (Campbell and Vogt, 1995). Hence, it is 
possible that the reduction in the level of dimeric RNA packaged affected the stability 
of the viral capsid and that these CA compensatory mutations restored it. This 
hypothesis would depend on the level of dimeric RNA packaged in the revertant virus 
as one might expect packaging, and possibly dimerisation, to be at least partially 
restored in those viruses; otherwise, another explanation for the reversion in CA is 
required. V26 is located in the alpha helix 1 of CA NTD. Interestingly, residues in helix 
1 of HIV-1 CA have also been linked with genome dimerisation as it was shown that
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mutations that disrupt alpha helix 1 but leave other region of CA intact - in particular 
the C-terminal domain - resulted in a dimerisation defect similar to that observed in 
protease-deficient viruses (Kafaie et al., 2009). Furthermore, helix 1 to 3 of HIV-1 CA 
have been found to play a role in mature capsid formation (von Schwedler et al., 2003a) 
and the V26I mutation might affect particle assembly or structure. In fact, the V26I 
mutation has been observed previously in HIV-1 in the context of a W23F CA mutant 
displaying a replication and assembly defect (Tang et al., 2007). In that study, it was 
reported that the NTD of CA and in particular residues involved in alpha helix 1 and 2 
contribute to proper core assembly and that the V26I reversion of the W23F mutant 
partially restored the conformation of CA.
The E35K mutation in p6 is located within the Vpx binding site (Pancio and Ratner, 
1998) and near the PTAPP motif which was shown to interact with TsglOl, an inactive 
E2 ubiquitin ligase homologue, triggering an increased ubiquitination of HIV-2 Gag 
(Myers and Allen, 2002). As monoubiquitination of Gag is important for its targeting to 
multivesicular bodies, the introduction of an extra lysine, which could be ubiquitinated, 
may alter the trafficking pattern of Gag.
The method used in this study did not allow us to determine whether either 
compensatory mutation alone was able to restore replication or if sets of reversions were 
necessary. However, the fact that the SM8 revertant carried only the MA T70I mutation 
and that mutation in MA were found in all three revertants suggested that mutations in 
this region of Gag conferred a significant replicative advantage to the virus.
Whilst the exact function of these compensatory mutations in MA, CA and p6 has not 
been elucidated, the aforementioned studies in HIV-1 and SIV seem to point towards a 
role either in RNA-protein or protein-protein interaction, possibly to help restore the
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packaging process, stabilise the RNA dimer or enhance/rescue retroviral assembly 
should the mutations introduced in SL-1 have impaired capsid formation.
It is important to note that the genome of the revertant viruses was not entirely 
sequenced due to technical difficulties during the amplification and sequencing 
processes. As a result, despite several studies of HIV-1 and SIV packaging mutants 
reporting the presence of compensatory mutations in the 5' leader and gag coding region 
only (Guan et al., 2001a; Liang et al., 1999b; Rong et al., 2003; Whitney et al., 2002), 
the possibility of more compensatory mutations elsewhere on the genome cannot be 
ruled out and it is impossible to draw any definitive conclusions regarding the 
reversions found in the gag coding sequence. To do so, a complete sequencing analysis 
of the integrated provirus as well as the cloning of the candidate reversions into the 
molecular clones of the mutant viruses is necessary.
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5 Role of RNA dimer formation in particle maturation
5.1 Introduction
Nucleic acids and RNA in particular have been suggested to play an important role in 
the correct assembly of retroviral particles. Although early studies of HIV-1 packaging 
mutants reported normal protein and particle production, as measured by the level of 
CA (p24) in the cells and culture supernatant (Aldovini and Young, 1990; Clavel and 
Orenstein, 1990; Gorelick et al., 1993; Gorelick et al., 1990; Lever et al., 1989; Luban 
and Goff, 1994), differences in particle morphology were observed. In some reports, 
HIV-1 Psi mutants appeared morphologically similar to wild type viruses (Gorelick et 
al., 1990; Lever et al., 1989), whereas in others, particles with an aberrant morphology - 
empty or less dense particles - were described (Aldovini and Young, 1990; Clavel and 
Orenstein, 1990), suggesting that normal genomic RNA packaging may be required for 
the orderly arrangement of the nucleoid components. A subsequent study in RSV and 
HIV-1 showed that the efficiency of in vitro assembly of purified CA-NC and CA-NC- 
p6 into VLPs was stimulated by the addition of nucleic acid (Campbell and Vogt, 
1995). Similar observations were made using an HIV-1 Gag protein lacking only the p6 
domain (Campbell and Rein, 1999). In both studies, the multimerisation of the Gag 
polyprotein into units larger than dimers was greatly enhanced by the presence of 
nucleic acid (Campbell and Rein, 1999; Campbell and Vogt, 1995), which support the 
hypothesis that particles assemble through the formation of an RNA:protein complex 
that serves as a nucleation core for the expansion of the viral capsid in an RNA-
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dependent manner. Further evidence that RNA was acting as a bridge in Gag-Gag 
interaction was provided by analysis of several Gag deletion mutants showing that the 
nucleic acid binding domain of Gag, NC, was required for the interaction and that 
RNAse treatment disrupted Gag multimerisation in vitro (Bumiston et al., 1999). 
Accordingly, HIV-1 NC mutants defective for specific and non-specific RNA binding 
showed impaired Gag-Gag interaction, suggesting that RNA binding is indeed required 
for Gag multimerisation (Cimarelli et al., 2000). Interestingly, this implication of RNA 
in Gag multimerisation and particle assembly is in accordance with the ‘fullerene’ 
model proposed for HIV-1 capsid assembly (Ganser et al., 1999; Li et al., 2000; Nermut 
et al., 1994).
The addition of RNA was also found to increase the efficiency of CA-NC particles 
assembly, which otherwise required very high salt concentration (Ganser et al., 1999). 
However, it is interesting to note that this stimulatory effect was not found to be specific 
of the viral RNA and that several nucleic acids such as yeast tRNA, bacterial rRNAs, 
tobacco mosaic virus RNA and DNA oligonucleotides were also found to enhance the 
assembly of CA-NC in vitro (Campbell and Rein, 1999; Ganser et al., 1999). Finally, 
the presence of nucleic acid in in vzYro-assembled HIV-1 VLPs was confirmed by 
immunogold staining (Fuller et al., 1997).
Interestingly, a study of MLV reported that particles that lacked genomic RNA due to a 
mutation in the packaging signal contained cellular RNA in place of viral RNA and that 
RNase treatment disrupted the virus cores, suggesting that RNA was a structural 
element of MLV particles (Muriaux et al., 2001). In addition, RNA was proposed to be 
required for the proteolytic cleavage of the HIV-1 NC (p i5) precursor (Sheng and 
Erickson-Viitanen, 1994), suggesting that binding of the NC protein to RNA might play 
a role in virion maturation.
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In HIV-1, deletions around the DIS were reported to cause a delay in the processing of 
the p2 peptide from the CA-p2 precursor (Liang et al., 1999a). Since the p2 peptide has 
been demonstrated to be involved in the sequential proteolytic processing of the Gag 
protein and the production of fully infectious particles (Pettit et al., 1994), this result 
implied that sequences important for RNA dimer formation play a role in protein 
processing and consequently in particle maturation. However, it was not possible to 
conclude whether the formation of an HIV-1 RNA dimer was important as the 
dimerisation abilities of these particular DIS-mutated viruses had not been established 
(Liang et al., 1999a). Nonetheless, further evidence that the dimerisation or the 
packaging of the genomic RNA contributed to correct particle assembly came from a 
study in SIV, where mutations in the SL-1 region that resulted in a reduction of 
encapsidation and dimerisation led to aberrant particle morphology (Whitney and 
Wainberg, 2006).
Whilst several reports have proposed a role for the RNA - possibly as a dimer - in 
particle assembly and morphogenesis, the HIV-1 and MuLV RNA dimers have been 
shown to undergo a ‘maturation’ process dependent on proteolytic cleavage by the viral 
protease (Fu et al., 1994; Fu and Rein, 1993) and therefore likely to occur 
simultaneously to the maturation of the viral particle. Gag cleavage alone is however 
not sufficient to promote the maturation of the dimer (Fu et al., 2006) and other factors 
might be involved. Interestingly, the proteolytic processing of the CA/p2 cleavage site, 
the ratio of Gag and Gag-Pol polyprotein synthesised and certain residues in the spacer 
peptide p i have also been implicated in the stability and maturation of the HIV-1 RNA 
dimer (Hill et al., 2002; Shehu-Xhilaga et al., 2001a; Shehu-Xhilaga et al., 2001b).
In this chapter, we explored the link between the encapsidation and dimerisation of the 
HIV-2 genome and the correct assembly of the virus particle. Wild type and DM mutant
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viruses were analysed by electron microscopy using negative staining. Micrographs of 
the DM virus revealed a decrease in the number of mature particles compared to the 
wild type virus. Yet, no increase in the number of immature particles was observed. 
Instead, an increased number of particles containing two or more cores was noted. The 
data obtained suggested that the DM mutant virus partly failed to produce adequately 
matured particles and that this maturation defect might in part account for the reduced 
infectivity observed with this mutant.
5.2 Effect of the DM mutation on particle morphogenesis
The synthesis and processing of the Gag polyprotein in the DM mutant has been 
assessed previously using western blotting and metabolic labelling (see Chapter 3 and 
Griffin et al., 2001). However, these analyses were conducted at a single time point of 
48 h post-transfection and are not sufficient to exclude the possibility of a delay in Gag 
or Gag-Pol processing, which could affect the maturation of the virus and account for 
the reduction in viral infectivity of this mutant virus.
In order to evaluate the impact of the Psi deletion on particle morphology and determine 
whether there was any contribution of RNA encapsidation and genome dimerisation to 
viral assembly in HIV-2, wild type and DM virions - produced by Cos-1 cells 
transfected with the appropriate envelope-deleted provirus - were purified through 20 % 
sucrose and analysed using negative stain electron microscopy. As in experiments 
performed on purified HIV-1 cores (Welker et al., 2000) and in vzYro-assembled HIV-1 
capsids (Campbell and Rein, 1999), samples were stained with 1 % uranyl acetate prior 
to observation by electron microscopy. Electron micrographs were examined by two 
independent observers and approximately two hundred particles were identified for each
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virus. Representative particles containing immature, mature and multiple cores are 
shown in Figure 5.1. Immature particles displayed a peripheral ring, likely composed of 
the structural polyprotein Gag orderly arranged below the lipid membrane as observed 
in HIV-1 (Fuller et al., 1997; Gelderblom, 1991; Hockley et al., 1988; Wilk et al., 
2001). HIV-2 mature particles appeared to contain a cone-shape core, as previously 
noted for HIV and SIV (Briggs et al., 2003; Gelderblom, 1991; Grief et al., 1989; 
Hockley et al., 1988; Kewalramani and Emerman, 1996; Palmer et al., 1988; Welker et 
al., 2000) and in accordance with the ‘fullerene’-model (Ganser et al., 1999; Li et al., 
2000; Nermut et al., 1994). Finally, some particles containing two cores were noticed. 
In most cases, the two cores were of conical shape, though some tubular cores were also 
detected (Figure 5.1). These type of particles, which may have resulted from the 
assembly of two cores near to each other and their subsequent budding in a single 
envelope, have been described previously (Briggs et al., 2003; Gelderblom, 1991) and 
were found to represent a third of mature HIV-1 particles (Briggs et al., 2003). 
Approximately two hundred wild type and DM particles were observed and classified 
according to their morphology and the results are presented in Figure 5.2. Interestingly, 
the preparation of purified DM virus was found to contain significantly fewer mature 
particles compared to the wild type virus preparation (Figure 5.2A). However, this 
reduced number of mature particles for the DM virus did not correlate with an increase 
in the number of immature virions (Figure 5.2A), suggesting that the particle maturation 
process may not be blocked at an early stage of the proteolytic processing. In contrast, 
there was a larger number of aberrant particles containing two cores in the DM sample 
(Figure 5.2A, multiple cores). The remaining proportion of the particles appeared to 
contain a core located off-centre (Figure 5.2A, eccentric cores). These particles may 
have been mature, as they contained the cone-shaped core typical of mature particles,
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yet, due to the eccentric position of the core inside the particle, these were classified and 
counted as a separate category. No difference was observed between the wild type and 
mutant virus preparation for these eccentric-core particles.
Finally, it was also noted that the average diameter of the mutant virions was larger than 
that of the wild type virions (Figure 5.2B). This did not appear to result from the 
increased number of particles containing multiple cores, as the average diameter of the 
DM virions (186.7 ±31.8 nm) was the same as the average diameter of the multiple 
core DM particles only (185.9 ± 22.6 nm; compare Figure 5.2B and C). It is interesting 
to note that an increase was observed between the average size of the total wild type 
virions (157.7 ± 38.5 nm) and the wild type multiple core particles only (169.3 ± 21.6 
nm), which could reflect the presence of the second core inside these particles; yet, this 
difference was not statistically significant.
The data presented here showed that a mutation in the HIV-2 packaging signal that also 
affected genome dimerisation resulted in a reduction in the number of mature particles 
and an abnormal proportion of particles containing more than one core and may in part 
explain the loss of infectivity associated with this mutation.
5.3 Discussion
Negative staining electron microscopy was used to analyse whether the HIV-2 
packaging mutant displayed a morphological or maturation defect which could explain 
the reduction in infectivity observed. Due to safety issues, the experiments were carried 
out using envelope-deleted virions.
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Multiple cores
Figure 5.1: Representative electron micrographs of HIV-2 particles.
Envelope-deleted wild type and DM mutant virions were produced by transfection of Cos-1 
cells with the appropriate molecular clones. At 48 h post-transfection, virions were harvested 
and purified through a 20 % sucrose cushion. Virions were then washed and stained as 
described in section 2.6.5 prior to visualisation by electron microscopy. Representative 
micrographs of three independent microscopy sessions using two independent virus preparations 
are shown. Five examples each of particles denominated as immature, mature and containing 
multiple cores are shown. Magnification: 20,000 x; scale bar: 100 nm.
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Figure 5.2: Effect of the Psi deletion on HIV-2 particle morphology.
(A) Quantification of wild type (WT) and DM mutant HIV-2 particles observed by negative 
staining electron microscopy. Immature, mature and multiple core particles are as described in 
Figure 5.1. Particles containing a single core in an off-centre position (eccentric cores) were 
also counted. Micrographs of three independent microscopy sessions using two independent 
virus preparations were analysed by two individuals not knowing which micrograph 
corresponded to which virus preparation. Average and sd for 193 WT and 199 DM particles is 
shown. Statistical significance measured by a two-tailed unpaired Student t test. The size of all 
particles (B) or those containing two cores (C) was measured by a single observer for the WT 
and DM mutant virus. Average and sd are shown. Statistical significance measured by a two- 
tailed unpaired Student t test.
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To ensure an objective, non-biased analysis, the electron micrographs were analysed by 
two observers who did not know which micrographs corresponded to which virus. 
Electron micrographs of the packaging mutant (DM) virus showed a modest, yet 
significant reduction in the number of mature particles compared to the wild type virus. 
However, the proportion of immature particles in the mutant virus sample was similar to 
that of the wild type sample, indicating that the maturation of the DM virus was not 
blocked at an early stage of the proteolytic processing. In addition, protein processing of 
the DM mutant appeared normal when analysed at the same time point of 48 h post­
transfection that was used in this study (Griffin et al., 2001). Nonetheless, a delay in 
protein processing cannot be excluded as the analysis was only performed at a single 
time point. Interestingly, a recent analysis of the SIV mac SL-1 region showed that 
deletions upstream of the SD, which affected RNA packaging, also had an effect on 
protein processing and particle morphogenesis (Whitney and Wainberg, 2006). With 
this in mind, it would be interesting to analyse the protein processing of the mutant 
virus at several time points and determine whether the processing of the Gag and Gag- 
Pol polyprotein is affected. Metabolic labelling of the neo-synthesised proteins at 
several time points would help determine whether the synthesis and subsequent 
cleavage, as well as the ratio, of the Gag and Gag-Pol polyproteins were correct. Due to 
a lack of time, this experiment could not be conducted.
As previously observed with HIV-1 (Briggs et al., 2003), a significant proportion (20 
%) of wild type HIV-2 particles was found to contain two or more cores. Interestingly, 
the number of particles containing two cores was increased by twofold in the DM 
mutant sample compared to the wild type sample. There has been no report regarding 
the infectivity of these ‘two-core’ particles. Hence, it is difficult to evaluate whether 
these represent infectious virions. Yet, the fact that their number was increased in the
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replication-incompetent DM virus preparation suggested that they may not be. 
Therefore, the higher proportion of these multiple core particles might account at least 
in part for the infectivity defect observed with the DM mutant.
In HIV-1, these particles containing two cores were found to be significantly larger (20 
nm) than those containing a single core (Briggs et al., 2003), which suggested that these 
particles may contain four copies of the genetic material, two in each core. Considering 
that the DM mutant showed a reduced level of dimeric RNA in the virions, it would be 
tempting to speculate that each core contained a single copy of genomic RNA, packaged 
as a monomer. Since the average diameter of the DM particles appeared to be the same 
as the average diameter of a DM particle containing two cores, it seemed unlikely that 
the two cores present in a single particle each contained two copies of the genomic 
RNA. Yet, one could not conclude from this experiment whether each of these two 
cores contained only a single copy of the genome. In fact, proving this rigorously would 
be technically challenging, as one would have to design dimer- and monomer-specific 
probes and label them with gold particles of different sizes to distinguish between 
monomeric and dimeric RNA within the two cores.
The DM particles appeared to be significantly larger than the wild type particles, by 
approximately 30 nm on average. Since the DM sample also comprised significantly 
more particles containing two cores, one could envisage that the higher proportion of 
multiple core particles accounted for the size difference. However, when the DM 
particles with two cores were measured, these were found to be of equal diameter 
compared to the average DM particle, indicating that the increased number of particles 
containing two cores did not account for the larger diameter of the DM particles. 
Interestingly though, the average wild type particle containing two cores was found to 
be larger than the average wild type virion by 11.5 nm. A possible explanation would be
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that, in the case of the wild type vims, these particles contained two complete mature 
cores, each comprising two copies of the genomic RNA. Further experiments would 
however be required to determine whether this size difference could be justified by the 
presence of twice the amount of genetic material in these particles.
Although the data obtained here showed that the DM mutant vims showed a maturation 
defect, even if modest, it remained unclear at which stage of the virion maturation this 
deficiency occurred. The fact that the number of immature particles did not increase as 
the number of mature virions decreased indicated that the block was probably not at an 
early stage of the maturation process. The reduction in the level of RNA packaged in the 
mutant vims may have resulted in a decrease stability of the virions after assembly at 
the plasma membrane, as proposed for HIV-1 (Wang and Aldovini, 2002). Indeed, 
abolition of RNA packaging by mutations of the NC domain did not affect the assembly 
of Gag particles at the plasma membrane but resulted in a drastic decrease in the level of 
Gag protein associated with sedimented retroviral particles (Wang and Aldovini, 2002). 
In particular, the interaction of the NC protein with RNA - viral or not - prevented the 
disassembly of the retroviral particle during proteolytic cleavage by the viral protease 
(Wang et al., 2004). In this case, the post-assembly defect or reduced stability of the 
particles occurring during particle maturation due to inefficient RNA incorporation 
would not affect the proportion of immature particles released from the cells. Hence, it 
is possible that the particles produced by the HIV-2 packaging mutant would dissociate 
rapidly after release due to a lack of RNA packaged in the virions.
As discussed in the previous chapter, long-term culture of non-infectious SL-1 mutants 
resulted in the emergence of a few revertant vimses bearing compensatory mutations in 
MA, CA and p6. Interestingly, one possibility was that the second site mutations 
observed in MA (V68E and T70I) and CA (V26I and T98A) would affect Gag
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multimerisation and particle assembly, hence rescuing the viral replication of the 
mutated viruses. This hypothesis supports the suggestion that mutations in the Psi/SL-1 
region result in a defect in particle assembly and/or stability, as observed with the DM 
mutant. It would have been interesting to analyse the morphology of these mutant 
virions prior to and after reversion to confirm (i) whether the Psi/SL-1 mutations 
disrupted capsid formation and (ii) whether the compensatory mutations in CA and/or 
MA could rescue particle assembly.
The diminution of the number of mature virions correlated with the augmentation of 
particles that contained two or more cores. These would be predicted to be non- 
infectious and could have arisen from the targeting and subsequent assembly of two 
cores at the same location on the plasma membrane, which would then be assembled 
into a single particle. Whether these ‘two-core’ particles would be infectious in the case 
of the wild type virus, where RNA packaging and dimerisation are normal, remains to 
be elucidated.
The presence of nucleic acid, and in particular RNA, has been shown to considerably 
enhance the assembly of retroviral VLPs in vitro (Campbell and Rein, 1999; Campbell 
and Vogt, 1995; Fuller et al., 1997; Ganser et al., 1999). In addition, MLV packaging 
mutants were shown to encapsidate cellular RNA in place of the viral RNA and viral 
cores were found to be RNAse-sensitive, suggesting that RNA was a structural element 
of the retroviral particle (Muriaux et al., 2001). The interaction of NC with viral or non­
specific RNA was also shown to promote HIV-1 Gag polyprotein mutlimerisation in 
vitro (Bumiston et al., 1999; Cimarelli et al., 2000), implying that an RNAiprotein 
complex is required during assembly. Yet, whether RNA dimerisation is required for 
this process remained unclear. The fact that non-specific RNA could stimulate Gag 
multimerisation as efficiently as a viral RNA would argue that the RNA does not need
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to be dimeric. Several studies have proposed that it is the interaction of the NC domain 
of HIV-1 Gag with an RNA that is critical for promoting Gag-Gag interaction and 
maintaining the particle stability during proteolytic cleavage by the protease (Bumiston 
et al., 1999; Cimarelli et al., 2000; Wang and Aldovini, 2002; Wang et al., 2004), again 
suggesting that the dimerisation efficiency of the viral RNA does not play a role in 
particle assembly and maturation.
Since it was not possible to discriminate between the packaging and the dimerisation 
defect of the DM mutant, it was difficult to conclude whether RNA dimerisation played 
some role in particle morphogenesis. The aforementioned evidence gathered in HIV-1 
tends to suggest that it does not and it seemed more likely that the defect in producing 
fully mature mutant virions was the consequence of the reduced genome encapsidation. 
Interestingly, genomic RNA packaging was also found to play a role in particle 
maturation in S IV m a c , where mutations of SL-1, which led to a decreased packaging 
and dimerisation efficiency, were reported to affect the production of fully mature 
particles (Whitney and Wainberg, 2006). Since the HIV-2 SL-1 was also shown to be 
involved in genome dimerisation and encapsidation (Griffin et al., 2001; McCann and 
Lever, 1997; present study), it was tempting to draw parallels between HIV-2 and SIV. 
Indeed, the present report showed that the DM packaging mutant failed to dimerise its 
genome and to efficiently produce fully infectious mature particles, corroborating the 
findings in SIV (Whitney and Wainberg, 2006). Furthermore, these results supported 
the suggestion of a close relationship between the packaging of the HIV-2 genomic 
RNA - and possibly its dimerisation -, the infectivity and replicative fitness of the virus 
and the correct assembly and maturation of HIV-2 virions.
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6 Concluding remarks
The major focus of this work was to determine the role played by the HIV-2 Psi/SL-1 
sequence and structure in genomic RNA dimerisation and to explore the possible 
connection between genome dimerisation and encapsidation, viral infectivity and 
particle morphogenesis.
Using a range of Psi/SL-1 mutants, we have determined that a palindrome located in the 
loop of SL-1 and previously named the HIV-2 DIS was not required for the dimerisation 
of HIV-2 genomic RNA in virio. Instead, a palindromic sequence within the Psi region, 
pal, was shown to be involved. The HIV-2 ‘DIS’ palindrome was not essential for RNA 
encapsidation and viral replication in T-cells, whereas mutations of pal affected both 
RNA packaging and infectivity.
Further mapping of the sequence and structural elements involved in HIV-2 RNA 
dimerisation revealed that a purine-rich motif (GGAG) at the 5' extremity of pal was 
absolutely required for genome dimerisation and viral replication. However, contrary to 
a previous report proposing that the formation of a stem B structure at the bottom of SL- 
1 was important for RNA packaging and viral replication, the formation of stem B was 
not found to affect HIV-2 encapsidation. Viruses bearing mutations that disrupted the 
formation of stem B showed a reduction in infectivity, which was restored by 
compensatory mutations. However, this result was only observed in a single-round 
infectivity assay and the disruption of stem B did not affect the replication kinetics of 
the virus, suggesting that the absence of stem B may affect early events during infection 
but that the defect is easily overcome by the virus, possibly due to the redundancy of the
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elements involved. The presence of a second purine-rich motif at position 439 of the 
HIV-2rod genome did however appear to be important for viral replication as 
substitution of this GGAG motif for a CCUC resulted in a delayed replication 
phenotype, and a double mutant of both GGAG sequences showed the most dramatic 
reduction in viral infectivity. The first motif, located in the Psi region, appears to have a 
dominant effect as shown by a comparison of the two individual GGAG mutants, SM2 
and SM6. The purine-rich motifs present in HIV-2 5' leader RNA therefore seem to play 
a role in the replication cycle.
In this study, eleven mutant viruses were analysed alongside wild type HIV-2. A 
correlation emerged between the capacity to form RNA dimers, the packaging 
efficiency and the replication fitness of the viruses. Importantly, while all mutants that 
showed a dimerisation defect also failed to efficiently package their genome, the reverse 
was not true, suggesting a nonreciprocal relationship between genome dimerisation and 
encapsidation (see Figure 6.1). These results imply that, in HIV-2, RNA dimer 
formation is important for encapsidation and that genome dimerisation likely occurs 
prior to packaging.
Genome dimerisation appears to be directly linked with viral infectivity and the GGAG 
motif at position 392-395 of the HIV-2rod genome is critical for both HIV-2 replication 
and RNA dimer formation, but not for encapsidation. Furthermore, mutants with 
packaging defects of up to 50 % could establish a productive infection in T-cells, 
demonstrating that viral replication and encapsidation are not interdependent (Figure 
6.1). Besides, viral infectivity was affected independently of the amount of RNA 
genomes targeted to the cells, suggesting that other aspects of the virus life cycle may 
be affected either by the mutation introduced or by the reduction in genome 
dimerisation. The efficacy of first-strand transfer during reverse transcription has been
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shown to decrease in HIV-1 mutants bearing mutations in the dimerisation site. 
Attempts were made to determine whether reverse transcription was affected in the 
Psi/SL-1 mutants, but these remained unsuccessful.
Long-term culture of SL-1 dimerisation-mutants resulted in the appearance of revertants 
with compensatory mutations in MA, CA and p6, suggesting a possible implication for 
either the RNA dimer or the 392-395 GGAG motif in protein synthesis, proteolytic 
processing, particle assembly and stability.
An effect on the stability of the particle was observed with the DM mutant, which failed 
to dimerise and package its genome efficiently. Fewer mature particles were observed, 
together with an increased number of particles containing two cores but the same 
proportion of immature particles, suggesting that the defect probably occurred after 
particle release and initiation of particle maturation. An interesting hypothesis is that the 
interaction of Gag with the RNA genome may prevent the destabilisation of the capsid 
during the proteolytic processing of the polyproteins. Studies in HIV-1 and SIV tend to 
suggest that the packaging of RNA rather than the dimeric nature of this RNA is 
important for particle assembly and stability. This would suggest that the 
morphogenesis defect observed by electron microscopy for the DM mutant resulted 
from its packaging defect rather than from its inability to form stable RNA dimers. 
Finally, the presence of purine-rich motifs (e.g. GGAG) in the HIV-2 5' UTR appears to 
be essential for viral infectivity. Based on in vitro studies of HIV-1 Gag-RNA 
interaction, these motifs represent obvious Gag/NC binding site and it seems likely that 
the binding of Gag to one or several of these sites would be involved in the regulation of 
dimerisation, packaging and possibly translation. Unfortunately, our attempts to 
determine the binding affinity of HIV-2 Gag to the SL-1 mutants were unsuccessful, 
and this hypothesis could not be verified.
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From the results presented in this report, it can be established that the presence of a 
purine-rich motif at position 392-395 of the HIV-2 genome correlates with RNA 
dimerisation and viral replication. Nonetheless, the connection with genome 
encapsidation remains uncertain. While genome dimerisation is required for viral 
replication and may be important for early steps of the virus life cycle such as reverse 
transcription, efficient RNA packaging, possibly in combination with the formation of a 
stable RNA dimer, seems to be essential for particle assembly and morphogenesis (see 
Figure 6.1). Therefore, it seems likely that these processes may be connected at specific 
times of the virus life cycle, potentially ensuring the correct regulation of events that is 
necessary for the production of infectious particles.
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Figure 6.1: Relationship between HIV-2 genome dimerisation, packaging and viral 
replication.
The association between genome dimerisation, packaging and viral replication is 
derived from the analysis of a series of Psi/SL-1 mutants, with phenotypes which fulfil 
the categories described. The dashed lines denote possible sites of action, based on 
previous findings in other retroviruses, which would be worth investigating in HIV-2.
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